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Abstract 
 
Plasmodium falciparum, the most highly virulent malaria parasite, still remains a big 
threat despite years of research and great advances in the field of science and technology.  
The particular virulence of this parasite is believed to be due to the ability of trophozoite 
and schizont stages of infected red blood cells to adhere to endothelial vasculature in 
various organs.  The sequestration of these late stages of the parasite, which makes them 
difficult to detect in peripheral blood smears, is an important factor limiting performance 
of microscopy, the most widely used method for diagnosing malaria in endemic areas.  A 
reliable technique for estimating the burden of sequestered parasites would also be an 
invaluable tool for investigations of pathogenesis and epidemiological field studies.  
 
The objective of this study was to develop methods for detecting sequestered loads and 
correlate the results obtained using these methods with estimates of sequestered loads 
obtained from a statistical model.  Quantification of either cytoadherence or schizogony 
using parasite density or biochemical (host or parasite) markers could resolve current 
problems in estimating the total parasite burden in malaria patients. 
 
The current status of malaria diagnosis was addressed by reviewing the performance of 
the following available diagnostic methods: standard optical microscopy; histidine rich 
protein 2 (HRP2); parasite lactate dehydrogenase (pLDH); acridine orange; quantitative 
buffy coat.  These methods are not 100% sensitive and are not reliable for detecting low 
density malaria infections.  Biochemical assays were established for the detection of the 
stage specific release of parasite biochemical markers in vitro: HRP2; pLDH and D-
lactate.  These assays together with an assay detecting the host marker soluble tumour 
necrosis factor (sTNF-R75) were then analysed in a small group of 30 month old children 
to establish the performance of these assays in measuring markers in vivo.  The disease 
severity was evaluated using the quantitative HRP2 method developed in 366 children 
aged 12 to 59 months.  These children had different symptoms: 98 severe malaria, 92 
mild malaria, 76 asymptomatic parasitaemia and 100 with no malaria.  Having 
determined suitable candidate markers for determination of sequestered loads, we then 
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evaluated a series of host markers: sTNF-R75, circulating host DNA, packed cell volume 
(PCV) and parasite markers: HRP2, pLDH, pigmented polymorphonucleated cells 
(PMNs) and pigmented monocytes, circulating parasite DNA (pDNA) in a series of 22 
patients with severe Plasmodium falciparum malaria treated with quinine.  We closely 
monitored the peripheral parasite density and used these to obtain estimates of 
sequestered loads from an established statistical model that inco-oporates the effects of 
quinine. 
 
The main findings were: 
 
i. HRP2 dipsticks perform better than microscopy in detecting P falciparum 
infections in clinical cases in endemic areas, while pLDH dipsticks are suitable 
for monitoring response to treatment. 
 
ii. P. falciparum releases stage specific products into culture supernatant with pLDH 
enzyme activity measured after schizont rupture, while HRP2 is released at 
trophozoite and during schizont rupture and the amounts at this later stage are 
greatly increased.  Both these biochemical markers are good candidate markers of 
sequestration though their release is altered by antimalarial administration.  D-
lactate is released by all stages of the parasite life cycle.   
 
iii. The methods developed for HRP2, pLDH and a commercially available method 
that measures a host molecule sTNF-R75 are suitable for distinguishing children 
with severe and mild malaria from healthy controls with or without P. falciparum. 
 
iv. The quantitative HRP2 method together with peripheral parasite densities could 
provide a better way of determining malaria disease severity. 
 
v. On admission of young children the markers that appeared to be most useful as 
predictors of sequestered loads were peripheral parasite densities, circulating 
pDNA and sTNF-R75.  However, these and all the other markers did not appear 
 x
to be good indicators of changes in sequestered load during the course of a 
clinical episode. 
 
Though we were unable to estimate the sequestered load using host or parasite 
biochemical markers in partially immune patients, we were able to exclud some 
candidates: D-lactate; pigmented PMNs, pigmented monocytes, PCV and circulating host 
DNA.  Though sTNF-R75 showed some correlation with sequestered loads its release is 
affected by host factors such as genetics and age making it unreliable as a marker of 
sequestration. The parasite markers HRP2, pLDH and circulating pDNA should be 
further evaluated as potential markers of sequestration.  Analyses should consider the 
effects of antimalarials on release of these markers, as well as the kinetics of their release 
and clearance in vivo. 
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Zusammenfassung 
Trotz jahrelanger Forschung und entscheidenden wissenschaftlichen und technischen 
Fortschritten bleibt Plasmodium falciparum, der virulenteste Malaria Erreger, eine grosse 
Gefahr. Es wird vermutet, dass die Virulenz des Parasiten auf der Fähigkeit der 
Trophozoiten und Schizonten der infizierten roten Blutkörper beruht, sich an 
endothelialen Gefässen von verschiedenen Organen anzulagern. Die Sequestrierung 
dieser späten Stadien des Parasiten verursacht, dass der Parasit nicht im peripheren Blut 
erscheintDies erschwert den direkten Nachweises des Pathogen durch Mikroskopie, der 
zurzeit immer noch die häufigste Untersuchungstechnik in endemischen Gebieten 
darstellt. Eine zuverlässige Diagnosemethode zur Schätzung der Bürde der sequestrierten 
Parasiten würde ein wertvolles Instrument für Studien der Pathogenese sowie auch für 
epidemiologische Felduntersuchungen darstellen.  
 
Das Ziel der vorliegenden Arbeit war die Entwicklung einer Diagnosemethode zur 
Quantifizierung der sequestrierten Parasitenlast und anschliessend das Korrelieren der 
Schätzungen der sequestrierten Parasiten mit den Resultaten von statistischen Modellen. 
Die Quantifizierung der Zytoadhärenz der infizierten Blutzellen oder der Feisetzung der 
Schizonten mittels peripheren Parasitendichten oder biochemischen  Marker (Wirte oder 
Parasiten) könnte die aktuellen Probleme der Schätzungen der gesamten Parasitenlast in 
Malariapatienten lösen.  
 
Der aktuelle Stand der Malariadiagnostik wurde durch einen Review der Leistung der 
vorhandenen Diagnosemethoden eruiert: Standarddiagnose mittels Lichtmikroskopie, 
Nachweis von Histidine reichen Proteinen 2 (HRP2), Nachweis der Laktatdehydrogenase 
des Parasiten (pLDH), Diagnose mittels Acridine Orange und Quantitative Buffy Coat 
(QBC) wurden in die Untersuchung einbezogen. Keines dieser Diagnoseverfahren ist 
100% sensitiv und keines kann zuverlässig geringe Parasitendichten nachweisen.  
 
Biochemische Assays wurden entwickelt um die stadienspezifische Freigabe der 
folgenden Marker des Parasiten in vitro nachzuweisen: HRP2, pLDH, und D-Laktate. 
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Diese Assays, in Kombination mit den Assays, die lösliche Marker der Infektion des 
Wirtes nachweisen, wie zum Beispiel der Tumornekrosefaktor (sTNF), wurden 
herangezogen um die Diagnoseleistung dieser Marker in vivo  zu messen. Diese 
Untersuchungen wurden in einer kleinen Gruppe von Kindern im Alter von 30 Monaten 
durchgeführt. Der Schweregrad der Erkrankung der Kinder wurde mittels quantitativer 
HRP2 Methode gemessen. Dieses Diagnoseverfahren wurde in 366 Kindern im Alter von 
12 bis 59 entwickelt. Die Kinder litten an verschiedenen Symptomen: 98 Kinder litten an 
einer schweren und 92 Kinder einer leichten Malaria. In  76 Kindern wurde ein 
symptomfreier Parasitenbefall festgestellt und 100 Kinder hatten keine Malariainfektion. 
 
Nachdem geeignete Marker zur Messung der sequestrierten Parasitenlast entwickelt 
worden waren, wurden diese mit Markern in einer Patientenserie von 22 Patienten mit 
einer schweren Plasmodium falciparum Infektion in Chininbehandlung evaluiert. Die 
folgenden Marker wurden dabei untersucht: sTNF-R75, zirkulierende Wirts-DNA, 
Haematokrit (Packed Cell Volume: PCV) als Marker des Wirtes und HRP2, pLDH, 
pigmentierte polymorphonukleide Zellen (PMNs), pigmentierte Monozyten, 
zirkulierende Parasiten-DNA (pDNA) als Marker des Parasiten. In diesen 22 Patienten 
wurden die peripheren Parasitendichten minutiös im zeitlichen Verlauf dokumentiert. 
Diese Messungen wurden verwendet um mit Hilfe eines etablierten statistischen Modells, 
das auch den Einfluss der Chininbehandlung einbezieht, die sequestrierte Parasitenlast zu 
schätzen.  
 
Die folgenden Resultate wurden beobachtet: 
 
vi. Die HRP2 Schnellstests (dipsticks) sind besser für den Nachweis von Plasmodium 
falciparum Infektionen in klinischen Patienten geeignet als die Diagnose durch 
Lichtmikroskopie. pLDH Schnelltests sind besonders für die Nachuntersuchung 
bei einer Behandlung geeignet.  
vii. P. falciparum setzt stadienspezifische Produkte mit pLDH Aktivitäten in das 
Kulturmedium welches nach Aufplatzen der Schizonten gemessen wird während 
dem HFP2 beim Aufplatzen der Trophozoiten und beim Aufplatzen Schizonten 
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freigesetzt wird. Das letztere Stadium setzt eine entscheidend grössere Menge 
frei. Beide Markes bieten sich als Mass der Sequestrierung an, obwohl ihre 
Freisetzung bei der Behandlung verändert wird. D-Laktate werden von allen 
Stadien des Lebenszyklus des Parasiten freigesetzt. 
viii. Die Diagnoseverfahren für HRP2, pLDH und die kommerziell verfügbaren 
Messmethoden des Wirtsmoleküls sTNF-R75 sind besonders geeignet, um Kinder 
mit einer schweren oder milden Malaria von gesunden Kontrollkindern mit oder 
ohne P. falciparum zu unterscheiden.  
ix. Die quantitative Messung von HRP2 in Kombination mit der Messung der 
peripheren Parasitenlast kann ein gutes Mass für den Schweregrad einer 
Malariaerkrankung sein.  
x. Bei der Hospitalisierung von kleinen Kindern sind die peripheren 
Parasitendichten, die zirkulierende pDNA und die sTNF-R75 die besten Marker 
für eine Vorhersage der sequestrierten ParasitenlastDagegen scheinen weder diese 
noch die anderen untersuchten Marker gute Indikatoren für die sequestrierte 
Parasitenlast während der Behandlung einer klinischen Episode zu sein.  
 
Obwohl es in dieser Studie nicht gelang, die sequestrierte Parasitenlast mittels 
biochemischen Wirts- oder Parasitenmarker zu schätzen, war es uns möglich einige 
Kandidaten auszuschliessen: D-Laktate, pigmentierte PMNs, pigmentierte Monozyten, 
PCV und zirkulierende Wirts-DNA. Obschon sTNF-R75 eine Korrelation mit der 
sequestrierten Parasitenlast zeigt, ist die Freisetzung von sTNF-R75 durch Wirtsfaktoren 
wie dem Alter oder genetischen Faktoren beeinflusst, was ihn als Marker der 
Sequestrierung unzuverlässig macht. Die Parasitenmarker HRP2, pLDH und die 
zirkulierende pDNA sollten weiter als mögliche Marker der Sequestrierung untersucht 
werden. Diese Studien sollten den Einfluss der Malariabehandlung auf die Freigabe 
dieser Marker sowie die in vivo Kinetik der Freigabe und des Abbaus untersuchen.   
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Muhutasari 
Plasmodium falciparum ndio kimelea kinayosababisha vifo zaidi kwa binadamu na bado 
ni tishio kubwa licha ya juhudi za kiteknologia na utafiti wa miaka mingi. Uhatari wa 
vimelea hivi unaamika ni kwasababu ya uwezo wa baadhi ya hatua za maisa ya vimelea 
hivi, ambao hushambulia chembe chembe nyekundu za damu kujificha kwenye sehumu 
za mwili. Vimelea hivi havionekani wakati wa uchunguzi wa damu wa kawaida kwa 
kutumia hadubini zinazotumika kuchunguza malaria. Njia sahihi ya kutambua 
waliojichimba inaweza kuwa na manufaa katika kuchunguza tabia za ugonjwa. 
 
Lengo la mradi huu ilikuwa ni kutafuta njia mpya ya kukaridiria kiwango cha vimelea na 
kuoamisha na kiwengo cha takimu za kimahesabu.  Kujua wingi wa vimelea vilivyo 
jificha kwa kutumia wingi wa vimelea kwenye damu ama kwa njia za kibiyolojia 
kunaweza kutatua tatizo lilipo sasa la kukadiria.  vilivyojitenga na kukusanya tarakimu 
hizo kwa utafiti. Hesabu ya cytoadherence ama schizogony kutumia windi wa vimelea 
ama alama za biokemia (za mgonjwa au kimelea) inaweza kutatua shida ya makisio ya 
jumla ya vimelea mwilini mwa mgonjwa wa malaria. 
 
Uchunguzi wa malaria ulipatikana kwa njia za utafiti zifuatazo: kwa darubini; protini2 
iliyo na histidine (HRP2); vimelea vyenye lactate dehydrogenase (pLDH); acridine 
orange na wingi wa buffy coat. Mbinu hizi hazina usahihi wa asilimia mia na sio 
tegemevu kwa kugundua vimelea vya malaria kwa mgonjwa mwenye wadudu wachache. 
Changanuzi na biokemia zilitumika kutambua vitambulishi vya hatua za biokemikali za 
vimelea maabara; HRP2; pLDH na D-lactate. Changanuzi hizi pamoja na uchanganuzi 
wa vitambulishi anuai kwa mgonjwa soluble tumor necrosis factor (sTNF-R75) 
zilichambuliwa kutoka kwenye kundi dogo la watoto wa miezi 30 ili kupima matokeo ya 
njia hizo kutambua vitambulishi kwa mgonjwa.  Madhara ya ugonjwa yalichunguzwa 
kwa kiwango cha HRP2 katika idadi ya watoto 366 wa umri wa kati ya miezi 12 hadi 59. 
Watoto hao walionyesha dalili tofauti. 98 malaria kali, 92 malaria ya kawaida, 76 malaria 
isiyokuwa na dalili na 100 hawakuwa na malaria. Baada ya kupata njia mwafaka ya 
kutambua kiwango cha malaria, tulianza kuchunguza vitambulisho mbalimbali; sTNF-
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R75, mzunguko wa vinasaba mgonjwa, packed cell volume (PCV), vitambulisho vya 
vimelea: HRP2, pLDH, pigment polymorphonucleated cell (PMNs) na pigment 
monocytes, mzunguko wa vinasaba ya vimelea katika mpangilio wa wagonjwa 22 
waliokuwa na malaria kali ya Plasmodium falciparum iliyotibiwa na dawa ya quinine. 
Kwa uangalifu tulichunguza dadi ya vimelea  na kuitumia kupata wingi wa vitengo vya 
vimelea kutokana na utafiti huu ukijumuishwa na matokeo ya utumizi ya dawa ya 
quinine.  
 
Matokeo ya jumla: 
 
i) HRP2 vijiti zina matokeo bora kuliko darubini katika kutambua maambukizo 
ya falciparum kwenye sehemu za malaria nayo pLDH vijiti ni bora katika 
kuchunguza uwezo wa dawa katika wagonjwa. 
 
ii) Plasmodium falciparum hutoa vitambulisho kihatua wakati inapokuzwa na 
vimeng’enya vya pLDH baada ya kupasuka kwa schizont, nayo HRP2 hutoka 
wakati wa trophozoite na kupasuka kwa schizont ambapo kiasi chake 
kuongezeka. Vitambulisho vyote viwili vinaashiria kuwepo kwa vitengo vya 
vimelea ingawaje madawa ya malaria huzuia vitambulisho. D-lactate nayo 
hutolewa katika kila hatua ya maisha ya kimelea. 
 
iii) Mbinu za HRP2, pLDH na nyinginezo za kibiashara za kupima vitambulishi 
anuai kwa mgonjwa sTNF-R75 ni bora kwa kutambua watoto walio na 
malaria kali, ya kawaida au malaria isiyokuwa na dalili ama pasiwe na 
Plasmodium falciparum. 
 
iv) Mbinu ya kupima wingi ya HRP2 pamoja na uzito wa vimelea unaweza 
kutambulisha madhara ya malaria. 
 
v) Kwa watoto waliolazwa vitambulisho vinavyojitokeza kuonyesha viwango 
vilivyojificha vya vimelea ni hatua za mwanzo za vimelea, circulating pDNA 
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na sTNF-R75. Ingawaje hivi vitambulishi havikuweza kutujulisha mabadiliko 
ya vimelea vilivyojificha katika uchunguzi huu. 
 
Ingawaje hatukuweza kukadiria viwango vya vimelea vilivyojificha kwa kutumia 
biokemia ya mgonjwa na vimelea katika wagonjwa walio na kingamaradhi kidogo, 
tulifaulu kutengamisha wengine; D-lactate, pigmented PMNs, pigmented monocytes, 
PCV na mzunguko wa vinasaba ya mgonjwa.  Ingawa sTNF-R75 ilionyesha ukaribiano 
na vimelea vilivyojificha haikuwa na utaratibu ama kutolewa kwake kulihitilafiwa na 
sababu za uasili, umri na hitilafu ya vitambulishi vya vimelea fichu. Vitambulishi vya 
vimelea HRP2, pLDH na vinasaba vinavyozunguka hazinabudi kuangaliwa tena kama 
vitambulishi. Utafiti lazima uchunguze athari za madawa ya malaria katika kutoa hivi 
vitambulisho pamoja na minyambuliko yake na udhahiri wake mwilini. 
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Chapter 1 
 
 
      Introduction 
 2 
 
1.1 Malaria 
Infectious agents - viruses, bacteria and parasites, cause the largest burden of 
disease worldwide, of which the top five are HIV/AIDs, diarrhoea, tuberculosis, the 
childhood clusters (measles, pertussis, tetanus, diphetheria and poliomyelitis) and malaria 
(The World Health Report 2004).  Malaria is the most important eukaryotic parasitic 
disease, threatening the livelihood of over 2.2 billion people. 
 
There are four main species of malaria occurring in humans, Plasmodium 
falciparum (P. falciparum), malariae (P. malariae), ovale (P. ovale) and vivax (P. vivax).  
All four species are transmitted by mosquitoes of the genus Anopheles, of which there 
exist over 400 species (Gilles and Warrell 1993). P. vivax a rarely lethal infection that is 
widespread in Central and South America, Asia and Oceania can exist as a latent 
infection in the hepatocytes of the liver, re-emerging after many months to several years 
(Mangoni et al 2003).  Though it causes morbidity and may be an important cause of low 
birth weight in pregnancy, it is associated with relatively fewer severe complications 
(Breman 2001,Nosten et al 1999).  Though commonly transmitted, infections due to P. 
ovale are rare as immunity is established early and parasitaemia remains low, thus long 
term latent infections like P. vivax are established.  It is found principally in Africa 
causing less than 0.5% of malaria infections (Breman 2001).  P. malariae is found 
worldwide but with a very patchy distribution.  It can cause renal complications or 
chronic nephropathy and if left untreated patients will remain parasitaemic though 
asymptomatic for years (Barsoum 2000,Hendrickse et al 1972).  
P. falciparum is the most highly virulent species and causes almost all of the 1.7-
2.5 million deaths worldwide from malaria (Aikawa 1988,Bray and Sinden 
1979,Ringwald et al 1993).  The clinical manifestations caused by this pathogen range 
from a mild asymptomatic parasitaemia through to severe and often fatal syndromes such 
as cerebral malaria or multi-organ failure.  In Africa P. falciparum is responsible for 30-
50% of hospital admissions and 50% of outpatient visits (Roll Back Malaria).  Children 
below 5 years of age together with pregnant women bear the brunt of this disease, which 
may infect its victim many times.  In addition malaria can lead to neurological and 
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cognitive impairment and is associated with anaemia in pregnant women leading to low-
birth weight babies (Carter et al 2003,Holding and Kitsao-Wekulo 2004,Newton and 
Krishna 1998).  Other secondary factors that contribute to the burden of malaria include 
the socio-economic conditions and behaviour of individuals (Breman et al 2004,Jones 
and Williams 2004).   
The complex biology of P. falciparum malaria is addressed and attempts to 
quantify the stages that sequester in deep tissues are undertaken with the aim of 
improving the current understanding of disease pathology as a way to control this 
devastating disease. 
 
1.2 P. falciparum natural history 
The life cycle of P. falciparum is complex, consisting of an exogenous sexual 
stage in the Anopheles mosquito and an asexual reproduction stage in the mammalian 
host (Figure 1.1).   
Ring stage
Trophozoite stage
Schizont stage
 
Figure 1.1 P. falciparum life cycle (Good et al 1998,Silamut et al 1999) 
Parasites are transmitted to humans in the form of sporozoites through the bite of an infected female 
anopheline mosquito.  Sporozoites can circulate for upto 45 minutes before entering the parenchyma cells 
of the liver whereby they undergo development and multiplication forming a large intracellular schizont 
(Gilles and Warrell 1993,Wernsdorfer and McGregor I 1998).  The swollen hepatocyte bursts after 5 to 6 
days releasing merozoites that invade red blood cells (RBCs) initiating the erythrocytic cycle. 
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The intra-erythrocytic parasite first develops within a parasitophorous vacuole in 
the form of a ring and then develops into a trophozoite, within which multiple nuclear 
divisions occur forming a schizont.  The mature pigment-containing trophozoites and 
schizont stages are not normally seen in the peripheral blood but are sequestered in deep 
vascular beds where they adhere to endothelial receptors. This cytoadherence was first 
described over a century ago by Bignami and Bastianelli in brain tissue of patients who 
had died of malaria (Sherman et al 2003) and is a unique feature of P. falciparum, not 
found in other human malaria.  Since then, this phenomenon has been shown to occur in 
autopsies from brain, heart, lungs and small intestines (Aikawa 1988,Barnwell 1989,Bray 
and Sinden 1979,Sein et al 1993).  Sequestration probably provides the parasite with the 
possibility of evading immune clearance by the host (Barnwell 1989,Hommel et al 1983) 
by avoiding passage through the spleen and its specific and non specific clearance 
mechanisms (Berendt et al 1994).  It provides the parasitized erythrocyte with a micro-
aerophillic environment suitable for re-invasion and rapid asexual multiplication.  It is 
also possible that sequestration in the bone marrow could promote gametocyte survival 
and thus enable the spread of disease (Sherman et al 2003).   
Once maturation of the schizont occurs, the RBC ruptures releasing 8 to 32 
merozoites that rapidly invade fresh erythrocytes.  This erythrocytic cycle may be 
repeated many times.  During a synchronised infection, the circulating parasite density is 
seen to fluctuate over days (Fig 1.2) with peaks resulting in release of new rings from the 
sequestered compartment into blood circulation and troughs from disappearance of 
parasites from circulation as they cytoadhere in deep vasculature following the 48 cycle.  
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Figure 1.2 Characteristic malaria therapy, Patient S-1044, (Collins and Jeffery 1999) 
---- gametocytes           asexual parasites.  Blood films were made daily during the first part of the infection, 
showing the characteristic two day cycle.  In addition there is a longer cycle of peaks and troughs resulting 
from predominance and immune control of successive antigenic variants. 
 
Some of the invading merozoites develop into sexual forms (gametocytes).  If 
viable gametocytes are taken up by feeding Anopheles, gametes from male and female 
will fuse and form a zygote from which infective sporozoites arise, a process that takes 
10 to 20 days.  These migrate to the salivary glands to await injection into the human host 
the next time the mosquito takes a blood meal thus, completing the malaria transmission 
(Ho and White 1999). 
 
1.3 Diagnosis 
Currently malaria control is heavily dependent on chemotherapy, to which 
resistance is quickly evolving in endemic regions (Nosten et al 2000,Sibley et al 
2001,White 2004).  One of the main interventions of the global malaria control strategy 
for effective disease management is prompt and accurate diagnosis (reviewed in A Global 
Strategy for malaria control, WHO, 1993).  In the tropics, malaria diagnosis is carried out 
mainly by microscopic methods while rapid diagnostic techniques (RDTs) are available 
mainly in non-endemic settings.  However, the performance of these diagnostic 
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techniques is however subject to many factors: the different forms of malaria species, the 
inter-relationship between parasite densities, immunity and symptoms under different 
levels of transmission, the use of chemoprophylaxis, and presumptive treatment on the 
basis of clinical diagnosis (Aikawa 1988,Rougemont et al 1991,Smith et al 1999a,Smith 
et al 1999b). 
The sequestration of the late stages of the parasite makes detection of parasites in 
peripheral blood smears difficult, and is an important factor limiting the performance of 
microscopy. Quantification of either cytoadherence or schizogony using parasite density 
or biochemical markers released from sequestered parasites could resolve problems in 
estimating the total parasite burden in patients 
 
1.4 Malaria pathology 
The clinical outcome of malaria infection involves many factors that include: (1) 
parasite factors (parasite load, multiplication rate, cytoadherence or sequestration); (2) 
host factors (immunity, age); (3) geographical and social aspects (Miller et al 2002).  Due 
to changes in one or several of these factors, people will move from having an 
asymptomatic infection (presence of P. falciparum and absence of symptoms) to 
developing fever (symptomatic) to severe malaria and finally death.  In malaria endemic 
areas asymptomatic infections are a common occurrence (Rougemont et al 1991) 
dependent on transmission intensity (high or low) (Snow et al 1997) and age which 
determines development of partial-immunity (Staalsoe and Hviid 1998) and protects 
against development of clinical disease (Farnert et al 1999).  In naïve individuals and in 
some cases in partially-immune hosts asymptomatic infections lead to increase in 
parasitaemia and development of symptomatic infections.  
The characteristic symptom of uncomplicated malaria is fever while severe 
malaria comprises several different overlapping syndromes. Sequestration and 
cytoadherence are important elements of the pathology of all these different 
manifestations of malaria disease. In the host, effects of sequestration might include, a 
mechanical obstruction of infected red blood cells (IRBCs) in capillaries and a 
hinderance to microcirculatory blood flow (Miller 1972,Trager et al 1966), hypoxia, focal 
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release of parasite toxins and inflammatory mediators (Clark et al 1989,Clark and 
Rockett 1996), cerebral oedema (Oo et al 1987) and raised intracranial pressure (Newton 
et al 1991,Newton and Krishna 1998). 
 
1.4.1 Fever and uncomplicated malaria 
Malaria fever results from release of pyrogens when schizonts rupture leading to 
an acute phase response comprising up-regulation of many host proteins including C-
reactive protein (Naik and Voller 1984), Tumour necrosis factor-α (TNF- α) (Clark 1987) 
and its soluble receptors sTNF-R55 and sTNF-R75 (Kern et al 1992,Kwiatkowski et al 
1989,Molyneux et al 1993,Nyakundi et al 1994).  In maternal malaria, TNF-α is 
associated with low birth weight and monocyte inflammatory proteins 1α, β and IL-8 are 
also up-regulated in the placenta (Fried and Duffy 1996,Fried and Duffy 1998).   
Field studies of uncomplicated malaria have used the consequent relationship 
between peripheral parasite densities to estimate morbidity rates.  However studies in 
different settings have suggested different pathogenic or pyrogenic thresholds of P. 
falciparum parasites ranging from 1000-15000 parasites/µl (Smith et al 1995b,Snow et al 
1988,Trape et al 1985).  Using threshold approaches in different areas is difficult because 
of high parasite prevalence rates reaching up to 90% in African children (Bottius et al 
1996) and depends on the population sampled (endemic zone, season, adults and children 
(Hogh et al 1993).   
Clearly the use of parasite density thresholds (Genton et al 1994,Rougemont et al 
1991,Trape et al 1985) is insufficient even for estimating risks at the population rather 
than individual level (Smith et al 1994).  Among all groups (asymptomatic, mild malaria 
and severe malaria), a wide variation in peripheral parasite loads is observed making this 
measurement unreliable.  One reason for this is that severity of disease is related to the 
number of schizonts rather than to the circulating parasites (Aikawa 1988,MacPherson et 
al 1985,Silamut and White 1993).  There is a need to develop means of using the total 
parasite biomass for such case definitions. 
In studies of drug resistance, undetectable parasitaemia may be of importance.  
Among uncomplicated (mild) malaria studies assessing the effectiveness of antimalarials 
(co-artemether, sulphadoxine-pyrimethamine, amodiaquine), recrudescence or re-
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emergence of parasitaemia on day 14 or 28 is common (Olliaro et al 1996,Omari et al 
2004).  Methods for detecting sub-patent parasitaemia in such studies are needed. 
 
1.4.2 Cerebral malaria 
One of the most serious complications of P. falciparum infection is cerebral 
malaria (CM), defined as an acute, diffuse, symmetric encephalopathy (MacPherson et al 
1985,Oo et al 1987).  CM is a frequent feature of severe malaria in all ages.   
The pathogenic mechanisms underlying CM and why a small percentage of patients 
develop CM are not fully understood, but the accumulation of large numbers of parasites 
in specific sites such as the brain or placenta (Aikawa 1988,MacPherson et al 1985,Ricke 
et al 2000,Rogerson et al 1995), associated with adverse clinical outcomes, suggests that 
organ-specific accumulation of parasites is important.  The majority of IRBCs found in 
brain sections are late stage trophozoites, tightly packed within vessels (MacPherson et al 
1985).  Blockage of cerebral vessels by parasitized cells (Aikawa 1988), deposition of 
immune complexes in brain capillaries, reduced humoral or cell-mediated immune 
responses, action of endotoxin, action of TNF (Clark et al 1987) all play roles in 
development of CM.   
Sequestration of IRBCs thus plays an important role in the pathology of CM.  
Children with a clinical case definition of CM have many sequestered parasites and intra- 
and perivascular pathology which includes hemorrhages, accumulation of pigmented 
white blood cells and thrombi (Taylor et al 2004).  The proportion of sequestered IRBCs 
in Thai adults with CM was higher in the brain when compared to the heart, lungs, 
kidneys or small intestines and overall, cerebral vessels contained more parasites in 
patients with CM than non-CM forms of malaria.  
In children with CM, very high peripheral parasitaemia (>1000000/µl) is 
significantly associated with fatal outcome (Molyneux et al 1989).  Yet attacks can occur 
when peripheral parasitaemia is low (Hogh et al 1993), very likely, because the 
peripheral parasitaemia does not necessarily reflect the total parasite biomass.  There is a 
need to develop means of measuring the total biomass in such patients. 
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1.4.3 Anaemia 
 Ruptured sequestered parasites release merozoites from IRBC schizonts that re-
invade new RBCs thus causing destruction of RBCs.  This results in a small degree of 
anaemia of which further progression leads to severe anaemia.  Anaemia is considered to 
be severe when the haemoglobin concentration falls below 5g dl-1 (Warrell et al 1990).  
Apart from destruction of RBCs by parasites, uninfected erythrocytes are further 
destroyed by immune sensitization as well as damage by oxygen free radicals (Das 
1999,Looareesuwan et al 1987).  It is thought that suppression of chronic release of 
cytokines like TNF in malaria could lead to dyserythropoiesis (Abdalla et al 1980,Clark 
and Chaudhri 1988). 
 
1.4.4 Metabolic acidosis 
 Sequestered IRBCs are metabolically active and release high amounts of lactic 
acid, leading to hypoglycaemia and lactic acidosis, (Krishna et al 1994,Marsh et al 1995).  
Anaerobic host tissue metabolism also produces large amounts of lactate in malaria 
patients (Dondorp et al 2004).  Severe acidosis has emerged as a major feature of severe 
malaria (English et al 1997,Taylor and Voller 1993).  Various mechanisms that play a 
role in the pathogenesis of metabolic acidosis include impaired renal clearance of fixed 
acids, and ingestion of exogenous acids in the form of salicylates (English et al 1996).  
Reduced hepatic blood flow caused from the packing of IRBCs in vessels leads to further 
accumulation of lactate (Jensen et al 1993).  Metabolic acidosis is therefore a strong 
prognostic factor in adults and children with severe malaria. 
 
1.5 P. falciparum adhesion molecules 
Sequestration involves a complex interaction between parasite-derived neo-
antigens that are expressed on the surface of IRBCs as proteins, and either one or more 
receptors expressed on the surface of vascular endothelium or syncytiotrophoblasts in 
placenta (Beeson and Brown 2004,Cooke et al 2000,Cooke et al 2001) as depicted in 
Figure 1.3a.   
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The best characterised parasite ligand involved in cytoadherence is the 240-260 
kDa var gene encoded family of proteins - P. falciparum erythrocyte membrane protein 1 
(PfEMP1) which is detected on the surface of IRBCs 16 to 20 hours post–invasion and 
corresponds with parasites disappearance from circulation (Gardner et al 1996).  There 
exist 40-50 var genes per haploid genome, each var gene comprises two exons, a highly 
variable extracellular domain 5’ exon and a highly conserved acidic terminal segment 
(ATS) 3’ exon, which anchors PfEMP1 to a submembraneous electron-dense knob 
structure, first demonstrated by Oo and others (1987) protruding from the membrane of 
IRBCs in microvessels of CM patients. (Figure 1.3b) (Baruch et al 1995,Smith et al 
1995a,Smith et al 1995b,Su et al 1995).  The PfEMP1 highly variable extracellular 
region consists of four basic building blocks: N-terminal segment (NTS), Duffy-binding-
like domains (DBL), Cysteine-rich InterDomain Region (CIDR) domains and C2 
domains.  Due to its variable domains and extensive sequence polymorphism, PfEMP1 
has been implicated in antigenic variation as well as adhesion (Smith et al 1995a,Smith et 
al 2000).   
The PfEMP1 var gene has been described as highly polymorphic and undergoing 
constant changes as a result of frequent recombinations that generate a vast repertoire of 
var genes, which alters the cytoadherence and antigenic phenotypes of IRBCs (Biggs et 
al 1991,Roberts et al 1992,Scherf et al 1998).  In vitro studies have revealed that even 
without selective pressure, parasites undergo rapid clonal antigenic switching at a rate of 
2.4% per generation (Biggs et al 1991,Roberts et al 1992).  Offspring clones showed 
diverse binding properties (Cooke et al 2001,Deitsch and Wellems 1996,Smith et al 
2000).  Indeed, a recent study in Papua New Guinea on chronically infected children 
showed that they express several var genes, which undergo a rapid change in var gene 
expression with some re-appearing after 10 weeks (Kaestli et al 2004). 
Apart from relying on these surface exposed proteins, electron microscopy has 
shown that parasites also develop 85 to 110 kDa knob-associated histidine rich protein 
(KAHRP) like protrusions on the membrane of IRBCs (Figure 1.3a) which serve as 
points of attachment between infected erythrocytes and endothelial cells (Leech et al 
1984,Pologe and Ravetch 1986).  Maintenance of knobby cultures for a long time in vitro 
will result in knobless variants (Biggs et al 1991) in which PfEMP1 distribution is 
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altered.  When physiological shear stresses that simulate those found in microvasculature 
are applied, sequestration does not occur (Crabb et al 1997). 
Other potential adhesion molecules expressed by IRBCs but whose function in 
vivo remains unclear include the repetitive interspersed family of genes (rifins), 
sequestrin, Cytoadherence linked asexual gene (Clag 9), Pf 332 and modified RBC band 
3 (Figure 1.3a).  Rifins formerly known as rosettins, are a group of 30 to 40 kDa proteins 
that were earlier described in sera from people in endemic regions due to the ability of a 
parasite lab isolate binding to erythrocytes, thus forming rosettes (Helmby et al 
1993,Kyes et al 1999,Weber 1988).  The rif family, subtelomeric variable open reading 
frames (STEVOR) (Cheng et al 1998,Kaviratne et al 2002) and Pf60 (Carcy et al 1994) 
may also undergo antigenic variation. 
Clag 9, is a 220kDa protein that is transcribed in mature stage parasites, and is 
able to bind to the endothelial receptor CD36 (Holt et al 1999) while sequestrin, a 
270kDa protein has been identified in a knobless cytoadherent parasite line that binds to 
CD36 (Ockenhouse et al 1991).  Unlike the other parasite derived proteins, band 3, a 95 
kDa protein, has been isolated from erythrocyte membranes and was shown to be 
involved in cytoadherence from studies of P. falciparum in Aotus or Saimiri monkeys 
(Crandall et al 1993).  Studies on sera from endemic regions have shown strong reactivity 
to well defined regions of band 3 (Crandall et al 1995).   
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Figure 1.3 PfEMP1 derived neo-antigen and parasite-host interactions 
(a) PfEMP1 and host (endothelial cells) ligand interactions (Cooke et al 2000), (b) A schematic diagram of 
PfEMP1 structure showing binding of host receptors (Craig and Scherf 2001,Smith et al 2000).  CR1, 
complement receptor 1; HS, heparin sulphate; CSA, chondrotin sulphate A; ICAM-1 intracellular adhesion 
molecule 1. 
 
1.5.1 Other cytoadherent properties of P. falciparum 
In vitro studies show that IRBCs can adhere to platelets, monocytes, lymphocytes, 
uninfected RBC (rosetting), auto-agglutinate to other IRBCs and clump or cytoadhere to 
platelets or to syncitiotrophoblasts.  The ligand PfEMP1 binds to Heparin sulphate (HS) 
proteoglycans located on the surface of RBCs where it functions as a receptor for IRBCs 
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during the formation of rosettes (Carlson et al 1990,Chen et al 1998).  Studies in 
Gambian children with CM showed a higher mean rosette frequency than those with mild 
or uncomplicated malaria (Carlson et al 1990,Treutiger et al 1992).  Alternatively, rosette 
formation may be mediated by complement receptor 1 (CR1) situated on the surface of 
RBCs where it has been shown to play a role in the pathogenesis of severe malaria among 
Kenyan children (Rowe et al 1995,Rowe et al 1997).  A recent study further showed that 
clinical isolates from children with severe malaria more frequently bound to multiple 
receptors forming rosettes than in mild disease (Heddini et al 2001). 
Furthermore, it has been illustrated that RBC CR1 deficiency is common in 
malaria endemic Papua New Guinea and that polymorphisms associated with CR1 
deficiency confer protection against severe malaria (Cockburn et al 2004).  Studies have 
also shown that blood group antigens A and B can act as co-receptors in rosette formation 
with different parasite isolates demonstrating different rosetting rates and sizes when 
cultured with RBCs of different blood groups (Barragan et al 2000,Carlson and Wahlgren 
1992).  Despite all this, rosette-like aggregates of cells have not been seen in vivo. 
IRBCs adhere to each other and form large auto-agglutinates a common 
phenotype seen in field isolates both from Kenya and Thailand.  Various studies 
(Chotivanich et al 2004,Roberts et al 2000) have observed a correlation between 
autoagglutination and severe malaria.  Another P. falciparum adhesive phenotype is 
platelet mediated clumping of IRBCs which has been associated with disease severity in 
Kenyan children (Pain et al 2001).  Yet several other studies showed that IRBC binding 
to Chinese hamster ovary (CHO) and C32 melanoma cells occurs in a chondrotin 
sulphate manner (Rogerson et al 1995).  This thus led to the discovery of placental 
parasites binding to glycosylaminoglycan (GAG) polysaccharide chondrotin sulphate A 
(CSA) (Fried and Duffy 1996); in contrast, IRBCs from peripheral blood of non-pregnant 
hosts did not bind to this protein. 
 
1.5.2 Endothelial receptors involved in cytoadherence 
IRBCs adhere to a diverse array of cell types in vitro, (human umbilical vein 
endothelial cells (HUVEC), amniotic epithelial cells and C32 amelanotic melanoma cell 
lines) that express various endothelial receptors.  Knobby P. falciparum parasites were 
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found to bind to the glycoprotein Thrombospondin (TSP) situated on the surface of 
macrophages, melanoma cells and a variety of endothelial cells (Roberts et al 1985).  
TSP in turn binds to CD36 and CD47 receptors and IRBCs, as well as playing a role in 
platelet clotting and regulation of angiogenesis (Sherman et al 2003).   
Through the use of a monoclonal antibody OKM5, Barnwell and others (1985) 
showed that this antibody prevented binding of IRBCs to an 88 kDa polypeptide located 
on the surface of melanoma cells, platelets, monocytes, dendritic cells and microvascular 
endothelial cells.  Polypeptide CD36 is involved in platelet clumping, a phenotype 
strongly associated with severe disease (Pain et al 2001).  Most clinical and lab isolates 
of P. falciparum bind to TSP and CD36 (Baruch et al 1996) and high levels of binding to 
CD36 receptor, not commonly found in the brain, was observed in patients with severe 
and non-CM (Marsh et al 1988).  However, Berendt and others (1989) observed parasite 
binding to HUVEC cells that was independent of CD36 or TSP receptors.  They 
developed an alternative cell adhesion assay using CHO cells transfected with 
complementary deoxyribonucleic acid (DNA) encoding Intracellular adhesion molecule-
1 (ICAM-1) from which they observed binding of an endothelial-binding P. falciparum 
cell line to this receptor.  ICAM-1 is expressed by a variety of cells including 
lymphocytes, monocytes, macrophages and HUVEC cells (Berendt et al 1989,Craig et al 
2000) and is upregulated by the inflammatory cytokine TNF-α.  Isolates that bind to 
ICAM-1 were found to be co-localised in the brain and were significantly elevated in 
non-anaemic disease remaining highest in CM malaria (Newbold et al 1997). 
Recently it was demonstrated that IRBCs isolates from a patient with severe 
complicated malaria bound to cytokine induced HUVEC cells and adhesion was found to 
be mediated through endothelial receptors, vascular adhesion molecule-1 (VCAM-1 or 
CD106) and E-selectin (also designated ELAM-1 or CD62E) (Ockenhouse et al 1992).   
As earlier mentioned, CSA is found on syncytiotrophoblasts and has been 
implicated in placental malaria leading to low birth weight, abortion, maternal and infant 
anaemia, intrauterine growth retardation, premature delivery and maternal mortality 
(Beeson and Brown 2004,Okoko et al 2003,Smith and Miller 2004).  Another receptor 
implicated in maternal malaria is Hyaluronic acid (HA) - a non-sulfated GAG, present 
not only in the placenta but also in the umbilical cord (Wahlgren and Spillmann 2000).  
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Studies have shown that clinical isolates are able to bind to either CSA or HA causing 
maternal malaria (Maubert et al 1997,Ricke et al 2000,Rogerson et al 1995). PECAM or 
CD31 (Treutiger et al 1997), αvβ3 integrin (Siano et al 1998) and P-selectin (Facer and 
Theodoridou 1994) also bind IRBCs, however, the expression of the receptors on the 
luminal surface of endothelial cells at the site of sequestration has not been confirmed 
(Baruch et al 2002,Berendt and Craig 1997). 
 
1.6 Estimating the Parasite Biomass 
The assessment of malaria disease severity rests on clinical and laboratory 
features such as the level of coma, the respiratory pattern, the circulatory status, the 
haematological and biochemical indicators of the degree of anaemia, vital organ 
dysfunction and the number of parasitized erythrocytes per unit volume of blood 
(parasitaemia) (WHO, 1990).  The quantification of ring stages using standard 
microscopy is also an important determinant of treatment in P. falciparum patients and 
should be performed within minutes of admission (White and Krishna 1989).   
Field and Niven first described the relationship between peripheral parasitaemia 
and mortality in 1937 (Field and Niven 1937).  These authors found that in places where 
malaria is not holo-endemic peripheral counts of over 100,000/µl (approx. 2-3%) in 
Asian male adults correlated with increased mortality while peripheral counts of 
500,000/µl were associated with over 50% of deaths. In non-immune individuals a single 
infection of P. falciparum is complex and if left untreated will lead to drastic increases in 
parasite loads and severe disease (Phillips and Warrell 1986).  Silamut and White (1993) 
further showed that a predominance of older parasites in Thai adults carries a poor 
prognosis than predominance of tiny ring stages as it reflects a higher sequestered 
biomass.  These differences were evident in patients who had a parasitaemia of between 1 
to 10%.   
The use of peripheral counts alone as an indicator of disease severity is clearly not 
sufficient.  After infection the peripheral parasitaemia increases exponentially, achieving 
a transient steady state that oscillates over 2 days (Collins and Jeffery 1999) and thus the 
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total parasite burden cannot be estimated with precision from the peripheral density at 
any single time-point. 
 
1.6.1 Estimating parasite loads using statistical models of parasite dynamics 
The need for measures of total parasite burden has led to considerable attempts 
using mathematical applications (modelling) to enable further understanding of the 
dynamics of P. falciparum infections, including several recent attempts that have been 
made to model parasite loads within patients. 
Davis and others (1990) were able to estimate the sequestered load in non-
immune Thai adults with severe malaria by describing the fall in haematocrit using three 
equations; (1) initial fall in haematocrit during first few hours leads to an increase in 
plasma volume, (2) zero order fall with a mean half-life of 25 hours occurred with a fall 
in parasitaemia (3) a fall with a half-life of 62 days due to loss of uninfected RBCs.  
Their model consisted of two compartments, circulating and sequestered cell volumes 
and they considered estimates before and during antimalarial therapy.  The model relies 
on several assumptions: (1) the body to peripheral venous haematocrit ratio remains 
constant throughout treatment and (2) the levels of sequestration are low.  These methods 
have not however, been verified in children or adults and have not as yet provided a 
generally applicable means of quantifying the sequestered loads and hence need to be 
further validated. 
Further studies to estimate the sequestered load have been reported by Gravenor 
and others (Gravenor et al 1998).  An age-structured model that described the flow rates 
between parasite stages using differential equations (Markov process) was developed.  It 
comprised both circulating and sequestered compartments that made use of estimates of 
sequential counts on blood samples.  Various parameters were generated from known 
data, the rate of transition between compartments, parasite death rate and release of new 
offspring.  All these parameters were based on previous in vivo or in vitro assessments  
(Gardner et al 1996,Gravenor et al 1995,Silamut and White 1993).  This model was 
validated in children attending a hospital in Gambia presenting with CM and who were 
administered artemether and quinine (Gravenor et al 1998).  The authors found a 
relationship between the estimated number of sequestered parasites at the start of 
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treatment and the severity of the disease.  The models were consistent with observations 
from in vitro studies that showed artemether as being more effective in clearing young 
ring stage parasites and preventing sequestration, whilst quinine mainly clears 
trophozoites and schizonts (ter Kuile et al 1993).  Though this process captures many 
aspects of sequestration it assumes a constant transition rate between compartments, 
which does not happen in nature due to the fact that an infected person undergoes many 
changes as a result of immune pressure in addition to other host or parasite factors 
possibly contributing to variations within each compartment.   
To address this problem, Gravenor and others (2002) modified the model 
developed earlier by reducing the variation in cycle length by increasing the number of 
compartments, thus providing estimates for some parameters via a second fitting method.  
The model was assessed in two sets of patients on quinine treatment, one set with 
irregular sampling intervals and the other with a structured sampling frame (samples 
taken every 6 hours).  When the model was initially fitted to in vitro data on the number 
of parasites in each stage, they found that it adequately described the parasites that would 
have been sequestered if in vivo.  However, when analysed in patients with irregular 
sampling they found that although the model fitted the peripheral counts, the range of 
predictions for sequestered loads were too wide.  The authors described a relationship 
between initial temperature and changes in the first 6 hours with sequestered parasite 
density.  This increase in temperature is thought to represent schizont rupture that 
precipitates a cascade of events within the host.  The Model, though appropriate, gave 
poor estimates of sequestered loads even using 6 hour intervals.  Without reliable 
methods for determining parasite loads or good correlates of by-products measured in 
vivo, parameters used for modelling cannot be estimated with confidence.  
Another discrete-time age-stage model was recently developed for estimating the 
sequestered parasites in 107 paediatric patients with P. falciparum in a randomised 
control study of quinine and artemether in Kilifi, Kenya (Smith et al 2004).  Parasite 
loads were modelled using 4 hourly peripheral parasitaemia determinations.  This method 
differs from those of Gravenor et al (1998, 2002) in that it assumes a fixed duration of the 
asexual cycle of the parasite.  Furthermore, this discrete time approach allows the model 
to be fitted simultaneously to the entire dataset, allowing point and interval estimates for 
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both population and individual patient parameters.  The model gave good estimates of the 
distribution of parasites at different stages in simulated test datasets, but still relies on 
blood smears in order to determine sequestered loads.  This model was developed with 
the aim of using it as an alternative method for cross validating biochemical approaches 
for estimating the sequestered load.  In vivo measures of parasite and host factors have 
never been assessed before as markers of sequestration and hence, this model would 
enable us to have a better understanding of malaria. 
 
1.7 Biochemical and haematological markers of sequestration 
The most obvious method for estimating the burden of sequestered parasites is to 
measure the concentration of one of their products.  The trophozoite and schizont stages 
that sequester release various biochemical products such as parasite antigens, molecules 
that are by-products of glycolysis or protein synthesis, merozoites and pigment into the 
blood stream.  Human host products might also be upregulated by factors produced by 
these sequestered stages or maybe released from damaged RBCs or other cells.  
Quantification of either parasite or host products unique to these stages that are released 
into the bloodstream could correlate with sequestered loads and thus provide ways to 
estimate sequestered loads or the total parasite biomass. 
 
1.7.1 Host Biochemical markers 
 
Cytokines 
The various cytokines up-regulated as part of the fever response, in particular 
TNF-α, and host endothelial receptors correlate with severity of disease and thus may 
correlate with sequestered mass.  Candidate markers include TNF-α itself, and IL-10, (in 
severe anaemia high ratios of TNF-α to IL-10 were observed (Dodoo et al 2002).  From 
measurements of cytokines taken over a 5 day period from patients with severe malaria 
and who had starting parasitaemia of 5%, it was observed that there was an increase in 
the levels of TNF-α, IL-6 and IL-10 on admission, however, a significant decrease was 
observed during treatment (Vogetseder et al 2004), possibly reflecting reduced total 
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parasite burden.  TNF-α was found to be elevated in children who had died from severe 
malaria in two different settings, Malawi and Gambia (Grau et al 1989,Kwiatkowski et al 
1990) and TNF-α, IL-1 and IL-6 were further substantially higher in children with severe 
malaria than in uncomplicated malaria (Wassmer et al 2003). These host proteins are 
unlikely to be good measures of sequestered loads across groups of hosts of varying age 
and immunological status because their levels are heavily modulated.  But a study on 
asymptomatic children showed that sTNF-R75 levels are more stable than sTNF-R55 and 
are significantly associated with parasite densities (Hurt et al 1995). Therefore, this 
molecule may be worth evaluating as a candidate indicator of schizogony and thus 
sequestered load. 
Some of the proteins involved are not good candidate markers of sequestration 
because they do not specifically indicate tissue damage caused by cytoadherence.  The 
release of soluble endothelial receptors ICAM-1, ELAM-1, VCAM-1 and laminin occur 
during acute P. falciparum malaria attacks (Wenisch et al 1994) but these are also found 
in P. vivax malaria (Jakobsen et al 1994,Kern et al 1992) in sepsis and in rheumatoid 
arthritis (Leeuwenberg et al 1994).  Some markers have complex non-linear relationships 
with levels of cytoadherence.  For instance studies under shear conditions showed that the 
selective up-regulation of CD36 with IFN-γ increases cytoadherence of IRBC in certain 
strains of P. falciparum (Johnson et al 1993). TNF-α together with Interferon-γ (IFN-γ) 
result in up-regulation and redistribution of endothelial receptors ICAM-1 and CD31 
(Chen et al 2000), and so might well increase levels of cytoadherence. 
 
Host red cell components 
Any molecule that is released from an infected red cell when it undergoes 
schizont rupture ought to be a potential marker of the true sequestered parasite biomass.  
Humans release natural antibodies to the most abundant proteins spectrin and band-3 
situated on the RBC membrane and involved in clearance of senescent human 
erythrocytes (Lutz et al 1987,Lutz and Wipf 1982).  The actual titre of these auto-
antibodies may relate to the degree of cell lysis, with higher levels in patients with 
increased destruction of RBCs and lower levels in healthy people.  Studies have 
described the elevation of autoantibodies titres to cytoskeleton RBC spectrin, in patients 
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with autoimmune cytotoxic reactions, viral infections and in patients with chronic active 
hepatitis (Chaponnier et al 1977,Garbarz et al 1981).  P. falciparum contains proteases 
that hydrolyse spectrin (Le Bonniec et al 1999) cleaving it into rather large pieces thus 
allowing for the possible loosening of the cytoskeleton without loss of antigenicity.  
Though release of spectrin and up-regulation of these natural antibodies may be a good 
measure of schizont rupture, the modulation by the immune system by cytokines and 
destruction of RBCs resulting in anaemia, makes it unfeasible to measure such proteins.   
 
Other host factors 
Alterations to other host factors such as packed cell volume (PCV), damage to 
host tissues due to P. falciparum infections, or to release of toxins as a result of schizont 
rupture could act as an indirect measure of the sequestered load.  RBC destruction as 
established earlier, may either contribute to anaemia as well, it may cause a drop in the 
haematocrit or PCV to levels below 45% of the optimal level (Riley et al 2001).  
Measuring changes in the haematocrit due to RBC destruction during schizont rupture 
may act as an indirect proxy for total parasite biomass.  In addition, malaria infections 
have been postulated to lead to host tissue damage with concomitant release of 
circulating host DNA (β-globin gene); this presumably could be another marker of 
pathology (Saiki et al 1985) relating to parasite biomass.  
 
1.7.2 Parasite markers 
Infected erythrocytes release parasite products into the blood stream using several 
mechanisms which include active transport of antigens (HRP2, S antigens, D-lactate) and 
schizont rupture.  In all cases, one would expect the amounts released into the circulation 
are proportional to the parasite biomass, though this may be affected by metabolism and 
clearance kinetics. 
 
Malaria pigment 
The malaria pigment or haemozoin is produced by malaria parasites during their 
intra-erythrocytic development as the end product of haemoglobin digestion (Krugliak et 
al 2002,Rosenthal and Meshnick 1998,Slater et al 1991).  At schizogony, the mature 
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sequestered parasite bursts releasing a new generation of daughter merozoites into the 
bloodstream and these invade new erythrocytes, leaving behind a ruptured red blood cell 
host in addition to exposed parasite remnants that include pigment (Nguyen et al 1995).  
It can be assumed that the amount of pigment released is in proportion to the number of 
schizonts in the body.  The insoluble pigment is phagocytosed by scavenger 
polymorphonucleated cells (PMNs) and monocytes and is easily detected by light 
microscopy.  Studies carried out to assess pigment in PMNs and monocytes showed a 
correlation with disease severity (Amodu et al 1997,Amodu et al 1998,Day et al 1996).  
Among severe malaria patients, those who died had significantly higher numbers of 
pigments in neutrophils and monocytes (Nguyen et al 1995).  Children with CM had 
more pigmented neutrophils on admission in contrast children with anaemia had higher 
levels of pigments in monocytes (Lyke et al 2003). 
 
Histidine rich protein 2 
At schizogony, the parasite bursts releasing various proteins, one of which is 
histidine rich protein 2 (HRP2).  This water-soluble protein has been extensively studied 
as a marker of parasites and furthermore, it has been developed as a diagnostic reagent. 
HRP2 synthesis begins in the immature stages (rings) and continues through to the 
trophozoite stage (Howard et al 1986).  HRP2 forms part of the knob structure on the 
surface of IRBCs involved in cytoadherence.  This protein is further secreted both from 
intact RBCs and during schizont rupture (Desakorn et al 1997,Desakorn et al 
2005b,Taylor and Voller 1993). 
Immobolisation of HRP2 antibodies on nitrocellulose membranes in the form of a 
dipstick allows for the measurement of this antigen in both whole blood and plasma. 
Detection levels are equivalent to >100 parasites/µl in whole blood and 1600 parasites/ µl 
in plasma (Desakorn et al 1997).  These dipsticks have been used extensively in 
diagnosing malaria and comparison to the “gold standard” of microscopy, both in clinical 
and epidemiological studies with varying results for sensitivity and specificity.  These 
range from 88% and 87.5% in clinical cases (Shiff et al 1993), 94% and 99% non-
endemic settings which takes into account travellers (Iqbal et al 2001) and 11% to 100% 
and 84% to 96% in epidemiological studies (Beadle et al 1994) respectively.   
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Though these dipsticks allow for the determination of HRP2 and thus presence of 
malaria, they are unable to quantify parasite load and for this, one requires blood smears.  
Furthermore, HRP2 has a low elimination rate persisting for up to 3 weeks in the 
bloodstream (Mayxay et al 2001) leading to false positives and mis-diagnosis.  Desakorn 
and others (2005) recently quantified the stage specific release of HRP2 from in vitro 
cultures of P. falciparum using a quantitative antigen capture enzyme-linked 
immunosorbent assay (ELISA), which confirmed that HRP2 is released during the mature 
trophozoite stage.  They calculated the median (range) of HRP2 released at ring stages to 
be 2.0×10-6 ng (0.5 to 4.3×10-6 ng) whilst schizont stages released 5.4×10-6 ng (2.1 to 
10.2×10-6 ng) per parasite.  Dondorp and others (personal communication) recently used 
these in vitro counts of HRP2 to assess the total parasite biomass in acute falciparum 
malaria in patients in Thailand.  They assumed that patients were infected with a single 
synchronous infection of P. falciparum.  Using the rate of release at schizont rupture 
from in vitro data, the number of parasites present at schizont rupture which was 
calculated from parasite density, together with a multiplication factor which takes into 
account expansion of infection, the total blood volume which was representative of HRP2 
blood volume as well as elimination half-life estimated from adult patients, the authors 
estimated the total parasite load. 
 
Parasite lactate dehydrogenase 
Intra-erythrocytic parasites require high levels of energy for their rapid 
multiplication rates.  As in human erythrocytes, glycolysis forms part of the major 
metabolic process generating adenosine triphosphate (ATP) as its energy source (Basco 
et al 1995).  Lactate dehydrogenase (LDH) plays an important role in the metabolism 
process of the parasite.  Parasite Lactate Dehydrogenase (pLDH) metabolises pyruvate to 
lactate and regenerates NAD, a requirement for ATP production in the glycolysis 
pathway.  One biochemical characteristic that differentiates this enzyme from human 
LDH is its ability to utilise the analog of, 3-acetyl pyridine Nicotinamide Adenine 
Dinucleotide (NAD) APAD+ at a higher rate than the human enzyme (Basco et al 
1995,Makler and Hinrichs 1993).  This property has been exploited in a dipstick, and 
allows for the detection of pLDH antigen in serum and whole blood (Makler and Hinrichs 
 23 
1993,Piper et al 1999).  In the same way as HRP2, pLDH dipsticks have shown varying 
sensitivities and specificities.  In clinical cases from endemic areas the values are 88% 
and 99% (Palmer et al 1998), in non-endemic setting they are 95.3% and 100% (Taylor et 
al 2002), whilst in epidemiological studies the values are 100% and 95% (Quintana et al 
1998) respectively.  Since pLDH is extremely labile and is presumably released into the 
serum at schizont rupture, it is potentially a good marker for the number of schizonts. 
 
D-lactate 
P. falciparum IRBCs release both L-lactate and D-lactate with particularly high 
rates from trophozoite or schizont stage parasites (Vander Jagt et al 1990) due to the high 
rate of glucose consumption.  Humans produce only L-lactate as a product of glycolysis  
(Berg et al 2002) and not D-lactate, though elevated concentrations of D-lactate have been 
found in serum of patients after gastrointestinal surgery (Thurn et al 1985) when it is 
produced by abnormal intestinal bacteria, as well as in patients suffering from diabetes 
mellitus and this impacts on the rate of glycolysis (Christopher et al 1995).  In P. 
falciparum it represents between 6 to 7% of the total lactate released by parasites and 
would allow for differentiation between parasite and host metabolism.  Quantification of 
D-lactate in malaria might provide a general indicator of the total load because in contrast 
to parasite protein, this should not stimulate an immunological response from the host. 
 
Circulating parasite DNA 
Both conventional polymerase chain reaction (PCR) and real-time PCR can detect 
specific DNA or ribonucleic acid (RNA) sequences using nucleic acid-based probes 
(Weiss 1995).  Several methods have exploited the use of small subunit rRNA gene, 
repetitive satellite DNA, dihyrofolate reductase-thymidylate synthase gene or the 
PF155/RESA (ring infected surface antigen) gene as part of the PCR assay as a means of 
diagnosing malaria parasites.  Both these PCR assays can detect circulating parasite DNA 
(pDNA) in the blood circulation even in situations where patients have less than 5 
parasites/µl (Grobusch et al 2003).  Circulating pDNA can also be detected in plasma 
(Gal et al 2001) which is suggestive of its release during schizont rupture (our 
unpublished observations).  
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Real-time PCR is a relatively new method and though able to quantify pDNA in 
both plasma and whole blood (Gal et al personal communication), is not available for 
studies in endemic areas where it could be used to quantify free DNA in plasma which 
was suggested correlated with sequestered load as it is released during schizont rupture 
(Gal et al 2001).  Therefore, quantification of pDNA, which has just been mentioned as 
being unique to the schizont stages, could provide an alternative method for estimation of 
sequestered loads. 
 
1.8 Rationale and research framework 
As highlighted earlier the quantification of cytoadherence of P. falciparum in 
deep vascular beds still remains unresolved and  
 
“When you cannot measure it, when you cannot express it in numbers, you 
have scarcely….advanced to the stage of Science, whatever the matter may be” 
William Thomson, Lord Kelvin 1824-1907. 
 
Clearly without an indication of the total parasite load in a malaria patient, we are unable 
to fully understand disease pathology and progression.  This report aims to describe 
methods used for measuring sequestered loads as well as using the resulting data as a 
means of validating statistical models for estimating sequestered loads in P. falciparum 
malaria. 
In summary the next chapter (Chapter 2) briefly describes the objectives of this 
study and study area and population.  This is followed by (1) Chapter 3 which reviews 
current methods available for malaria diagnosis (2) Chapter 4 which discusses methods 
for quantification of stage specific release of parasite markers (3) Chapter 5 which 
assesses levels of parasite markers and a host receptor in malaria patients (4) Chapter 6 
which assesses the measurement of HRP2 as a way of improving clinical diagnosis (5) 
Chapter 7 which considers estimates of sequestered loads and biochemical parasite and 
parasite markers of sequestration in severe malaria cases.  The final chapter (Chapter 8) 
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discusses all the results and makes recommendations for further work in this area of 
research. 
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Chapter 2 
 
 
General Objectives and Study Population 
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2.1 Study Goal 
P. falciparum sequestration deep within vascular beds has been studied in great 
depth using molecular techniques and assessed using mathematical models to promote 
better understanding of the complex interaction between host and parasite but 
quantification of the “hidden” mass of parasites is still not possible.  Our main aim was to 
develop and validate method(s) for routine assessment of P. falciparum malaria. 
 
2.2 Specific Objectives 
• Assess current methods that are used to diagnose malaria, without the use of a 
“gold standard”, especially given that microscopy is not always reliable at low 
parasite densities or parasites are not observed. 
• To establish in vitro parasite biochemical markers released by P. falciparum 
trophozoite and schizont stages known to sequester in vivo. 
• To establish the performance of assays to measure D-lactate, HRP2, pLDH, and 
sTNF-R75 in plasma samples from patients. 
• Quantify the levels of HRP2 in severe cases, mild cases, controls slide positive 
and negative for malaria parasites to see if this protein is useful in differentiating 
severity of disease (Ethical clearance, Appendix 4). 
• To determine candidate markers of sequestration in vivo, by measuring host and 
parasite markers in severe patients to see if these correlate with measures of 
sequestered load established using statistical methods (Smith et al, 2004).  
Appendix 1 and 3 (SOPs, consent form); full details of other methods: pDNA, 
human DNA (Appendix 6), sTNF-R75 
 
2.3 Study Area, Population 
 
2.3.1 Study Area 
These studies were carried out at the Kilifi District Hospital, Kilifi district which 
is 60 km north of Mombasa on the Kenya Coast (Figure 3).  The district has a savannah 
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type vegetation and lies between latitudes -3° 38′ South of the equator and between 
longitudes 39° 51′ East of the zero meridian.  It covers an area of 12,646 km2 including 
109 km2 of water surface in the Indian Ocean.  The hospital serves nearly 100,000 people 
consisting of government officials and traders in Kilifi town (21%) and inhabitants of 
rural homesteads which form the majority of the population (79%) along the coast and 
inland (Snow et al, 1994).  The population are predominantly Giriama, a sub-group of the 
Miji Kenda ethnic group that comprises of nine closely related subgroups. The rural 
communities are predominantly farmers of maize and cassava for consumption and 
coconut and cashew nut as cash crops. 
Malaria transmission is perennial with peaks following the main rainy season in 
April and September. The main mosquito vectors are the Anopheles gambiae complex 
and A. funestus (Mbogo et al., 1995). Data from a paediatric ward death survey between 
1991 and 1995 put the yearly malaria-attributable mortality at 1.2 per 1000 in children 
below 4 years. However, it is estimated that twice as many children die at home and the 
corrected rate is 3.8 children per 1000 per year (Snow et al., 1998a). Although 
transmission is higher south of the creek (EIR= 60-200) than north of the creek (EIR= 10-
30), the rate of children admission to hospital with severe malaria differs in a somewhat 
paradoxical manner so that it is higher in the north than it is in the south:  25.9 vs. 16.7 
per 1000 children under the age of 10 years (Snow et al., 1997). 
 
2.3.2 Study Population 
The KEMRI-Wellcome Trust Programme is closely linked to the Kilifi District 
Hospital comprising an out-patients department (OPD), general paediatric ward (Ward 1) 
and high dependency unit (HDU) that sees more than 5000 paediatric admissions a year.  
This link provides the basis for a comprehensive clinical surveillance system and 
underpins the Programme's research activities on severe childhood illnesses.  The Unit is 
primarily a malaria research centre with interests in related areas, including Respiratory 
Syncital Virus, Pneumococci Bacteria study and community Based Research.   
Children less than 6 years of age, admitted into the HDU ward were defined as 
severe malaria cases if they had a primary diagnosis of P. falciparum malaria by blood 
smear, had no other detected cause for their illness and had one of the following:(1) 
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Prostration (2) Respiratory distress (3) Severe anaemia (Haemoglobin less than 5 gd l-1) 
(Marsh et al, 1995).  Parental consent was obtained.  All patients were treated with 
intravenous quinine and received full supportive therapy as described elsewhere (Murphy 
et al, 1995). 
2.4 Ethical Considerations 
 
The proposal for this study was reviewed and passed as ethically acceptable by 
the Kenya National Ethic review board. In addition, a fully informed consent (Appendix 
1) was obtained from parents/ guardians on their own or on behalf of their children.  For 
additional screening of the quantitative HRP2 method an addendum to the parent is 
included in Appendix 2. 
Kilifi
Malindi
Mombasaasa
ilifi
alindi
 
Figure 2.1 Map of Kenya, showing location of Kilifi Town (Mbogo et al, 2003) 
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1 Abstract 
 
Background 
Recently, rapid diagnostic tests (RDT) for malaria have been developed for detecting and 
quantifying malaria parasites in humans. Estimates of sensitivity and specificity of these 
tests have usually been made by using optical microscopy as a “gold standard”. This 
makes it difficult to assess their reliability for the diagnosis and management of clinical 
malaria in different population groups since optical microscopy is itself error prone. We 
conducted a systematic review on available literature to identify the most appropriate 
tests for different circumstances.  
Method 
We searched articles in the Medline and Pubmed databases, and selected those papers in 
which the RDTs could be compared to Giemsa stained method. Sensitivity and specificity 
of each RDT and microscopy were estimated using a statistical method that avoided 
defining either as a “gold standard”. 
Results 
Out of 891 papers published between 1966 and 2004 only 48 papers were selected. The 
perfomance of these tests for diagnosis and managemant of clinical malaria vary 
depending on species of the malaria parasite, level of parasitaemia, immunity and age of 
the subjects. Histidine Rich Protein-2 (HRP2) based dipsticks performed better than 
microscopy in determining P.falciparum infections in clinical cases in endemic areas 
with an overall sensitivity (92.7%; 95% credible interval [CI] 91.0, 94.5) and high 
specificity (99.2%; 95%CI 98.2, 99.9).  The Acridine Orange (AO) test was more 
sensitive than microscopy in determining P.falciparum infections in field studies in 
asymptomatics with an overall sensitivity (97.1%; 95%CI 94.9, 99.4) and specificity 
(97.9%; 95%CI 95.2, 99.8). Methods detecting parasite lactate dehydrogenase (pLDH) 
are best for monitoring treatment during falciparum malaria infection.  
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Conclusion 
HRP2 dipsticks perform better than microscopy in detecting falciparum infections in 
clinical cases in endemic areas whilst AO is suitable for asymptomatic infections. 
Microscopy detects non-falciparum infections more reliably than do the RDTs. The 
pLDH dipsticks are suitable for monitoring response to treatment. 
 
3.2 Introduction 
 
One of the main interventions of the global malaria control strategy for effective disease 
management is prompt and accurate diagnosis (WHO 2000). The detection of 
Plasmodium species using microscopic examination of blood smears has been the most 
widely used technique for detection of malaria parasites but is laborious, requires 
experienced technicians and is an imperfect “gold standard” (Collier and Longmore 
1983,Payne 1988). Over the past two decades rapid diagnostic tests (RDTs) for malaria 
have been developed. These include tests based on histidine rich protein 2 (HRP2), 
parasite lactate dehydrogenase (pLDH)/OptiMAL®) and fluorescent microscopy 
including quantitative buffy coat (QBC) and acridine orange (AO) based tests 
(Kawamoto 1991,Long et al 1991,Moody et al 2000,Singh et al 1997). 
The accuracy of these RDTs for the detection of malaria parasites and management of 
clinical malaria in different population groups under different settings has not been 
clearly established. A number of studies have reviewed the sensitivity and specificity of 
RDTs (Cruciani et al 2004,Hanscheid 1999,Keiser et al 2002,Moody 2002,Murray et al 
2003,Wongsrichanalai 2001).  Other studies assessed sensitivity and specificity in 
different populations and epidemiological settings with optical microscopy as a “gold 
standard” (Arora et al 2003,Beadle et al 1994,Fryauff et al 2000). However, the 
sensitivity of optical microscopy is limited and can vary greatly especially at low parasite 
densities (Coleman et al 2002c,Craig and Sharp 1997). Where comparisons of different 
diagnostic techniques have been made in more than one population, it is possible to 
estimate sensitivity and specificity without assuming any of the methods to be perfect 
(Johnson et al 2001,Joseph et al 1995). 
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In this paper, we conducted a systematic review to assess the accuracy of RDTs in the 
detection, diagnosis, and management of clinical malaria in endemic areas, non-endemic 
areas (travelers), and epidemiological studies in different populations across the globe 
without the presence of a “gold standard”. 
 
3.3 Methods 
 
Search strategy 
Studies on malaria diagnosis in populations from endemic and non endemic regions 
including those of non-immune travelers were considered for inclusion in this review. 
Literature searches were carried out using three databases: MEDLINE® (1966 – Dec 
2004) and PUBMED® (1966 – Dec 2004) using a combined text word (malaria diagnosis 
test NOT review OR letter) and MESH or subject heading to identify relevant papers. 
Additional articles were identified by hand searching the bibliographies of these papers. 
The strategy was developed by breaking the review question into its elemental facets, as 
recommended by the National Health Service Centre for Reviews and Dissemination 
(Khan et al 2001). To increase the sensitivity and specificity of the search, two trial 
searches were conducted before the final search was completed. Publication language 
was restricted to English and French. The bibliographies of key references were later 
hand-searched to identify articles missed in the database search. Full details of the search 
strategy are available from the corresponding author (LO). 
 
Selection Criteria and data extraction 
We selected studies using the following inclusion criteria (1) study population described 
in detail, to include age (2) type of study, either epidemiological or clinical, (3) RDTs 
compared to Giemsa, (4) species of Plasmodium defined (5) statistical methods for 
calculating and comparing measures i.e. sensitivity, specificity defined, (6) the range of 
parasitaemia given, (7) report estimate of diagnostic accuracy, (8) interpreted findings. 
Reviews were excluded. Data on the above inclusion criteria were extracted and 
tabulated. 
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Statistical analysis 
We used the statistical approach of Johnson et al. (2001) for estimating sensitivity and 
specificity in the absence of a gold standard. We extended the model to simultaneously 
include multiple studies. This method assumes that there is a single, true but unobserved 
prevalence of P. falciparum and non-falciparum in each study, common sensitivity and 
specificity of each RDT across the group of studies and common sensitivity and 
specificity of microscopy. Results (+/-) from each RDT (say T1) were cross classified 
with the results of the microscopic examination (say T2). The joint distribution of the 
results of the two tests T1 and T2 was assumed to be multinomial with four categories 
corresponding to all possible combinations of the results of the two tests, that is ++, +-, -
+,--, where the first reading refers to T1 and the second reading T2. The multinomial 
probabilities were expressed as functions of the prevalence of P. falciparum and of the 
sensitivities and specificities of the two tests. We also assumed independence of the 
studies conditional on the sensitivity and specificity parameters. We formulated the 
model within the Bayesian framework and assumed Uniform prior distributions U(0.5,1) 
for all model parameters. For the purpose of identifiability of the diagnostic error 
parameters we constrained their prior distributions to be greater than 0.5. Estimation was 
carried out using Markov chain Monte Carlo (MCMC) simulation in the statistical 
software Winbugs 1.4. (Imperial College and MRC, UK.). Separate analyses were run for 
the clinical studies and for the field studies. 
 
3.4 Results 
Available data 
We found a total of 891 of papers on malaria diagnosis published between 1966 and 
2004. However, only 177 studies from 1980-2004 were retrieved using the search 
strategy. These varied in the study populations, from people living in endemic areas, 
semi-immunes to travelers and other non-immune populations. Using the selection 
criteria, 48 papers were selected for inclusion in the present analysis. 
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Techniques for detecting malaria parasites in the blood are summarized in Table 3.1. 
These include conventional microscopy using Giemsa, Field, or other stains. Giemsa 
stain has the widest application. Fluorescent microscopy involves the staining of the 
parasite with fluorescent dyes such as AO, or QBC that utilize centrifugation to separate 
infected red blood cells stained with acridine orange. Immunological-based methods 
involve immobilizing antibodies to parasite antigens, parasite lactate dehydrogen (pLDH/ 
OptiMAL) and histidine rich protein 2 (HRP2) in a dipstick assay. The pLDH dipstick 
consists of a soluble glycolytic enzyme that is expressed at high levels in asexual stages 
of malaria parasites. In contrast HRP2 dipsticks have a water soluble species specific 
protein produced by asexual stages and young gametocytes of Plasmodium spp. Several 
commercial dipsticks have been produced for detection of HRP2 in P. falciparum: 
ParaSight F (Becton Dickinson), Immunochromatographic test (ICT) Pf (Amrad ICT) 
and Program for Appropriate Technology in Health (PATH) Falciparum malaria 
immunochromatographic (IC) test.  Since they all measure the same antigen, for the 
purpose of this review, we have considered them all as a single HRP2 diagnostic tool. We 
did not consider studies of conventional PCR and the novel real-time PCR because, 
though very sensitive (detecting ≤ 5 parasites/µl, (Hanscheid and Grobusch 2002) is not a 
rapid technique and is not used for routine diagnosis of malaria. Another method that 
uses automated flow cytometry was also not considered because the cost of the machine 
and maintenance limits its use in resource poor countries. 
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Table 3.1 
Techniques currently available for detecting malaria parasites 
 Technique Plasmodium spp. Limits of 
detection /µl 
References 
Presence of Plasmodium 
spp. (Thick film) 
5 to 20 Microscopy Stains: 
Giemsa 
Field 
JSB 
Leishman/ Wright 
All Plasmodium spp. 
(Thin smear) 
50 to 200 
Moody 2002 
Shute 1988 
AO Presence of Plasmodium 
spp 
100 Kawamoto 1991 
Moody 2002 
QBC Presence of Plasmodium 
spp 
100 Moody 2002 
Wongsrichanalai et al 
2002 
Fluorescent 
microscopy 
Rhodamine 123 Presence of Plasmodium 
spp 
ND Srinivasan et al 2000 
pLDH (OptiMAL®, 
DiaMed) 
specific to P. falciparum, 
non-falciparum spp. 
100 Moody 2002 
Quintana et al 1998 
Antigen 
HRP2 (10 dipsticks include 
ICT, PSF, KAT) 
All Plasmodium spp, 
specific to P. falciparum, 
 P. vivax 
100 Moody 2002 
Singh et al 2000 
PCR genomic DNA, DHRS 
gene, 
18S rRNA, CS, SSU rRNA 
gene 
<5 Moody 2002 
Snounou et al 2002 
Molecular 
Real time-PCR SSU rRNA 
gene, 18s rRNA 
 
All Plasmodium spp 
0.7 (Pf) 
4 (Pv) 
1.5 (Po) 
Lee et al 2002 
Perandin et al 2004 
Automated, 
Flow 
Cytometry 
Haemozoin  
(Full blood count) 
Presence of Plasmodium 
spp 
2×104 PCM Grobusch et al 2003b 
Mendelow et al 1999 
 
JSB, Jaswant Singh Battacharji ICT, ICT malaria Pf test, PSF, ParaSight F, KAT, KAT-Quick Malaria 
test, DHRS, dihydrofolate reductase-thymidylate synthetase, CS circumsporozoite,rRNA ribosomal RNA, 
SSU, small subunit, Pf, P.falciparum, Pv, P. vivax, Po P. ovale, PCM, pigment containing monocytes 
ND, no data 
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Among the selected publications of RDTs, HRP2 was the most studied method (n=28) as 
compared to Giemsa. This was followed by pLDH (n=16). The least studied RDTs were 
the fluorescent methods such as QBC (n=6), and AO (n=5), although the former is no 
longer available. 
 
Diagnostic performance of microscopy 
As observed by microscopy (Tables 3.2 and 3.3), clinical cases of malaria admitted to 
hospitals in endemic areas have higher parasite densities than asymptomatic cases from 
field studies (Arora et al 2003,Bualombai et al 2003).  This leads to higher estimates of 
the sensitivity and specificity for P. falciparum and non- falciparum infections (Table 3.5 
and 6). Our analysis showed that microscopy was more sensitive than pLDH or QBC at 
screening for infections of Plasmodium spp. in clinical cases in endemic areas and in 
field studies of asymptomatics. Microscopy also performed better than AO in clinical 
cases with an estimated sensitivity of 96.2% (CI, 95% 91.9-99.8), but not in 
epidemiological studies. The highest sensitivity estimates for P. falciparum and non-
falciparum infections was 99.5% (95% CI, 98.1-99.9) and 99.1% (95% CI, 96.9-99.9) 
respectively for clinical studies in non-endemic areas (travelers) (Tables 3.5, 3.6). 
Estimates of specificity were always above 95.9% and were even 99.9% in some 
instances. 
 
Diagnostic performance of Histidine Rich Protein 2 (HRP2) 
HRP2 tests demonstrated high sensitivity estimates of 92.7% (95% CI, 91 to 94.5) in 
detecting P. falciparum infections in clinical cases in endemic areas while the specificity 
was 99.2% (95% CI, 98.2 to 99.9) (Table 3.5). In a study using microscopy as a gold 
standard, the sensitivity when measured post admission was only 74% (Mayxay et al., 
2001). Two studies on non-falciparum infections that used microscopy as a gold standard 
had low sensitivities (Table 3.2) (Huong et al 2002,Mason et al 2002). This was due to 
the poor diagnostic quality of the dipsticks used. The mean sensivity of HRP2 to detect 
falciparum infections in travelers from non-endemic areas (n=2 studies) when compared 
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to microscopy was 88.2%, and a specificity of 96.8% (Table 3.3). A single study 
comparing HRP2 dipsticks to microscopy yielded a sensitivity of 57.9% and a specificity 
of 99.5% for non-falciparum infections (Gatti et al 2002).  Epidemiological studies (n=9) 
of falciparum infections (Table 3.5) yielded a lower estimate of sensitivity than the 
clinical cases, viz., 88.1% (95% CI, 86 to 90.2) and a high specificity of 99.9% (95% CI, 
99.7 to 100). The sensitivity estimates for non-falciparum infections (n=4) was 52.2% 
(95% CI, 0 to 51.8) and a specificity of 99.9% (95% CI, 0 to 99.9) (Table 3.6c). 
 
Diagnostic performance of parasite lactate deydrogenase (pLDH) 
pLDH based tests had a sensitivity of 67.1% (95% CI, 62.8 to 71.3) and a specificity of 
98.4% (95% CI, 97.5 to 99.6) in falciparum infections in clinical cases in endemic areas 
(Table 3.5). In non-falciparum studies, the sensitivity was higher 97.6% (95% CI, 92.4 to 
99.9) while the specificity was 99.1% (95% CI, 98.5 to 99.8). In clinical cases in non-
endemic areas this method yielded a higher sensitivity 95.5% (95% CI, 92.1 to 98.4) and 
a specificity of 99.3% (95% CI, 98.7 to 99.8) for falciparum and sensitivity 95.9% (95% 
CI, 91.3-99.4) and a specificity of 99.8% (95% CI, 99.1-99.9) for non-falciparum 
infections (Tables 3.5 and 3.6). In epidemiological studies of falciparum infections the 
sensitivity was 71.1% (95% CI, 67.3 to 74.7) and specificity was 99.2% (95% CI, 97.5 to 
99.9) (Table 3.5) while for non-falciparum infections the sensitivity was 50.1% (95% CI, 
50 to 50.2) and specificity was 99.9% (95% CI, 99.6 to 100) (Table 3.6). 
 
Diagnostic performance of Quantitative Buffy Coat (QBC) 
Few studies have assessed the presence of parasites in clinical and epidemiological 
studies using QBC. In endemic areas, QBC had a high estimate of sensitivity 83.9% 
(95% CI, 79.5 to 88.0) and a specificity of 99.6% (95% CI, 98.9 to 99.9) for P. 
falciparum in clinical infections (Table 3.5) and a sensitivity of 85.9% (95% CI, 78.2 to 
92.4) and a specificity of 99.6% (95% CI, 98.7 to 99.7) for non-falciparum infections 
(Table 3.6). Comparison of epidemiological studies (n=2) to a gold standard of 
microscopy, gave a lower sensitivity of 72.5% and a specificity of 97.1% (Table 3.3). 
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One study on non-falciparum infections gave 84% and 76% for sensitivity and specificity 
respecitively (Clendennen, III et al 1995). 
 
Diagnostic performance of Acridine Orange (AO) 
This method, as with QBC, was used to detect malaria in clinical cases in endemic areas 
(Table 3.1) and in epidemiological studies (Table 3.3). AO had a high sensitivity 
estimated at 92.5% (95% CI, 82.8 to 99.7) and a specificity of 99.2% (95% CI, 97.9 to 
99.9) for P. falciparum infections in clinical cases in endemic areas (n=2), while in 
epidemiological studies (n=2), the sensitivity was 97.1% (95% CI, 94.9 to 99.4) and the 
specificity was 97.9% (95% CI, 95.2 to 99.8). In epidemiological studies on non-
falciparum infections (n=2), sensitivity was 86.7% (95% CI, 68.3 to 98.3) and specificity 
was 99.8% (95% CI, 99.4 to 100). 
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Table 3.2. Selected studies that compared Giemsa stained slides to RDTs in clinical cases in endemic areas 
First Author, Year RDT Country 
No. 
subjects 
Range of 
parasitemia/ 
µL 
Sensitivity 
(%) 
Specificity 
(%) 
Monitoring 
infection 
Other 
observations 
Prevalence 
by 
microscopy 
Estimate 
of true 
prevalence 
(Shiff et al 1993) HRP2, PSF Tanzania 138 40 to 4000 88.9 87.5 Pf, Po, Pm (5) false +ve 0.5 0.56 (0.49-0.62) 
(Caraballo and Ache 
1996) 
HRP2, PSF Venezuela 1398 >10 86.7 99.3 Pf  
0.22 0.22 (0.19-0.24) 
HRP2, ICT 92.3 (CI, 
83.4-96.8) 
92.2 (CI, 
84.7-96.3) 
(Kilian et al 1997) 
HRP2, PSF 
Uganda 180 >1 
87.2 (CI, 
77.2-93.3) 
96.1 (CI, 
89.7-98.7) 
Pf  
  
HRP2, ICT 89 100 0.55 0.54 (0.42-0.66) 
HRP2, PSF 86 93 0.55 0.57 (0.45-0.69) 
(Gaye et al 1998) 
HRP2,CELISA 
Senegal 66 500 to 86286 
88 87 
Pf, Pm, Po (4) False +ve 
with all RDTs 
(2) false –ve 
PSF, CELISA 0.52 0.57 (0.45-0.68) 
LS 93.5 86.2 0.51 0.58 (0.55-0.6) (Kilian et al 1999) HRP2, PSF Uganda 1326 >100 
HU 94.3 82.6 
Pf (89) False +ve  
0.53 0.58 (0.55-0.61) 
(Lema et al 1999) HRP2, PSF Kenya 213 >320 90-92 99 Pf, Po (1) False +ve, -
ve 
0.24 
0.25 (0.19-0.31) 
(Stephens et al 1999) HRP2, PSF Thailand 301 >500 88.7 88.3 Pf Mixed 
infections, (2) 
false -ve   
(Wongsrichanalai et al 
1999) 
HRP2 ICT Thailand 309 >60 90 96 Pf Gametocytes, (1) 
false -ve, (18) 
false +ve 
0.25 0.27 (0.22-0.32) 
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(Mayxay et al 2001) HRP2 PSF Thailand 
(adult) 
310 Pv >4968 
and Pf >76 
74 97.2 Pv, Pf patients post 
treatment (2) 
false +ve, 
gametocytes 
0.08 0.12 (0.10-0.15) 
(Wolday et al 2001) HRP2 RTM Ethiopia 306 >100 97.2 96.2 Pf, Pv False (10) +ve, -
ve (1) 
0.12 0.14 (0.10-0.19) 
HRP2, PC 97.4 88.1   
HRP2 PCD 97.2 87.7   
HRP2, PH 97.6 87.3   
HRP2, B 89.5 93.1   
(Guthmann et al 2002) 
HRP2, MR 
Uganda 600 ≥100 
98.3 75.3 
Pf false +ve (38) of 
which (12) had 
gametocytes 
  
HRP2 PC Site 1 55 to 100 100 Pf   
27 to 100 100 Pf   HRP2 ICT Site 1 
0 to 100 100 Pv   
HRP2 PC Site 2 88 to 100 100 Pf   
88 to 100 Pf   
(Huong et al 2002) 
HRP2 ICT, Site 2 
Vietnam 252 1000-100000 
0 to 89 
100 
Pv 
 
  
86.2 76.9 Pf, 0.41 0.54 (0.47-0.60) (Mason et al 2002) HRP2, ICT Thailand 229 61 to 300 
2.9 100 Non- Pf 
20% 
gametocyte, 
(13/34) false 
misdiagnosis Pf,  
poor for non-Pf   
(Mockenhaupt et al 
2002) 
HRP2, ICT Ghana 
Women 
596 0.001% to 
16% 
    
0.35 0.40 (0.36-0.44) 
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pg 50 to 800000 80 90 Pf 
95.2 (88.2-
98.7) 
94.9 (85.8-
98.9) 
Day 0, Pf False +ve (3) for 
Pv 
0.59 
 
0.61 (0.53-0.69) 
86 (72.1-
94.7) 
83.1 (73.3-
90.5) 
Day 3, Pf  
0.34 
0.44 (0.35-0.53) 
(Taylor et al 2002) HRP2, PSF Indonesia 152 20 to 74432 
75 (19.4-
99.4) 
83.7 (75.1-
90.1) 
Day 7, Pf  
0.04 
0.16 (0.10-0.24) 
(Arora et al 2003) HRP2, PSF India 200 1280 to 
516320 
94.4 88.2 Pf  
0.16 
 
0.16 (0.12-0.22) 
Peru and 98 22 Pf HRP2, FV 98 
Thailand 
(>18) 
OPD 
93 26 Pv 
 94 83 Pf HRP2, FV 99-1 
 93 26 Pv 
 98 93 Pf   
(Forney et al 2003) 
HRP2, FV 99-2 
 
4894 >500 
87 87 Pv 
Compared two 
countries, 3 
prototypes 
false –ve (<1%) 
  
(Buchachart et al 
2004) 
HRP2, KAT Thailand 90 11481± 5.0 
(88 to 
713838) 
96 (86..3 to 
99.5) 
92.5 (79.6 to 
98.4) 
Pf (3) false +ve, (2) 
false -ve 
0.56 0.59 (0.49-0.69) 
88 99 Pf 0.08 0.11 (0.10-0.15) (Palmer et al 1998) pLDH Honduras 202 50 to 60000 
94 100 Pv 
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100 90 Pf 0.07 0.13 (0.10-0.20) (Quintana et al 1998) pLDH  Honduras 84 ≥59100 
(average) 87 100  Pv 
 
  
(Aslan et al 2001) pLDH India 190 >500 91-100 100 Pv False –ve (5) 0.43 0.41 (0.33-0.48) 
80 to 6488 89.3 (70.6 to 
97.2 
100 (84.3 to 
100) 
Pf 
0.25 
0.26 (0.18-0.34) 112 
80 to 28800 98.2 (89 to 
99.9) 
96 (77.7 to 
99.8) 
non-Pf 
(1) False +ve, -
ve (3)  
Gametocytes 0.52 0.52 (0.42-0.61) 
80 to 20720 100 (39.6 to 
100) 
100 (75.9 to 
100) 
Pf 
  
(Ferro et al 2002) pLDH Colombia 
80 
Patients 
recruited 
during 
<1month 
160 to 20320 95 (85.2 to 
98.7) 
98 (89.9 to 
99.9) 
Pv 
 
  
9 to 69 Pf   pLDH site 1 
45 to 100 
100 
Pv   
29 to 91 Pf   
(Huong et al 2002) 
pLDH site 2 
Vietnam 252 1000 to 
100000 
10 to 100 
100 
Pv 
 
  
42.6 97 Pf 0.41 0.42 (0.36-0.49) (Mason et al 2002) pLDH Thailand 133 61 to 300 
47.1 96.9 Non Pf 
57% false –ve 
0.15 0.11 (0.10-0.14) 
78 98 BHU Pf 0.14 0.15 (0.12-0.17) 
61 98 BHU Pv 0.14 0.12 (0.10-0.15) 
85 76 DHQR Pf 0.22 0.23 (0.20-0.26) 
(Iqbal et al 2003) pLDH Pakistan 930 >500 
99 99 DHQR Pv 
1 to 2 % False 
+ve, species 
differentiation 
difficult 
0.22 0.18 (0.15-0.21) 
(Singh et al 2003) pLDH India 80 Pf 40 to 95.8 100 Day 0, Pf  0.3 0.31 (0.21-0.41) 
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370574 75 100 Day 2, Pf 0.21 0.25 (0.11-0.44) 
100 98.2 Day 0, Pv 0.28 0.29 (0.19-0.39) 
    
Pv 318 to 
9970 
100 82.6 Day 2, Pv 
 
0.04 0.16 (0.10-0.31) 
(Rickman et al 1989) QBC Philipines 180 3 to 89000 96 93 Pf, Pv, Pm No false +ve 0.56 0.59 (0.52-0.66) 
95 80 Pf 0.49 0.59 (0.53-0.65) (Wongsrichanalai et al 
1992) 
QBC Thailand 79 ≥150 
77 99 Pv 
(26) false +ve 
thick smear 
(23)false +ve 
AO, Pf 
gametocyes 0.20 0.20 (0.16-0.25) 
(Lema et al 1999) QBC, Field Kenya 213 ≥320 88-98 58-90 Pf, Po  0.29 0.4 (0.32-0.48) 
Pf 712.8 to 
1397.07 
  Pf 
0.06 0.10 (0.10-0.11) 
(Carrasquilla et al 
2000) 
QBC / PCR Colombia 833 
Pv 563.4 to 
1214.6 
  Pv 
False –ve (3) 
0.06 0.10 (0.10-0.11) 
(Caraballo and Ache 
1996) 
AO Venezuela 1398 ≥21 82.2 98.5 Pf  
0.22 0.21 (0.18-0.24) 
(Lema et al 1999) AOField Kenya 213 ≥320 81-98 81-90 Pf, Po  0.24 0.25 (0.19-0.32) 
 
HRP2 (histidine rich protein 2), PCR (polymerase chain reaction), pLDH (plasmodium lactate dehydrogenase), QBC (Quantitative buffy coat), AO (Acridine orange), OPD (out-patient dept.), Pf 
(Plasmodium falciparum), Pv (Plasmodium vivax), Po (Plasmodium ovale), Pm (Plasmodium malariae),  ICT (ICT malaria Pf test) Other HRP2 tests include: KAT; MM; CB; Q; PC; PCD; PH; B and 
MR, CELISA.  LS (Lab staff), HU (Health unit), three different ParaSight F  prototypes devices (Becton Dickinson Diagnostic systems) FV98, FV99-1, FV99-2, BHU (Basic health units), DHQC 
(District health quarter centre), magn (magnification) RTM Rapid Test Malaria, Quorum diagnostics Inc, Canada, number in paranthesis, number of patients, false +ve, no parasitaemia but RDT 
positive, false –ve high parasitaemia but RDT negative, pLDH P sp, contains pLDH enzyme common to the four Plasmodium species, CI (95% confidence intervals) 
*parasitaemia calculated using WHO criteria for severe malaria (Hänscheid, 1999). 
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Table 3.3. Selected studies that compared Giemsa stained blood smears to RDTs in clinical cases in non-endemic areas (travelers)  
First Author, year RDT Country No 
subjects 
Range of 
parasitaemia 
/µl 
Sensitivity 
(%) 
Specificity 
(%) 
Monitoring 
infection 
Other 
observations 
Prevalence 
by 
microscopy 
Estimate of 
true 
prevalence 
Pf 94.4 94.5 Pf   (Gatti et al 2002) HRP2, ICT Italy 241 50 to 1500000 
57.9 99.5 Non Pf 
False -ve 
(5/14),Pv, 
(18/19) Po   
HRP2, ICT 82 99 False +ve (4)   (Iqbal et al 2001) 
pLDH 
Kuwait 515 ≥40 
89 99.5 
Pf, Pm, Pv 
False +ve (2) 0.13 0.12 (0.10-0.15) 
95.3 100 Pf 0.56 0.56 (0.51-0.60) (Moody et al 2000) pLDH/ Field UK 636 5 to 50000 
96 100 Pv 
Gametocytes 
0.34 0.34 (0.29-0.39) 
(Hernandez et al 
2001) 
pLDH France 244 ≥150 80 98 Pf, Pv, Po, Pm gametocyte 
0.23 0.21 (0.16-0.27) 
99 99 Pf 0.15 0.15 (0.11-0.20) (Palmer et al 2003) pLDH USA 216 ≥5000 
94 100 Pv  
 
0.05 0.11 (0.10-0.13) 
 
PSF (ParaSight-F test), ICT (ICT malaria Pf test) * all ages or not specified, number in paranthesis, number of patients, false +ve, no parasitaemia but RDT positive, false –ve high parasitaemia but RDT 
negative 
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Table 3.4. Selected studies that compared Giemsa stained blood smears to RDTs in epidemiological studies 
First Author, Year RDT Country No. 
subjects 
Range 
parasitemia/ 
µl 
Sensitivity 
(%) 
Specificity 
(%) 
Monitoring 
infection 
Other 
observations 
Prevalence 
by 
microscopy 
Estimate of 
true 
prevalence 
121(adult) 11 to 100 90 (CI, 84 to 
96) 
0.57 0.61 (0.54-0.68) (Beadle et al 1994) HRP2 PSF Kenya 
173 
(children) 
>10 
39 to 100 87 (CI, 82 to 
91) 
Pf Gametocytes false 
+ve (17) 
0.45 0.53 (0.48-0.59) 
Iraniese 60 97 0.17 0.17 (0.13-0.21) (Fryauff et al 2000) HRP2 PSF Indonesia 369 >40 
Transmigrants 
84 
84 
Pf, Pv False –ve Iraniese 
126 (CI 86-185), 
trans 110 (CI 67 to 
182) 
False +ve trans 32 
(14 Pv) 
0.49 0.58 (0.52-0.63) 
95.5 89.8 Pf 0.82 0.49 (0.45-0.54) (Tjitra et al 1999) HRP2, ICT Indonesia 560 >50 
75 94.8 Pv 
False +ve (11/32) 
Pf, Pv (14/30) 
Gametocytes 0.06 0.16 (0.13-0.20) 
(Wongsrichanalai et 
al 1999) 
HRP2 ICT Thailand 207 >60 74 96 Pf False +ve, 
Gametocytes 
0.09 0.13 (0.10-0.18) 
35.4 (CI 25.3-
46.8) 
99.7 (99.3- 
99.9) 
Pf 0.04 0.10 (0.1-0.10) (Coleman et al 
2002b) 
HRP2 ICT Thailand 559 28 to 14000 
2 (CI 0.4-7.9) 99.9 (99.6-
100) 
Pv 
Different lots false 
+ve not specified 
0.05 0.10 (0.1-0.10) 
(Forney et al 2001) HRP2 PSF Peru 
Thailand 
2988 >100 95 86 Pf, Pv False -ve (7) 0.29 0.35 (0.33-0.37) 
82.2 94.9,  HW, Pf 0.29 0.33 (0.27-0.39) 
91.3 93.3 MW, Pf 0.44 0.49 (0.45-0.53) 
66.7 88.3 HW, Pv 0.14 0.30 (0.23-0.37) 
(Cho and Gatton 
2002) 
HRP2 ICT Myanmar 250 >50 
79 97 MW, Pv 
False +ve (72) 
0.11 0.16 (0.13-0.20) 
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80 Pf (9) false +ve 0.11 0.18 (0.12-0.25) (Bualombai et al 
2003) 
HRP2, ICT Thailand/ 
Myanmar 
border 
436 80 to 58240 
50 
92.6 
Pv (7) false –ve 
0.11 0.21 (0.14-0.30) 
100 100 Pf 0.06 0.11 (0.10-0.13) (Fernando et al 2004) HRP2 ICT Sri Lanka 328 >500 
70 99 Pv 
 
0.30 0.38 (0.31-0.44) 
(Quintana et al 1998) pLDH  Honduras 550 400 to 132000 52.9-100 95 Pf, Pv  
  
(Cooke et al 1999) pLDH/ Field Mixed, 
UK 
409 >500 91.3 92 Pf False +ve (20), 
gametocyte 0.34 0.38 (0.32-0.43) 
60.4 97 reader 1 0.45 0.48 (0.43-0.53) (Fryauff et al 2000) pLDH 
 
Indonesia 
 
225 
 
≥40 
 
70.2 89 reader 2 
 
0.45 0.51 (0.45-0.56) 
5.7 to 25 100 All lines Pf 0.01 0.10 (0.1-0.10) 
11.8 to 100 100 All lines Pv 0.02 0.30 (0.29-0.32) 
8.6 100 2 lines >Pf 
  
(Coleman et al 
2002a) 
pLDH 
 
Thailand 
 
529 
 
≥1  
 
23.5 100 2 lines >Pv 
False +ve (26%) 
 
0.02 0.11 (0.1-0.15) 
81 Pf (4) false +ve 0.15 0.16 (0.11-0.23) (Bualombai et al 
2003) 
pLDH 
(Diamed) 
Thailand/ 
Myanar 
border 
436 80 to 58240 
100 
96.7 
Pv (4) false –ve 
0.02 0.10 (0.1-0.10) 
97.7 93.6 Pf, Day 0 0.59 0.63 (0.51-0.75) 
100 84.6 Pf, Day 2 0.09 0.16 (0.10-0.26) 
 
Pf 100 to 
90000 
 
83.3 100 Pf, Day28 
0.16 0.20 (0.11-0.34) 
90 Pv, Day 0 0.07 0.19 (0.11-0.29) 
 Pv, Day 2   
(Singh et al 2003) pLDH India 75 
 
 
Pv 835to 4320 
100 
97.3 Day 28, no 
true +ve 
 
  
(Rickman et al 1989) QBC Philipines 408 3 to 89000 70 99.1 Pf, Pv, Pm  0.2 0.19 (0.14-0.24) 
(Baird et al 1992) QBC Indonesia 167 >20 75 95 Pf, Pv  0.39 0.40 (0.31-0.49) 
(Clendennen, III et al 
1995) 
QBC Indonesia 20 Pf, 240 to 
2960 
75 84 Pf  
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    Pf, 800 to 
4480 
84 76 Pv  
  
66.7 to 100 Pf 0.04 0.11 (0.10-0.12) (Wongsrichanalai et 
al 1991) 
AO Thailand 326 >100 
≤66.7 
 95.6 to 97.1 
Pv 
False +ve (7), 
gametocytes 0.02 0.11 (0.10-0.12) 
82.8 97.1 Pf 0.41 0.48 (0.45-0.51) 
100 98.6 Pv 0.04 0.10 (0.10-0.11) 
(Htut et al 2002) AO Myanmar 1390 >100 
50 100 Pf/ Pv 
  
  
O/P out-patients, HW (village health worker), MW (midwife), no true pos (no true positives), CI, confidence intervals Coleman1 (Coleman, Mancheechai, Rachapaew et al., 2002), Coleman2 (Coleman, 
Mancheechai, Ponlawat et al., 2002). CI (95% confidence intervals), number in paranthesis, number of patients, false +ve, no parasitaemia but RDT positive, false –ve high parasitaemia but RDT 
negative,  
*parasitemia calculated using WHO criteria for severe malaria (Hänscheid, 1999) 
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Table 3.5 Estimates of sensitivity and specificity for P. falciparum infections 
 
Clinical studies comparing RDTs and microscopy in endemic areas 
Diagnostic error of RDT Diagnostic error of microscopy RDTs n 
Sensitivity Specificity  sensitivity specificity 
 
HRP2 
 
13 
 
92.7 (91-94.5) 
 
99.2 (98.2-99.9) 
 
89.5 (87.8-91.2) 
 
98.9 (97.8-99.8) 
 
pLDH 
 
6 
 
67.1 (62.8-71.3) 
 
98.4 (97.5-99.6) 
 
95.9 (89.5-99.8) 
 
99.7 (99.0-99.9) 
 
QBC 
 
4 
 
83.9 (79.5-88.0) 
 
99.6 (98.9-99.9) 
 
95.6 (92.8-97.9) 
 
99.4 (98.2-99.9) 
 
AO 
 
2 
 
92.5 (82.8-99.7) 
 
99.2 (97.9-99.9) 
 
96.2 (91.9-99.8) 
 
97.2 (94.8-99.8) 
 
Clinical studies comparing pLDH and microscopy in non-endemic setting (travelers) 
 
pLDH 
 
4 
 
95.5 (92.1-98.4) 
 
99.3 (98.7-99.8) 
 
99.5 (98.1-99.9) 
 
98.8 (97.4-99.8) 
 
Field studies of asymptomatics comparing RDTs and microscopy 
 
HRP2 
 
9 
 
88.1 (86-90.2) 
 
99.9 (99.7-100) 
 
78.6 (76.8-80.4) 
 
99.1 (98.5-99.6) 
 
pLDH 
 
5 
 
71.1 (67.3-74.7) 
 
79.2 (77.9-80.5) 
 
84.1 (77.6-90.7) 
 
99.9 (99.8-100) 
 
QBC 
 
2 
 
80.9 (69.5-95.0) 
 
99.2 (97.5-99.9) 
 
94.2 (88.2-99.2) 
 
96.6 (91.8-99.8) 
 
AO 
 
2 
 
97.1 (94.9-99.4) 
 
97.9 (95.2-99.8) 
 
84.1 (80.2-88.3) 
 
99.2 (97.8-99.9) 
 
sensitivity and specificity are given as % 
number in parenthesis are 95% credible intervals 
n=number of studies analysed 
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Table 3.6 Estimates of sensitivity and specificity for non-P. falciparum infections 
Clinical studies comparing RDTs and microscopy in endemic areas 
Diagnostic error of RDT Diagnostic error of microscopy  n 
sensitivity specificity sensitivity specificity 
 
pLDH 
 
5 
 
97.6 (92.4-99.9) 
 
99.1 (98.5-99.8) 
 
98.4 (95.3-99.9) 
 
95.8 (94.7-97.1) 
 
QBC 
 
2 
 
85.9 (78.2-92.4) 
 
99.6 (98.7-99.9) 
 
90.1 (82.3-98.3) 
 
99.8 (99.3-100) 
Clinical studies comparing pLDH and microscopy in non-endemic setting (travelers) 
 
pLDH 
 
2 
 
95.9 (91.3-99.4) 
 
99.8 (99.1-99.9) 
 
99.1 (96.9-99.9) 
 
99.5 (99.3-99.9) 
Field studies of asymptomatics comparing RDTs and microscopy 
 
HRP2 
 
4 
 
52.8 (0-51.8) 
 
99.9 (0-99.9) 
 
61.5 (0-61.5) 
 
99.5 (0-99.6) 
 
pLDH 
 
3 
 
50.1 (50.0-50.2) 
 
99.9 (99.6-100) 
 
80.0 (76.3-83.9) 
 
99.9 (99.5-100) 
 
AO 
 
2 
 
86.7 (68.3-98.3) 
 
99.8 (99.4-100) 
 
71.8 (55.2-86.2) 
 
99.9 (99.5-100) 
sensitivity and specificity are given as % 
number in parenthesis are 95% credible intervals 
n=number of studies analysed 
 
Performance of RDTs in different in population groups  
Irrespective of the population assessed, there was an increase in the sensitivity and 
specificity with an increase in parasitaemia (Figures 3.1 a, b). Despite low peripheral 
counts (≤ 100 parasites/µl) in some clinical cases, in both endemic and non-endemic 
areas, RDTs such as HRP2 and AO are still highly sensitive, though in Africa HRP2 
RDTs had poor sensitivities at 100/µl (Figure 3.1a) which is the detection limit of this 
method (Kilian et al 1999,Wolday et al 2001).  Some epidemiological studies have 
shown that in malaria endemic areas, the perfomance of HRP2, pLDH, AO and QBC is 
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very poor (Coleman et al 2002a,Rickman et al 1989,Wongsrichanalai et al 1991).  This 
can be attributed to development of immunity in people living in these areas which allow 
them to control parasite load. This often results in asymptomatic carriers who have low 
parasitaemias (Coleman et al 2002a). 
There are some cases when poor sensitivity was due to the quality of the diptstick, 
especially when the overall sensitivity is low despite high parasite densities (Huong et al 
2002). This finding highlights the importance of testing a diagnostic tool in the field. Two 
studies in Asia that reported poor sensitivities for pLDH/ Optimal method (Figure 3.1b) 
at either high or low parasite densities were explained by the poor performance or quality 
of the dipstick (Huong et al 2002,Mason et al 2002). The cause of poor sensitivities 
reported in some studies is not entirely clear. There were no data available to answer the 
question of effect of immunity on the different population groups, but Fryauff and others 
(1997) have suggested that differences in host expression, metabolism of HRP2, 
genotypic and phenotypic differences in HRP2 structure or production and binding by 
host immune complexes could contribute to poor performance of RDT and the same may 
occur for the pLDH dipstick. 
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Figure 3.1 Sensitivity of RDT for P. falciparum infections 
(a) HRP2, circled area denotes studies in Africa with low sensitivity (Kilian et al, 1999; Wolday et al, 
2001) 
(b) pLDH, circled area denotes studies in Asia (Huong et al, 2002; Mason et al, 2002) 
(   ) Asia, (   ) Non-endemic settings (travelers), (  ) South America, (  ) Africa 
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Value of RDTs for monitoring response to treatment 
The HRP2 and pLDH dipsticks were the only RDTs used for assessing malaria treatment. 
A decrease in HRP2 and pLDH antigens in patients followed closely that of parasitaemia 
(Singh et al 2003). In some studies these tests were still able to detect HRP2 antigen in 
the absence of parasitaemia (Huong et al 2002,Taylor et al 2002), due to the persistence 
of HRP2 in the bloodstream. Presence of gametocytes also contribute to false positivities 
with both the HRP2 and pLDH dipsticks (Beadle et al 1994,Cooke et al 1999,Ferro et al 
2002,Mason et al 2002,Mayxay et al 2001,Wongsrichanalai et al 1999). With HRP2, 
false positives were observed in 60% (15 out of 25) of studies in endemic, non-endemic 
and epidemiological studies (Tables 3.1, 3.2, 3.3). Although the number of false positives 
may be as low as 0.5% (1 out of 213) in some studies (Lema et al 1999), other studies 
had rates as high as 6% (89 out of 1326) (Kilian et al 1999). In one study, false positive 
rates were attributed to the inability of observers to distinguish the presence of positive 
bands on HRP2 dipsticks (Kilian et al, 1999). With pLDH, this was problem was 
observed in fewer studies 25% (4 out of 16 studies) in endemic, non-endemic and 
epidemiological settings. (Tables 3.1, 3.2, 3.3). 
 
Another problem is that of false negatives, where the HRP2 or pLDH dipsticks are unable 
to detect the presence of parasitaemia. This was reported in cases where parasitaemia fell 
below 50 parasites/µl (Aslan et al 2001,Kilian et al 1999). In two studies, the high rate of 
false positivity was attributed to the poor quality of the dipstick (Huong et al 2002,Mason 
et al 2002). Clearly this presents problems in reliability of using this RDT as an effective 
tool to measure a patient’s response to treatment. 
 
3.5 Discussion 
Conventional Giemsa stained blood films are not always appropriate for diagnosing 
malaria and several rapid tests have been developed including, HRP2, pLDH/ OptiMAL, 
QBC, AO. Many studies have evaluated these rapid tests, and systematic or meta 
analyses are required to pool this body of information with the aim of determining the 
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accuracy of RDTs in endemic or non-endemic settings. A recent systematic review 
summarized the accuracy of ParaSight-F test in the diagnosis of P. falciparum malaria 
and found it to be reasonably accurate in diagnosing malaria in travelers returning from 
endemic areas (Cruciani et al 2004). Most of the evaluations have assumed that 
microscopy has an acceptable performance and have used this as a “gold standard” in 
evaluating the RDTs. 
 
We estimated a very good performance of microscopy in clinical studies, but lower 
sensitivity in field studies. When examining thick blood films experienced microscopists 
are able to detect 5 to 20 parasites/µl (Shute 1988) below which, reliable detection 
becomes difficult. Low densities are more frequent in asymptomatics than in clinical 
cases, and this explains this difference.  We are skeptical about the very high estimates of 
specificity estimated for microscopy (Table 5) but it is likely that microscopists are more 
careful in research studies than in routine diagnosis, where we would expect a lower 
specificity. Overall, microscopy seems to perform better than the RDTs in detecting both 
P.falciparum and non- falciparum infections in non-endemic settings. 
 
False negatives with RDTs occur with low parasite density, but even when parasite 
density is high, host factors sometimes form complexes with the antigen that prevent the 
binding of the antibody (Arora et al 2003). False positives can arise because of the 
presence of gametocytes or an antigen persisting from infections that have already been 
treated. The quality and batch of RDT dipsticks (HRP2 and pLDH) is of great 
importance. Guthmann and others (2002) emphasise the importance of maintaining 
dipsticks (HRP2 and pLDH) at optimal temperature and humidity ranges. Since one can 
obtain varying performances using different batches of dipsticks (Forney et al 
2003,Huong et al 2002), or poor diagnosis using pLDH (Coleman et al 2002a), 
establishing the performance of a dipstick within an area is crucial before it can be used 
reliably for detecting malaria.   
 
We find that the performance of the RDTs is dependent on the species of the malaria 
parasite, level of parasitaemia, chemotherapy, presence of gametocytes and quality of the 
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diagnostic method. The wide confidence intervals for each RDT method demonstrate the 
broad variation between studies in sensitivity and specificity. In general, HRP2 
performed better than microscopy and the other RDT methods in diagnosing malaria in 
clinical cases in endemic areas. The sensitivity of HRP2 dipsticks was much higher for 
falciparum than for non- falciparum infections in field studies of asymptomatic malaria 
infections (Cho and Gatton 2002,Gatti et al 2002,Huong et al 2002,Mason et al 
2002,Tjitra et al 1999), while the specificity was always high. In studies of asymptomatic 
infections in endemic areas, a group important for intervention studies (vaccine or drug 
trials), AO showed the best performance followed by HRP2. Epidemiological studies 
frequently enrol people who have high tolerance to parasitaemia many of whom will have 
low parasite densities of <100/µl; the HRP2, pLDH and QBC, therefore, do not perform 
as well in these groups (Beadle et al 1994,Rickman et al 1989,Wongsrichanalai et al 
1999). In particular, pLDH-based methods are not a reliable tool in diagnosing P. 
falciparum malaria in clinical cases in endemic or field studies.   
 
Where the application involves monitoring viable parasites during treatment, HRP2 
methods have unacceptably low specificity and pLDH-based methods are more suitable. 
This is because the HRP2 protein can persist in the bloodstream for up to three weeks, 
and when parasites have long since been cleared, the antigen may still be measurable 
(Mayxay et al 2001). Unlike HRP2, positivity with pLDH does not persist as long as it 
detects mainly live parasites from the release of the parasite enzyme pLDH (Singh et al 
2003). Gametocytes can also release both HRP2 and pLDH antigens and this will lead to 
false positives at low rates (Ferro et al 2002,Guthmann et al 2002). AO and QBC 
methods have not been studied for use in monitoring treatment, but are not likely to be 
suitable as AO is taken up by both viable and non-viable parasites, and thus may detect 
parasite debris. 
 
3.6 Conclusion 
HRP2 provides a better diagnostic performance than microscopy except in monitoring 
treatment in clinical cases in endemic areas. pLDH/ OptiMAL is suitable for monitoring 
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treatment of malaria infection in clinical cases in non-endemic areas. AO can be applied 
in assessment of patients and field studies. Microscopy still has an advantage in the 
diagnosis of mixed infections and in parasite quantification. More work is needed on 
whether the gravidity status (multigravid or primagravid) of pregnant women influences 
the effectiveness of the the RDTs.   
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4.1 Abstract 
The pathogenic trophozoite and schizont stages of Plasmodium falciparum are not 
observed within blood smear preparations from patients with malaria.  Measurement of 
stage specific release of biochemical products that are released by these stages could 
provide means of estimating the load of sequestered parasites in an infected host, and 
provide valuable tools for malaria diagnosis. 
The parasite produces a range of biochemical molecules.  We assessed the in vitro stage 
specific release of three potentially useful markers histidine rich protein 2 (HRP2), 
parasite lactate dehydrogenase (pLDH) and D-lactate.  HRP2 was released during ring to 
trophozoite stages and the amount was greatly elevated at schizont rupture.  pLDH 
enzyme activity was associated with tiny ring stages, suggesting that it remains attached 
to cell membrane after initial release. 
An alternative method for measuring D-lactate using an enzyme based fluorescent assay 
is described.  D-lactate was released during the late ring stages to late trophozoite stages, 
but not during during schizont rupture. 
 
4.2 Introduction 
The complete life cycle of Plasmodium falciparum seen in vitro is not observed in vivo as 
the trophozoite and schizont stages of the parasite cytoadhere or sequester deep within 
the microvasculature.  In vitro studies suggest that large ring stage parasites start to 
adhere to endothelium 16 hours post invasion (Gardner et al 1996) while in vivo, mature 
trophozoites adhere around 24 to 26 hours (Silamut and White 1993).  As a consequence 
of this cytoadherence mature trophozoites and schizonts are rarely observed in peripheral 
blood samples.  Quantification of biochemical products released from sequestered 
parasites could help to estimate the numbers of these stages present, improve our 
understanding of the pathology of severe malaria and solve the complication faced in 
detecting and quantifying parasite loads (MacPherson et al 1985,Rogerson et al 2003). 
 
Intraerythrocytic parasites metabolize carbohydrates leading to the production of lactate 
through a series of enzymatic reactions the last step involving the conversion of pyruvate 
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to lactate using lactate dehydrogenase (LDH) enzyme.  Nutrients and glucose are 
obtained from blood plasma to maintain the rapid multiplication rates and high metabolic 
activity (Sherman 1979).  While mammals produce only L-lactate, P. falciparum 
produces both L-lactate and D-lactate though levels of the latter are much lower and 
represents only 6-7% of the total lactate (Vander Jagt et al 1990).  D-lactate in the blood 
might thus be measure of parasite load within malaria patients.  Parasite lactate 
dehydrogenase (pLDH) utilizes 3-acetylpyridine adenine dinucleotide (APAD) an analog 
of NAD more rapidly than the natural cofactor NAD, a property exploited in malaria 
diagnostic dipsticks, OptiMAL® (Basco et al 1995,Oduola et al 1997,Quintana et al 
1998).  A parasite product measured from lysed IRBCs and in plasma (Makler and 
Hinrichs 1993,Piper et al 1999), measuring pLDH enzyme activity could therefore also 
provide estimates of sequestered load. 
 
Apart from having an active glycolytic cycle, parasites breakdown haemoglobin within 
erythrocytes as a source of amino acids for protein synthesis (Francis et al 
1997,Rosenthal and Meshnick 1998).  Histidine rich protein 2 (HRP2) is a water soluble 
protein implicated in the detoxification process of haemoglobin and is released from P. 
falciparum infected erythrocytes as early as 2 to 8 hours post invasion of merozoites 
(Papalexis et al 2001,Parra et al 1991).  Dipsticks (ParaSight F, ICT Pf and Binax NOW® 
ICT) have been developed to measure this antigen in malaria patients.  HRP2 has been 
assessed semi-quantitatively in plasma, whole blood and in vitro cultures of P. 
falciparum (Cavallo et al 1997,Desakorn et al 1997,Singh et al 2000,Tjitra et al 1999).  
Desakorn and others (2005) recently described the quantification of HRP2 in vitro for use 
in assessing total parasite mass within patients. 
 
We now describe the stage specific release of parasite products D-lactate, pLDH enzyme 
activity and HRP2 into culture supernatant of P. falciparum, with the objective of using 
them as markers of sequestration.  The parasite products were assayed using ELISA and 
enzymatic methods that have been modified or developed.  We further assess effects of 
cultures exposed to quinine and pyrimethamine on the release of these products, to help 
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predict how the dynamics of these markers might be altered during chemotherapy in 
malaria patients. 
 
4.3 Materials and Methods 
Cultures. 
Strain 3D7 of P. falciparum were grown in vitro using the method by Trager and Jensen 
(1976) with O-positive erythrocytes and albumax.  After synchronization using sorbitol 
(Lambros and Vanderburg 1979) and adjustment of parasitaemia to 0.5 to 1%, P. 
falciparum cultures with a haematocrit of 5% were set up in triplicate to last the 54 hour 
sampling time frame without media change.  Parasites were staged using the method by 
Silamut and others (1999).  Cultures set up at T=0, initially comprised predominantly 
small rings (SR) stages, with a cytoplasm width of approximately ≥ 1 or 2 times that of 
the nucleus (Figure 1).  Culture supernatant was obtained every 6 hours (T=6, 12 …..54 
hours) and kept at -20˚C.  Blood smears of infected red blood cells (IRBCs) were 
prepared using 10% Giemsa solution to monitor parasite growth during each 6 hour time 
interval and parasite staged using the method of Silamut and others (1999). 
 
Cultures of P. falciparum exposed to anti-malarial drug activity of quinine at the IC 90 
concentration (IC90 0.75 µg/ml) and pyrimethamine (IC90 0.8ng/ml) were set up in 
parallel.  The IC90 had been established from in vitro experiments using the hypoxanthine 
incorporation method (Webster et al, 1985; Bjorkman et al, 1991).  The amounts of D-
lactate, pLDH enzyme activity and HRP2 released into cultures exposed to 
pyrimethamine, quinine and no drug exposure were then quantified using the enzyme 
assays described below. 
 
HRP2 enzyme-linked immunosorbent assay 
HRP2 in culture supernatant was measured using an HRP2-specific P. falciparum 
sandwich ELISA method based on the work of Taylor & Voller (1993) and Desakorn and 
others (1997).  A 96-well ELISA plate was coated over night at 4°C with 2µg/ml anti-
mouse IgM.  The plates were then blocked with 5% milk powder in phosphate-buffer 
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saline followed by coating with 4µg/ml of anti-HRP2 IgM for 1 hour.  200µl of 
supernatant samples (diluted 1:2) and controls were added to wells incubated for 2 hours 
followed by 5µg/ml of anti-HRP2 IgG for 1 hour then anti-mouse IgG (diluted 1:30000) 
for a further 1 hour.  Finally tetramethyl benzidine substrate was added and incubated for 
30 minutes at room temperature.  The reaction was stopped by adding 100µl of 1M 
phosphoric acid and results read spectrophotometrically at 450nm. 
The detection limit was 0.1ng/ml.  HRP2 negative and positive controls consisted of 
cultured supernatant from 3D7 strain of P. falciparum.  The HRP2 standard consisted of 
recombinant protein from Dr. Hans Peter-Beck and Cornelia Spycher (Swiss Tropical 
Institute, Basel) and Dr. Leann Tilley (La Trobe University). 
 
pLDH enzyme linked immunosorbent assay 
pLDH was measured using an immunocapture method based on the work of Makler and 
Hinrichs (1993) and Piper and others (1999).  Briefly, a 96 well microtiter plate was 
coated with 100µg/ml of monoclonal 17E4 specific for P. falciparum (Flow, Inc. 
Portland Oregon) overnight at 4°C.  Culture supernatant (100µl) was added and plates 
incubated at room temperaturefor 3 hours followed by 100µl of Malstat® reagent for 1 
hour (Makler and Hinrichs, 1993; Piper et al, 1999).  100µl of a mixture of nitroblue 
tetrazolium and diaphorase (1:2) was added and plate read kinetically at 650nm for 20 
minutes.  Results are given as the rate of enzyme activity expressed as OD/min.  The 
detection limit was 0.1 OD/min.  Standards consisted of dilutions of infected erythrocytes 
of known parasitaemia.  These were stored as frozen aliquots. 
 
D-lactate Fluorescent assay 
D-lactate was measured using an enzyme based fluorescent assay (Furst and Schiesser, 
1999; Dorn A, personal communication).  10µl of culture supernatant was added to 
microtiter plate (“black view”, Costar), 20 µl of NAD+reaction buffer (6.4mM NAD+, 
200mM glycine, 60mM glutamic acid; pH 9.5) and the reaction was started by addition of 
30µl enzyme mixture (205U/ml D-LDH, 14U/ml ALT and 50µl of amplex red reagent: 
(5mg/ml Amplex red, 200U/ml horseradish peroxidase, reaction buffer dilute 1:5 0.5M 
NaH2PO4, 0.25M NaCl, 25mM cholic acid; 80µM MnCl2, pH 7.4).  The plate was then 
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incubated for 15 minutes at 37˚C and fluorescence measured at a wavelength of 530nm 
(Excitation) and 590nm (Emission).  The standard consisted of D-lactate (D-(-) lactic 
acid) lithium salt (Sigma, L-100).  The detection limit was 2 nmol/litre. 
 
Statistical methods 
The amount of parasite markers, pLDH enzyme activity, HRP2 and D-lactate were 
estimated as follows: 
Let tx  be the concentration of the marker molecule in the culture at time t.  The 
concentration released in time tδ  is then t t tx x+ −δ .  Let jλ  be the rate of release of the 
marker per parasite and 
,j ty  be the density of parasites of stage j at time t.  The average 
density of parasites of stage j throughout the interval is then ( ), , / 2j t j t ty y ++ δ  and the 
total concentration of the marker released by these parasites is then ( ), , / 2j j t j t tt y y ++ δλ δ  
.  The overall total concentration released in the interval is then: 
( ), ,2t t t j j t j t tj
t
x x y y+ +− = +∑δ δ
δ λ  (Figure 4.1, a-c). 
We assume tx  (and hence t tx +δ ) to be log-normally distributed.  We observe 
, ,
,   and j t j t tt y y +δδ , and so can estimate the unknown quantities jλ  from this relationship.  
We do this using a Markov chain Monte Carlo algorithm in the program WinBugs 
(Imperial College and MRC, UK.). 
 
To compute the cumulative amounts released during the asexual cycle of the parasites we 
first reconstruct the total duration of each morphologically defined stage (Figure 4.1, d-
e).  We assume that in the absence of drug treatment the average density of parasites of 
stage j throughout the cycle is proportional to the duration of that stage.   
 
4.4 Results 
Microscopic analysis of cultures. Using sorbitol, P. falciparum resulted in synchronous 
cultures with the majority (60%) of cultures in the small ring stages (Figure 4.2b) and the 
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remaining 40% were large rings as monitored by standard microscopy.  Schizonts 
ruptured between T= 30 to 36 hours resulting in the emergence of new rings and an 
increase in parasitaemia to 5% (approx. 44000 parasites/ml).  The estimated proportion of 
parasites in each stage over the period sampled are shown in figure 4.1.  Parasite cultures 
exposed to either quinine or pyrimethamine, reached mid trophozoite and large 
trophozoite stages respectively (Figure 4.1 b and c) and then the cytoplasm started to 
fragment at T=36 hours followed by parasite death.   
Tiny rings
Small rings
Large rings
Early Trophozoites
Mid Trophozoites
Large Trophozoites
Schizonts
a
b
c
 
Figure 4.1 The proportion of P. falciparum parasites in each stage, (a) not exposed to 
anti-malarial drug, (b) exposed to quinine (IC90 0.75 µg/ml) and (c) exposed to 
pyrimethamine (IC90 0.8 ng/ml). 
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Figure 4.2. P. falciparum cultures treated with sorbitol alone, showing parasite density (parasites/ml) at different stages during every 6 
hour sampling (Troph, trophozoite).  Arrow shows time at which schizonts ruptured. 
 65 
Anaylsis of culture supernatant with different assays. 
The estimated pLDH enzyme activity in culture supernatant expressed as release per 
parasite is shown in figure 4a, d.  The analysis revealed that enzyme activity/ parasite was 
associated with and highest during tiny ring stages (first 6hours), with this stage having 
an enzyme activity of 2.5×10-6 OD/min per hour.  The enzyme activity in supernatant 
then decreased in the other stages falling to below 5×10-6 OD/min per hour, with no new 
release (Figure 4.3d).  In cultures of P. falciparum exposed to quinine and pyrimethamine 
the overall cumulative enzyme activity was greater than in cultures with no drug (Figure 
4.3d). 
In cultures with quinine, pLDH enzyme activity/ parasite was found to increase during 
mid trophozoite where they remained until death.  In cultures with pyrimethamine pLDH 
enzyme activity/ parasite was seen to decrease after tiny ring stages.  
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Figure 4.3. The estimated release per parasite of different markers into P. falciparum 
culture supernatant during each parasite stage for details of stages see figure 4.1 (a-c) and 
the estimated cumulative release of markers during each time interval (d-f).  pLDH 
enzyme activity (a, d), HRP2 (b, e) and D-lactate (c, f). 
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The estimated concentration of HRP2 measured in culture supernatant increased 
considerably from 4×10-6 to 8×10-6 ng/ parasite per hour during the mid trophozoite to 
schizont stage.  Ring stages were found to release 1×10-6 ng/ parasite per hour.  There 
was a cumulative increase in the concentration of HRP2 in cultures not exposed to drugs, 
quinine and pyrimethamine, seen during the latter part of the parasites life cycle (Figure 
4.3e).  Cultures with quinine gave the highest concentration of HRP2, 1.4×10-6 ng/ 
parasite per hour during early to large trophozoite stages (4.3a) when they persisted in 
this stage and later died.  In cultures of pyrimethamine, the overall concentration of 
HRP2 released per parasite was less than 1×10-6 ng per hour. 
 
During tiny ring stages the estimated amount of D-lactate measured in culture supernatant 
was 2×10-6 nmol/litre/ parasite per hour after which the concentration decreased, then 
increased to 1.4×10-6 nmol/litre/ parasite per hour during the mid trophozoite stage 
(Figure 4.3c).  A rapid increase in D-lactate was observed during the late to early 
trophozoite stages in cultures exposed to quinine, after which there was no more D-lactate 
released.  In cultures exposed to pyrithmethamine, D-lactate was measured when 
parasites persisted in the latter mid to large trophozoite stages.  The cumulative release of 
this parasite marker increased more in cultures exposed to pyrithmethamine than to 
cultures of quinine or no drug (Figure 4.3f). 
 
4.5 Discussion  
Actively growing P. falciparum releases various proteins and products of glycolysis into 
the surrounding environment as by- or toxic products or as inhibitors against the host’s 
defence mechanisms (Parra et al 1991).  These may be released during intraerythrocytic 
growth or during schizont rupture.  Antigens like pLDH, HRP2 and the metabolic 
product D-lactate have previously been detected within in vitro cultures (Desakorn et al 
1997,Makler and Hinrichs 1993,Vander Jagt et al 1990).  We have now studied the 
release of these parasite products in vitro to see if they relate to trophozoite or schizont 
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stages of parasites.  We hope to use this to provide a way of determining sequestered 
parasite loads in vivo. 
The pLDH/ OptiMAL® method was developed for measuring pLDH activity in IRBCs 
(Makler and Hinrichs 1993,Piper et al 1999).  pLDH parasite protein is expressed during 
all stages of parasite growth (Bozdech et al 2003) with the early trophozoite sorbitol 
treated cultures having the greatest expression (Le Roch et al, 2003, website: 
plasmodb.org).  pLDH enzyme activity though measurable in culture supernatant using 
the method of Makler & Hinrichs (1993) was found to be close to the limit of detection 
0.1OD/min.  Another enzyme involved in the glycolysis pathway, GAPDH remains 
associated with erythrocyte membrane following cell lysis and is associated with the 
cytoskeleton (Heard et al 1998,Mercer and Dunham 1981).  Analysis of pLDH activity 
showed that it was greatest at small ring stages and this is probably because this enzyme 
like GAPDH may remain initially bound to cell membranes after schizont rupture and is 
only gradually released into solution.   
 
HRP2 protein is expressed starting from ring stages (Akompong et al 2002).  Desakorn 
and others (1997) showed that HRP2 was secreted into culture supernatant predominantly 
during the second half of the asexual life cycle and more recently they confirmed the 
median amounts as 2×10-6ng (0.5 to 4.3×10-6ng ) during ring stage increasing to 5.4×10-
6
ng (2.1 to 10.2×10-6ng g) during schizont stages (Desakorn et al 2005).  We observed a 
release of 1×10-6ng at ring stage, 4 ×10-6ng at trophozoite stage and 8×10-6ng per parasite 
per hour at schizont stage. 
 
We have described an alternative fluorescent method for assessing D-lactate in cultures of 
P. falciparum.  Previous methods described the use of perchloric acid to deproteinize 
samples, but we found that using this acid for deproteinization resulted in high 
backgrounds.  P. falciparum produces L-lactate which increases as parasites mature 
(Pfaller et al 1982), while the maximum amount of D-lactate is produced during 
trophozoite stages (Vander Jagt et al 1990).  We confirmed an increase in D-lactate 
during the mid trophozoite stages translating to an increase in the parasites energy 
demands (Le Roch et al, 2003; website: plasmodb.org).  Vander Jagt and others (1990) 
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found that the rates of release of D-lactate from ring stage parasites were 11.3 nmol h-1 
(108 cells) -1 and in trophozoite stage parasites 19nmol h-1 (108 cells) -1 using standard 
absorbance spectroscopy.  The estimated concentration of D-lactate released per parasite 
in rings was 2 ×10-6nmol/litre/hour and in mid trophozoites 1.4 ×10-6nmol/litre/hour.  The 
malaria parasite exhibits rapid growth and multiplication during many stages of its life 
cycle.  Expression of genes for carbohydrate metabolism is dramatically increased during 
trophozoite stages, supporting the rapid growth of parasites at this time (Ben Mamoun et 
al 2001, Le Roch et al, 2003, website: plasmodb.org). The rapid uptake and metabolism 
of glucose by parasites was reflected in our observed increase in D-lactate in culture 
supernatant during rings to trophozoite.  As the parasite enters schizogony it begins to 
address components required for invasion, hence a drop in the D-lactate levels is 
observed. 
 
Studies on P. falciparum in vitro exposed to antimalarial drugs like chloroquine resulted 
in the formation of swollen red blood cells and the expulsion of degenerate trophozoite 
and schizonts (Gu and Inselburg 1989).  Quinine is cytotoxic to the parasite inhibiting 
plasmodial haem polymerase with subsequent build up of toxic haem (Rimchala et al 
1996), while pyrimethamine is a slow acting drug that interferes with synthesis of 
nucleotides required for DNA formation (Yuthavong 2002).  The fact that drugs are able 
to lead to damage of parasites within IRBCs and to cell membrane damage, would 
explain the observed pLDH enzyme activity in culture supernatant exposed to quinine 
and pyrimethamine.  Since quinine and pyrimethamine do not directly interfere with the 
glycolysis pathway we were still able to measure D-lactate release during the mature and 
late ring stages before parasites metabolic activity ceases.   
 
HRP2 is involved in haemoglobin detoxification (Papalexis et al 2001) and from these 
studies exposure to antimalarial drugs like quinine result in the amount of HRP2 released 
increasing drastically to 1.4×10-5ng per hour.  The involvement of quinine in the 
detoxification of toxic haem together with damage to the cell membrane results in large 
amounts released into culture supernatant.  Trophozoites release large amounts of HRP2 
and cultures exposed to both pyrimethamine and quinine remained in these stages for a 
 69 
longer time before they died.  Desakorn and others (2005) have described the 
measurement of HRP2 at the different stages and its usefulness in determining total 
parasite load in patients, the release of HRP2 in patients is clearly affected by 
chemotherapy and this needs to be taken into account in estimating the dynamics of 
sequestered loads in patients. 
 
In conclusion, P. falciparum releases stage specific products into culture supernatant, 
especially those that are unique to trophozoite and schizont stages.  Increased pLDH 
enzyme activity though associated with rings suggests a slow release from RBC ghosts 
after schizont rupture.  HRP2 is released at trophozoite stages and during schizont rupture 
and the amounts at this stage are greatly increased.  Both these parasite antigens should 
be good candidate markers of sequestration, though their release may be altered by 
antimalarial administration.  D-lactate is released by all stages of parasite life cycle and 
could be useful in assessing the effect of novel anti-malarials on the glycolysis pathway.  
We plan to use these results in making quantitative estimates of the sequestered loads in 
patients with severe malaria. 
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5.1 Abstract 
We have compared the levels of Plasmodium falciparum histidine rich protein 2, parasite 
lactate dehydrogenase, D-lactate and soluble cytokine receptor R75 in severe and mild 
malaria cases and in community controls, in order to evaluate the utility of these markers 
as severity indicators and candidate markers of the sequestered parasite load.   
Histidine rich protein 2, parasite lactate dehydrogenase and sTNF-R75 can differentiate 
patients with either severe or mild malaria from healthy community controls, but are 
unable to distinguish severe malaria from mild malaria.  D-lactate levels were not related 
to the severity of malaria disease in the patients analysed. 
 
5.2 Introduction 
Assessment of malaria disease severity relies on clinical features such as level of coma, 
the respiratory pattern, the circulatory status, the haematological and biochemical 
indicators of the degree of anaemia and the number of parasitized erythrocytes per unit 
volume of blood (parasitaemia) (Warrell et al 1990).  Microscopy detects only the ring 
stages of the parasites and not the trophozoite or schizont stages that sequester deep 
within the vascular endothelium.  It is likely that total body parasite mass is more closely 
related to prognosis than peripheral parasitaemia.  Maturing parasites release a number of 
biological molecules and also stimulate the release of a number of host molecules.  If 
such molecules are released or induced in proportion to the number of parasites, they may 
offer a way to better estimate total body parasite biomass. 
Actively growing parasites use the enzyme parasite lactate dehydrogenase (pLDH) in the 
glycolysis pathway to generate energy.  This enzyme is produced both in vivo and in vitro 
and can be used as an indicator of parasite viability (Makler and Hinrichs 1993,Piper et al 
1999).  pLDH enzyme activity in infected erythrocytes correspond to the parasite density 
and increase during the intra-erythrocytic development of P. falciparum (Makler and 
Hinrichs 1993). pLDH enzyme activity can be detected in culture supernatant during 
schizont rupture (Ochola et al, in preparation).  Apart from L-lactate, parasites also 
release D-lactate that corresponds to 6 to 7% of the total lactate produced.  This is 
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released from the parasite as a product of glycolysis during ring and trophozoite stages, 
the levels being greater in the latter stage (Vander Jagt et al 1990).  
Another product thought to be involved in haemoglobin breakdown is histidine rich 
protein 2 (HRP2).  Levels of this protein are closely related to parasite density (Desakorn 
et al 1997,Howard et al 1986) and release occurs as early as 2 to 8 hours post invasion of 
merozoites (Papalexis et al 2001,Parra et al 1991).  Desakorn and others (1997, 2005) 
described its secretion into culture supernatant from ring to schizont stages, with the 
greatest amount released during schizont rupture. 
Human host factors that include tumor necrosis factor (TNF-α) and other pyrogenic 
cytokines are upregulated during malaria infections (Kwiatkowski et al 
1990,Kwiatkowski 1990,Nyakundi et al 1994).  Release of TNF-α stimulates production 
of soluble TNFs, sTNF-R55 and sTNF-R75 receptors.  These form complexes with TNF-
α buffering and regulating its release (Tartaglia and Goeddel 1992).  sTNF-R75 a 
predominant receptor, has been measured in children with acute (Hurt et al, 1995) and 
severe malaria (Molyneux et al 1993) and relationships with both parasite density and 
magnitude of fever have been observed.  The levels of this receptor were more elevated 
in patients with malaria than in those with non malaria infections. 
Both pLDH and HRP2 have been used as the basis for new diagnostic techniques (Aslan 
et al 2001,Beadle et al 1994,Moody et al 2000,Shiff et al 1993) while D-lactate and 
sTNF-R75 would not be appropriate for this purpose.  As these parasite products relate to 
parasite density we measured and compared the levels of D-lactate, HRP2, pLDH and 
sTNF-R75 in plasma samples as potential indicators of disease severity and of the 
sequestered parasite load. 
 
5.3 Methods 
Study Site and population 
This study was carried out at the Kilifi District hospital situated 60km north of Mombasa 
on the Kenyan Coast.  Over 10% of children under 5 years of age are admitted annually 
to the hospital.  The area has prolonged seasonal transmission of P. falciparum with two 
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annual peaks of intense transmission and subsequent disease in June to August and 
December to January.  The Anopheles gambiae s.l. is the main vector, contributing to an 
EIR of between 0 to 120 infective bites per person per annum (Mbogo et al 2003,Mbogo 
et al 1995). 
 
Populations  
We studied the following groups of children all with an average age of 30 months: (1) 20 
children admitted to the Kilifi District Hospital with severe malaria (defined as 
prostration, coma or difficulty breathing (Marsh et al 1995), (2) 14 children with mild 
malaria who attended the OPD ( fever in the presence of a P falciparum parasitaemia 
with no other explanation and no signs of severe disease) (3) 16 parasite positive 
community controls (well children with a positive blood smear) (4) 15 parasite negative 
community controls ( these children were recruited as part of a cohort study evaluating 
the natural history and acquisition of immunity to malaria described in detail previously 
(Mwangi, 2003) (5) 7 children admitted to KDH with a bacteraemic illness (Salmonella, 
Streptococcus group A, Escherichia coli, Streptococcus pneumoniae) (6) 4 children with 
neonatal tetanus ( i.e., severe illness caused by bacteria but without bacteraemia). 
 
Measurement of markers 
D-lactate, HRP2 pLDH and sTNF-R75 were assessed using methods described below. 
HRP2.  Briefly, a 96-well ELISA plate was coated over night at 4°C with 2µg/ml anti-
mouse IgM.  The plates were then blocked with 5% milk powder in phosphate-buffered 
saline followed by coating with 4µg/ml of anti-HRP2 IgM for 1 hour.  200µl of field 
samples (diluted 1:2) and controls (plasma samples of a known high and low HRP2 
concentration) were added to wells incubated for 2 hours followed by 5µg/ml of anti-
HRP2 IgG for 1 hour then anti-mouse IgG (diluted 1:30000) for a further 1 hour.  Finally 
tetramethyl benzidine substrate was added and incubated for 30 minutes at room 
temperature.  The reaction was stopped by adding 100 µl of 1M phosphoric acid and the 
optical density determined at a wavelength of  450nm (Tecan, Spectrafluor, V3.40-09/00 
UV). 
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pLDH.  Briefly a 96 well microtiter plate was coated with 100µg/ml of monoclonal 17E4 
(Flow, Inc. Portland Oregon) overnight at 4°C.  Field samples (100µl) was added and 
plates incubated at room temperature for 3 hours followed by 100µl of Malstat® reagent 
for 1 hour (Makler and Hinrichs, 1993; Piper et al, 1999).  100µl of a mixture of nitroblue 
tetrazolium and diaphorase (1:2) was added and plate read kinetically at 650nm for 20 
minutes.  The results were expressed as the rate of enzyme activity in OD/min.  This is a 
measure of an enzyme coupled assay in which the product APADH (analog of NADH) is 
used to reduce the chromogenic substrate nitroblue tetrazolium to a blue formazan salt 
using diaphorase (Molecular devices thermo max microplate reader). 
 
D-lactate.  Briefly, 10µl of Field samples were added to a microtiter plate (“black view”, 
Costar), 20 µl of NAD+reaction buffer (6.4mM NAD+, 200mM glycine, 60mM glutamic 
acid; pH 9.5) and reaction was started by addition of 30µl enzyme mixture (205U/ml D-
LDH, 14U/ml ALT and 50µl of amplex red reagent: (5mg/ml Amplex red, 200U/ml 
horseradish peroxidase, reaction buffer dilute 1:5 0.5M NaH2PO4, 0.25M NaCl, 25mM 
cholic acid; 80µM MnCl2, pH 7.4).  The plate was then incubated for 15 minutes at 37˚C 
and fluorescence assessed at excitation wavelength 530nm and emission wavelength 
590nm (Tecan, Spectrafluor, V3.40-09/00 UV). 
 
sTNF-R75.  An ELISA kit purchased from Biosource (sTNF-RII EASIA kit, KAC 1772) 
was used to determine sTNF-R75 levels in plasma from patients.  Briefly, 50µl of each 
standard, control or sample was added to each well coated with monoclonal antibodies to 
sTNF-R75.  200µl of anti-sTNFR75 conjugate solution were added.  The plate was 
incubated for 1 hour at room temperature on a horizontal shaker set at 700 ± 100 rpm, 
then washed and then 50µL of a tetramethyl benzidine substrate chromogenic solution 
added.  The plate was finally incubated for 15 minutes on shaker at room temperature, 
followed by addition of 200µl of stop solution.  The plate was then read 
spectrophotometrically at 450nm and 490nm (reference filter: 630 or 650nm).  Standards 
consisted of 0, 1.9, 4.6, 18.6, 51, 145ng/mL.  Plasma samples were diluted appropriately 
using an available standard that consisted of bovine serum and preservatives). 
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Statistical analysis 
Non-parametric comparisons between groups of patients in the levels of each marker 
were carried out using the Wilcoxon test in Stata (Stata Corp).   
 
5.4 Results 
The parasite densities and levels of HRP2, pLDH and sTNF-R75 are shown in Table 5.1.  
The levels of these biochemical markers were greatly elevated in patients with severe 
malaria (Figure 5.1).  However, they were not significantly different from those in mild 
cases.  Levels of all three markers were greatly reduced when measured in plasma from 
community controls.  We observed significant differences between either severe and 
controls or mild cases and controls with the following methods, HRP2 pLDH and sTNF-
R75 (p=0.0001, Wilcoxon test).  There was no significant difference in the levels of 
HRP2 and pLDH enzyme activity in plasma from healthy controls with or without 
parasites (Figure 5.1 a and b).  There were no data available for measures of sTNF-R75 in 
healthy controls with parasites.   
 
Table 5.1 Parasite densities and levels of markers in plasma in children of 30 months. 
 Severe 
 
Mild Com +ve Com -ve Tetani Bacteria 
pLDH 
(OD/min) 
0.8 (0.4-1.3) 0.8 (0.5-0.9) 0.3 (0.2-0.3) 0.3 (0.2-0.5) 0 0 
HRP2  
(ng/ml) 
19 (11-59) 16 (11-24) 0 (0-0.5) 0.2 (0-2.6) 0 0 
sTNF-R75 
(ng/ml) 
44 (41-55) 30 (24-40) ND 4 (4-8) 22 (17-31) 31 (27-83) 
D-lactate 
(µmol/l) 
4.3 (3.4-4.9) 3.1 (2.7-4.4) 5.5 (4.7-6.9) 5.4 (4.2-6.6) 4 (2.3-8.8) 3.3 (2.9-5.9) 
Parasitaemia 
(/µl) 
20670  
(22450-536555) 
37009  
(33010-40632) 
840  
(270-1710) 
0 0 0 
Median values (inter-quartile range); Com +ve (community control malaria slide 
positive); Com –ve (community control malaria slide negative) 
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Figure 5.1.  Plasma levels of different markers in children aged 30 months, (a) pLDH (b) 
HRP2, (c) sTNF-R75, (d) D-lactate. 
severe, severe malaria cases, mild, mild malaria cases, con +ve, community controls slide positive for P. 
falciparum parasites, con –ve, community controls slide negative for P. falciparum parasites, tetani, 
children with tetani, bacteria, children with bacterial infections. 
 
The human receptor sTNF-R75 was the only marker elevated in children with either 
bacterial infections or tetanus, We assessed the average coefficient of variation (%CV) of 
standards.  For both pLDH and HRP2 the intra-assay and inter-assay variations were 
between 4% and 9% with the greatest percent variation taking place at lower 
concentrations.  While for sTNF-R75 and D-lactate the intra-assay and inter-assay 
variations were less than 9% and 3% respectively.   
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There were no significant differences in concentrations of D lactate between the groups 
in which it was determined (Figure 5.1d).  
 
5.5 Discussion 
Infections of P. falciparum lead to release and up-regulation of host receptor sTNF-R75 
and parasite products HRP2 and pLDH in the blood circulation.  The current analysis 
formed part of a pilot study to assess the levels of sTNF-R75, HRP2, pLDH and D-lactate 
in plasma samples in a small population of children with malaria.   
D-lactate has been quantified as a parasite specific marker, in vitro cultures of P. 
falciparum Vander Jagt et al, 1990; Ochola et al, Manuscript in preparation) but we 
observed no differences in the levels of D-lactate when assessed in children with severe 
malaria or parasite positive or negative community controls.  The poor sensitivity of this 
method in detecting D-lactate in plasma samples is probably because it represents only 6 
to 7% of the total lactate produced by P. falciparum (Vander Jagt et al 1990) or its short 
half-life of 36.4 minutes (Roberts et al 1989).  There is also a possibility that processing 
of human samples and other factors within them may cause conversion of the D-isomer to 
the L- form of lactate (Marti et al 1997) suggesting that this product of glycolysis is 
unstable.  D-lactate is thus not suitable in determining presence of malaria in patients.   
Both HRP2 and pLDH enzyme activity have previously been widely used in the detection 
of P. falciparum in whole blood samples (Beadle et al 1994,Makler and Hinrichs 
1993,Parra et al 1991,Piper et al 1999).  A semi-quantitative ELISA has been used to 
quantify HRP2 titres in plasma and blood samples from adult patients in Thailand 
(Desakorn et al 1997), who found that HRP2 titres in plasma from severe malaria cases 
were high (1:1280) whilst those from uncomplicated malaria cases were low (1:80).  We 
also observed higher HRP2 levels in severe cases than in mild cases though there was no 
significant difference with severity.  Studies assessing pLDH in whole blood have shown 
that this method can detect up to 50 parasites/µl (Piper et al 1999).  We have shown that 
pLDH enzyme activity can be measured in plasma samples though the levels are greatly 
reduced and are close to the limit of detection 0.1 OD/min of the assay.  
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The cytokine receptor sTNF-R75 is up-regulated in febrile children with malaria and it 
known to correlate with parasitaemia and disease severity in malaria (Hurt et al 
1995,Kern et al 1992,Molyneux et al 1993).  We confirmed this among the severe 
children selected and further showed its increase during mild malaria disease.  
Leeuwenberg and others (1994) showed that LPS from Escherichia coli and Salmonella 
minnesota enhances the levels of sTNF-R75 released from monocytes.  Our current 
findings show that co-infections with pathogens such as neonatal tetanus or bacterial 
infections such as Salmonella, Streptococcus group A, Escherichia coli, Streptococcus 
pneumoniae could also result in increases in the soluble cytokine receptor sTNF-R75.   
Plasma levels of the parasite antigens, HRP2, pLDH and the host moleculesTNF-R75 are 
able to distinguish between children with clinical malaria (severe or mild disease) and 
healthy controls with or without P.falciparum parasites.  We propose to assess these 
markers as potential markers of sequestration as they relate to disease severity in P. 
falciparum malaria infections. 
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6.1 Abstract 
 
In malaria endemic areas asymptomatic parasitaemia is common, complicating diagnosis 
of true clinical malaria.  This is further made even more difficult by the parasites ability 
to sequester in deep vascular beds so that they do not appear on blood films.  Attempts to 
improve malaria diagnosis are a key step in the management of clinical disease.  We now 
consider whether quantitation of the P. falciparum histidine rich protein-2 (HRP2) can 
play a role in improving diagnosis. 
Admission parasite densities and plasma HRP2 levels were determined in 366 children 
aged between 12 to 59 months 98 who had severe malaria and 92 with mild malaria, 76 
asymptomatic parasitaemia or 100 no malaria.  The ratio of parasite density to HRP2 was 
used to differentiate disease from non-disease cases using the severe and mild malaria 
cases and asymptomatic controls. 
The median HRP2 concentration in severe cases (45ng/ml) was not significantly higher 
than that in mild malaria cases (44ng/ml).  The median HRP2 concentration in children 
with asymptomatic parasitaemia was 5ng/ml while among healthy children who were 
slide negative there was no measurable HRP2.  The geometric mean ratio of HRP2 to 
peripheral parasites in severe malaria was 1:0.63 ×10-6ng/ parasite, in mild malaria was 
1:0.73×10-6ng/ parasite and in asymptomatic controls was 1:1.40 ×10-6ng/ parasite.  
Combining both parasitaemia and HRP2 measurements can improve diagnosis of clinical 
malaria because a low ratio of HRP2 to parasites is indicative of a recent expansion in the 
parasite population. 
 
6.2 Introduction 
Despite a huge increase in our understanding of the pathophysiology of P. falciparum and 
improvements in the management of malaria, there are still approximately 515 million 
clinical attacks of malaria each year with 365 million occurring in Africa (Snow et al 
2005).  The median estimate for malaria specific mortality among children under five 
years is 9.4 per 1000 children per year (Snow et al 1999).  Most of these deaths will 
occur within 24 hours of admission (Marsh et al 1995,Newton and Krishna 1998) as a 
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result of severe malaria presenting as cerebral malaria, severe anaemia or metabolic 
acidosis (Aikawa 1988,Hendrickse et al 1972,Newton and Krishna 1998).  
 
Clinical diagnosis and management of P. falciparum malaria relies on detection of 
parasites in thick and thin Giemsa stained films (Payne 1988) and on clinical and 
haematological indices.  The use of blood films presents problems in areas of malaria 
endemicity where asymptomatic parsitaemia is highly prevalent.  Distinguishing cases of 
severe malaria from cases of other diseases with incidental parasitaemia is difficult.  It is 
normally resolved by applying a quantitative threshold, for example above 10,000 
parasites per microlitre, and presence of fever greater than 37.5°C (Genton et al 
1994,Rougemont et al 1991).  Threshold approaches, are used mainly as epidemiological 
tools in counting the number of cases based on the probability that a given episode is a 
case.  But in clinical situations these cut-off’s maybe misleading because parasites may 
be synchronously sequestered or the patient may have recently taken anti-malarial 
chemotherapy. 
 
An alternative approach to malaria diagnosis, which has been exploited in several 
commercial dipstick kits, is the detection of Histidine Rich Protein 2 (HRP2) an 
invariable and unique protein of P. falciparum which is found in serum or plasma and in 
higher levels yet in whole blood.  Less than 5% of the HRP2 produced is secreted to 
plasma, the rest remaining either within parasites or bound to infected red blood cells 
(Desakorn et al 1997).  A recent review that compared the accuracy of HRP2 to light 
microscopy found that the HRP2 was valuable in diagnosing malaria in travellers 
returning from endemic areas (Cruciani et al 2004).  HRP2 also appears to perform better 
in detecting P. falciparum infections among clinical cases in endemic areas than 
conventional slide reading (Ochola et al, Manuscript in preparation). 
 
Measures of HRP2 in plasma may be useful because they act as summary measures of 
infection over the preceding days or of the presence of sequestered parasites.  A 
diagnostic algorithm making use of a combination of HRP2 and parasitaemia 
determinations could allow for differentiation of “true” cases of malaria that have 
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transient low parasitaemia either due to sequestration or because of recent therapy.  This 
report assesses whether a fully quantitative ELISA, providing HRP2 concentrations can 
allow greater precision in the determination of severity and differentiation of mild cases 
and asymptomatic control populations.   
 
6.3 Methods  
 
Study Site 
This study was conducted at Kilifi District Hospital situated 60 km North of Mombasa on 
the Kenyan Coast.  The pattern of malaria transmission is stable and endemic with two 
annual peaks of intense transmission and subsequent disease in June to August and 
December to January.  The mean annual EIR for this study area vary from 0 to 120 bites 
per person and is dependent on the rates of transmission (Mbogo et al 2003,Mbogo et al 
1995).   
Ethical clearance for this study was granted by the National Ethical Review Committee 
of Kenya Medical Research Institute (KEMRI) in Nairobi. 
 
Study design 
We analysed blood samples collected from children between 12 to 59 months recruited 
into two studies, (1) acute malaria cases admitted to hospital between 1994-2002 and (2) 
a community based cohort study of fever and malaria episodes from 1998 to 2005.  
Severe malaria cases were selected from those previously described by Bull et al, 2000.  
Children with a primary diagnosis of malaria admitted to hospital with malaria were 
defined as severe malaria.  Children who were slide positive for P. falciparum and had no 
clinical features of severe malaria attending only the out-patients department (OPD) were 
defined as mild malaria.  We selected the first two severe or mild patients in each age 
band from 1996.  In some of the age strata cases there were no patients in this year so 
subjects were systematically selected from years 1995, 1997 or 1998 in that order. 
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Healthy controls with the same age distribution were selected systematically from an 
ongoing cohort study evaluating the natural history and acquisition of immunity to 
malaria described in detail previously (Mwangi 2003).  The study began in 1998, 
consisting of residents from randomly selected households identified during a pre-study 
census of a prescribed area.  Community controls with a defined parasite density 
(controls slide positive) and those without parasitaemia (controls slide negative) without 
fever or not given anti-malarials were selected initially from a cross-sectional venesection 
study in 1998 and when children with a given age were not found subjects were selected 
from subsequent years.  Among children aged 12 to 48 months the parasite prevalence in 
the dry and wet season is between 11% and 25% respectively (Mwangi 2003).  HRP2 
concentrations were determined from stored plasma samples using the ELISA method 
described below. 
 
HRP2 enzyme-linked immunosorbent assay 
HRP2 in field samples were measured using an HRP2-specific P. falciparum sandwich 
ELISA method based on the work of Taylor & Voller (1993) and Desakorn and others 
(1997).  Briefly, a 96-well ELISA plate was coated over night at 4°C with 2µg/ml anti-
mouse IgM.  The plates were then blocked with 5% milk powder in phosphate-buffer 
saline followed by coating with 4µg/ml of anti-HRP2 IgM for 1 hour.  200µl of field 
samples (diluted 1:2) and controls (plasma samples of a known high and low HRP2 
concentration) were added to wells incubated for 2 hours followed by 5µg/ml of anti-
HRP2 IgG for 1 hour then anti-mouse IgG (diluted 1:30000) for a further 1 hour.  Finally 
tetramethyl benzidine substrate was added and incubated for 30 minutes at room 
temperature.  The reaction was stopped by adding 1M phosphoric acid and results read 
spectrophotometrically at 450nm. 
The detection limit was 0.1ng/ml.  HRP2 negative and positive controls consisted of 
plasma from non-immune pooled sera that were confirmed to be HRP2 negative, and 
positive controls consisted of cultured supernatant from A4 strain of P. falciparum.  
HRP2 standard consisted of recombinant protein from Dr. Hans Peter-Beck and Cornelia 
Spycher Swiss Tropical Institute, Basel and Dr. Leann Tilley, La Trobe University. 
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Statistical Analysis 
Data were analysed using the Kruskal-Wallis (Stata Version 8, Stata Corp.) test which as 
a non-parametric test compares three of more unpaired groups.  The data included 
comparisons of the levels of parasite density or HRP2 concentrations in different clinical 
groupings.  We further calculated the correlation coefficients of the age or haemoglobin 
to geometric mean ratio of HRP2 to parasitaemia using to Spearman (rs).   
 
6.4 Results 
 
Parasite densities and HRP2 concentration in plasma. 
A total of 366 patients with complete clinical data were selected, for details on numbers 
per group refer to Table 1.  Fifty three percent (52/98) of the severe cases had a 
parasitaemia of between 100,000- 1,000,000/µl.  Parasite densities of between 10,000- 
100,000/µl were most frequent among the mild cases and of 1,000- 10,000 among 
asymptomatic parasitaemia community controls (Figure 6.1).  The median parasite 
density on admission (207300/µl) in severe cases was significantly higher than in the 
other groups (p<0.0001, Table 6.1) as were the differences in parasite densities between 
mild cases and parasite positive community controls were also significant (Wilcoxon test, 
p=0.0001). 
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Figure 6.1. Distribution of parasitaemia against selected cases 
Severe, severe disease; mild, mild disease; com pos, community controls malaria slide positive 
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Table 6.1 Parasite densities and HRP2 levels in plasma 
  
n 
Age (range in 
months) 
Male 
no. (%) 
Parasite count  
(per microlitre) a 
HRP2  
(ng/ml) a 
Severe malaria 98 12-59 54.5 207330 (38664-485660) 45 (28-154) 
Mild malaria 92 12-59 54.2 39456 (24687-68102) 44 (16-80) 
Community 
controls  
(slide positive) 
76 12-59 45 2199 (549-8972) 5 (1-9) 
Community 
controls  
(slide negative) 
100 12-59 57 0  0 
a
 median (IQR), n, number of patients selected 
 
The median concentration of HRP2 in plasma samples of severe and mild cases were 
45ng/ml (IQR, 28-154) and 44ng/ml (IQR, 16-80) respectively (Wilcoxon test, p=0.03).  
When comparisons of HRP2 were made between severe and parasite-positive controls 
with a median HRP2 concentration of 5ng/ml (IQR, 0.7-9.2) and mild cases against 
parasite-positive community controls a significant difference was found (Wilcoxon test, 
p=0.0001).  We also measured HRP2 antigen in plasma from community controls who 
had a low grade parasitaemia of <10000 parasites/ µl (Figure 6.2) and found a median 
HRP2 concentration of 5ng/ml (IQR, 0.7-9.2).  We observed that an overall increase in 
parasitaemia lead to an increase in the quantity of HRP2 measured in plasma which were 
significantly correlated (rs =0.5, p<0.0001, Figure 6.3). 
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Figure 6.2. HRP2 levels in plasma samples of various patient groups. 
severe, severe malaria disease, mild, mild malaria disease and community controls that 
are malaria slide positive, control (positive), community controls that are malaria slide 
negative for parasites control (negative). Box plots represent median, interquartile ranges 
and outside values. 
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Figure 6.3 HRP2 concentration in all patients plotted against parasitaemia  
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Parasite densities and HRP2 measurements stratified by age 
We stratified cases according to the following ages: 12 to 23, 24 to 35, 36 to 47 and 48 to 
59 months (Figure 6.4).  Among the severe cases we observed an increase in the levels of 
parasitaemia with an increase in age (Figure 6.4, Row a, severe cases).  Children aged 48 
to 59 months had the highest parasite density (median 478302/µl, IQR, 66720-869610) 
but this was not significantly different from the other age categories.  Trends in HRP2 
concentrations were the opposite of those of parasite density, HRP2 concentrations in 
plasma decreased with increasing age starting from 24 months.  HRP2 concentrations in 
children 12-24 and 48-59 months were significantly higher (Wilcoxon test, p<0.001).  
Children aged 12-23 months had slightly lower HRP2 levels than those aged 24-34 
months, but this was not significantly different (Figure 6.4, Row b, severe cases).  The 
geometric mean ratio of HRP2 to parasite density, decreased with increasing age (Figure 
6.4 Row c, severe cases), with the highest age group (48-59 months) having a 
significance difference in the geometric mean ratio of HRP2 to parasite density when 
compared to other age groups (Wilcoxon test, p<0.01). 
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Figure 6.4.  Parasite density and HRP2 levels in severe cases, mild cases and controls 
(slide positive). Row (a) parasite density (parasites/µl), Row (b) concentration of HRP2 
(ng/ml), Row (c) geometric mean ratio of HRP2: parasite density (× 10-6ng/ parasite).  In 
figures (a) and (b) error bars represent the median and interquartile ranges. 
 
The patterns observed among severe cases were not observed with the mild cases or slide 
positive community controls.  Among mild cases and asymptomatic children who were 
slide positive for malaria, there was no overall difference in the parasite density, HRP2 
concentration or the geometric mean ratio of HRP2 concentration to parasite density 
when compared across different age groups.  The geometric mean ratio of HRP2 to 
parasite density was lowest among severe cases 1:0.50 ×10-6ng/ parasite (CI, 1: 0.33×10-6 
-0.75×10-6) while that of mild cases was 1:0.73× 10-6ng/ parasite (CI, 1:0.54× 10-6 -0.99× 
10-6) and that of slide positive controls was 1:1.45× 10-6ng/ parasite (CI, 1:0.93× 10-6 -
2.2× 10-6) (Figure 6.4, Row c).  The geometric mean ratio of HRP2 to parasite density 
among the severe cases was significantly different to that of mild cases or in 
asymptomatic children who were slide positive, Wilcoxon test p=0.02 and p<0.001 
(a) 
(b) 
(c) 
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respectively.  We also observed a significant difference between mild cases and 
asymptomatic children who were slide positive (Wilcoxon test p<0.01).  There was no 
statistical correlation between other variables such as haemoglobin levels (rs=0.10, 
p=0.4). 
 
6.5 Discussion 
 
In endemic regions tolerance of incidental high parasite densities is common (Trape et al, 
1985) although in naïve hosts even low parasite densities (<0.02%) can lead to admission 
of patients with coma, liver or renal dysfunction (White 1997).  In epidemiological 
studies, clinical malaria cases may be defined using parasite density thresholds (Trape et 
al 1985, Rougemont et al 1991, Genton et al 1994) or may be used for estimating the risk 
caused by fever (Smith et al 1994).  However some studies in endemic areas (Bassett et 
al 1991) have found no significant association between clinical symptoms and 
parasitaemia so the true significance of parasite densities still remains poorly understood. 
The lack of a convenient measure of sequestered parasite loads makes it difficult to assess 
the true relationship between the parasite density and disease severity, with implications 
for epidemiological studies and clinical management.  A combination of techniques could 
improve malaria diagnosis in order to differentiate clinical disease from incidental 
parasitaemia or asymptomatic cases. 
 
HRP2 dipsticks and semi-quantitative ELISAs have been widely used as malaria 
diagnostic tools in clinical and epidemiological settings.  To assess their performance, 
microscopy or PCR have been used as a gold standard (Humar et al 1997,Richardson et 
al 2002) but the sensitivity of optical microscopy is limited and can vary greatly 
especially at low parasite densities (Coleman et al 2002c,Craig and Sharp 1997).  
Analyses that considered a diagnostic tool in the absence of a gold standard suggested 
that HRP2 probably has a higher sensitivity than microscopy (estimate of 92.7% (95% 
CI, 91 to 94.5)) when used to detect P. falciparum infections in clinical cases in endemic 
areas (Ochola et al, Manuscript in preparation).  While in epidemiological studies 
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assessing the use of HRP2 dipsticks a lower estimate of sensitivity 88.1% was obtained 
though the estimates of specificity remained high.   
 
HRP2 dipsticks have been assessed in clinical endemic areas and epidemiological studies, 
yielding high sensitivities especially with the former.  The advantage of using this 
method is it can detect HRP2 antigen in the absence of parasites probably released from 
sequestered parasites, but longitudinal studies have shown its persistence in the blood for 
upto 3 weeks even after peripheral parasite clearance (Mayxay et al 2001).  Preliminary 
analysis of data collected on patients in Kilifi has shown that HRP2 persists on average 9 
days after start of treatment (data not shown), other studies in Kenya and Tanzania have 
estimated plasma persistence at 6 and 14 days respectively (Beadle et al 1994,Shiff et al 
1993).  Furthermore, HRP2 is also released by immature gametocytes leading to slow 
clearance of this antigen (Beadle et al 1994).  Despite this HRP2 may act as a marker of 
overall parasite density over the preceding few days.   
 
A semi-quantitative ELISA has been used to quantify HRP2 titres in plasma and blood 
samples from adults patients in Thailand (Desakorn et al 1997), who found that HRP2 
titres in plasma from severe malaria cases were higher (1:1280) than those from 
uncomplicated malaria cases (1:80).  In comparison, our quantitative ELISA applied to 
samples from a population with relatively highly endemic P. falciparum, gave 
concentrations of 45 ng/ml for severe malaria cases, 44 ng/ml for mild malaria cases and 
5ng/ml for slide-positive healthy controls.  However, the ratio of HRP2 levels to 
parasitaemia showed the opposite trend.  We found a lower geometric mean ratio of the 
HRP2 to P. falciparum parasite density in severe cases 1:0.50× 10-6ng/ parasite than in 
either mild cases 1:0.73× 10-6ng/ parasite or parasite positive controls 1:1.40× 10-6ng/ 
parasite.  Among the severe malaria cases, the ratio of HRP2 to parasite density is lower 
in older children (48-59 months) than in younger children. 
 
These ratios can be explained by the dynamics of HRP2 clearance.  Since HRP2 can 
persist for a long time, the levels of accumulating protein largely reflect the parasite level 
averaged over days and weeks and so the ratio of HRP2:parasites is high in individuals 
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with long-term chronic parasitaemia (Figure 6.5 patient 1).  Low ratios of HRP2 to 
parasites indicates an acute infection that has probably recently rapidly expanded (Figure 
6.5, patient 3). 
 
This suggests that it could further provide an additional tool in diagnosis of clinical 
malaria as the severe malaria cases were seen to have a lower ratio of HRP2 to parasite 
density.  Together with clinical features such as level of coma, and respiratory pattern it 
could provide evidence of a recently expanded infection.   
 
Among the severe malaria cases, the mean ratio of HRP2 to parasite density is lower in 
older children (48-59 months) than in younger children.  We considered two possible 
explanations for this: firstly older children are relatively more likely to suffer from 
cerebral malaria (Lalloo et al 1996,Weatherall et al 2002), while younger children are 
more likely to develop chronic infections that result in severe anaemia (Snow et al 
1997,Weatherall et al 2002).  We expect chronic infections (and hence severe anaemia 
cases) to have higher ratios of HRP2 to parasites.   However there was no correlation 
between haemoglobin levels and this ratio.  We therefore preferred the alternative 
explanation of acquired immunity to HRP2 (Dondorp et al personal communication).  
This could account for why the HRP2: parasite ratio is lower in the older age group in 
both severe patients and in asymptomatic hosts. 
 
Quantitative determination of HRP2 is potentially valuable as it gives a precise measure 
of the parasite antigen released, including the effects of sequestered parasites.  It could 
also give a better indication of ‘true’ clinical malaria cases especially in epidemiological 
studies in young children in endemic areas where accurate data is required on the disease 
burden of malaria.  Within our analysis we considered severe and mild malaria, further 
work should consider the ratio of HRP2: parasites in different clinical syndromes such as 
cerebral malaria, severe anaemia and metabolic acidosis. 
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Figure 6.5. Examples illustrating dynamics of (a) parasite density, (b) HRP2 and (c) ratio 
of HRP2: parasite density in different hypothetical patients. (1) patient 1 with persisting 
parasitaemia, (2) patient 2 with a moderately increasing parasitaemia and (3) patient 3 
with a rapidly increasing parasitaemia. 
The model uses estimates of HRP2 levels released per day per cycle (2.6×10-6ng) (Desakorn et al, 2005) 
and elimination half-life of HRP2 (2.77 days) calculated from HRP2 profiles of children in Kilifi (Ochola 
et al, in press).  The HRP2 elimination follows an exponential decay with a constant of k=0.25 per day 
(Dondorp personal communication). 
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7.1 Summary 
 
The virulence of the malaria parasite Plasmodium falciparum is due in part to its ability 
to cytoadhere in deep vascular beds.  Our inability to quantify the load of sequestered 
parasites hampers our understanding of the pathophysiological mechanisms involved in 
disease progression and complicates diagnosis.   
 
In this study we evaluate potential biochemical markers of sequestered load by 
comparing them with estimates of the sequestered load from a statistical model fitted to 
longitudinal patterns of peripheral parasite densities in a series of 22 patients with severe 
Plasmodium falciparum malaria.  The markers comprised the host factors: haematocrit, 
circulating host DNA, sTNF-R75 and parasite derived products HRP2, pLDH, pigments 
and circulating parasite DNA. 
 
We investigated the suitability of these markers in determining sequestered loads in 
patients on quinine treatment.  Observed peripheral parasitaemia, plasma levels of sTNF-
R75 and circulating parasite DNA were most strongly correlated with estimates of 
sequestered loads on admission.  However the dynamics of both sTNF-R75 and 
circulating parasite DNA during follow-up were very different from those of the 
estimated sequestered mass.  These analyses suggest that none of the markers gave 
reliable estimates of the current sequestered load, though they may reflect the history of 
infection.  Longitudinal analyses are needed that allow for the clearance rates of the 
marker molecules and for variations between hosts in the history of parasitaemia. 
 
Key words: Plasmodium falciparum, sequestration, biochemical and parasitological 
markers, statistical models. 
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7.2 Introduction 
Plasmodium falciparum is by far the most virulent malaria parasite infecting humans, being 
responsible for almost all malaria related deaths.  The particular virulence of P falciparum is 
believed to be due to the ability of red blood cells containing mature stages of the parasite to 
sequester in deep vascular beds, through a process of cytoadherance to vascular endothelium 
(Aikawa 1988,Sein et al 1993). Sequestration of mature stages makes it difficult to estimate the 
true parasite burden which is likely to be an important prognostic indicator, and in extreme cases 
where all parasites are sequestered at a particular time point, it may complicate diagnosis. 
Both in vitro and in vivo studies have shown that parasite products including histidine rich 
protein-2 (HRP2) (Desakorn et al 1997,Kilian et al 1999,Parra et al 1991), parasite lactate 
dehydrogenase (pLDH) (Makler and Hinrichs 1993,Piper et al 1999), malaria pigment (Day et al 
1996,Lyke et al 2003), circulating parasite DNA (Gal et al 2001) are released into circulation 
when schizonts rupture.  Assays of some of these components form the basis of diagnostic tests 
that have been, or are being developed as alternatives to microscopic examination of blood films.  
Quantitation of these substances represents one possible approach for measuring total parasite 
burdens. 
Measurement of host products released as a result of sequestration might also be used to estimate 
the sequestered load.  Sequestration and schizont rupture precipitate a cascade of events leading 
to an acute phase response within the host, including up-regulation of cytokines such as the 
interleukins IL-1β, IL-6, IL-10, interferon gamma (IFN-γ), tumor necrosis factor α (TNF-α) 
(Chen et al 2000,Vogetseder et al 2004) and its receptors soluble sTNF-R75 and sTNF-R55 
(Hurt et al 1995,McGuire et al 1998).  Tissue damage leads to the release of circulating host 
DNA and might be a marker of pathology (Saiki et al 1985).  In principle, quantification of such 
markers might be used to estimate the sequestered parasite load.  By radiolabelling of 
erythrocytes, Davis et al (1990) found that the venous haematocrit provided an indirect estimate 
of total sequestered volume in a small number of Thai patients. However no studies to date have 
validated measures of levels of any host or parasite factors as markers of the sequestered parasite 
load. 
We have studied 22 severe P. falciparum malaria patients in Kilifi, Kenya and made estimates of 
the sequestered load during therapy, using a range of candidate host and parasite markers.  We 
have attempted to optimise these estimates by comparing them with each other and with 
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corresponding estimates from a statistical model fitted to the longitudinal patterns of peripheral 
parasite densities. 
 
7.3 Materials and methods 
Patients and blood sampling 
Twenty two children under the age of 6 years admitted to the high dependency unit (HDU) in 
Kilifi District Hospital were recruited into this study.  Children were defined as having severe 
malaria if they were malaria slide positive (P. falciparum), had no other detected cause for their 
illness and  had one of the following:(1) Prostration (2) Respiratory distress (3) Severe anaemia 
(Haemoglobin less than 5 gms per deciliter) (Marsh et al 1995).  Parental consent was obtained.  
All patients were treated with intravenous quinine and received full supportive therapy as 
described elsewhere (Murphy et al 1995). 
Peripheral parasite densities were assessed every 4 hours over 48 hours and 0.5ml of venous 
blood was taken every 8 hours.  This was separated into RBC pellet and plasma and frozen 
initially at –20°C before being transferred to –80°C. 
 
Analyses of biochemical and parasitological markers  
Samples were tested for a range of potential biochemical markers of the sequestered parasite load 
(Table 7.1). 
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Table 7.1 Biochemical and parasitological markers used to assess the sequestered parasite load  
Markers Method Type of Sample Rationale Reference for method 
Peripheral 
parasitaemia 
Light Microscopy Giemsa-stained thick 
& thin blood smears 
Assess the quantity of parasites in peripheral blood for model  
Candidate Parasite markers of sequestration 
HRP2 Sandwich ELISA,to quantify this protein in ng/ml 
(Ochola, unpublished observations) 
Plasma HRP2 is released from growing IRBCs into blood circulation. HRP2 levels 
are elevated during schizont stage and could relate to sequestered load.  
Parra et al, 1991;  
Desakorn et al, 1997 
Plasma In vitro measurement has shown that pLDH is measurable during schizont 
rupture and could relate to estimates of sequestered load  
pLDH An immunocapture based ELISA measuring 
pLDH as rate of enzyme activity, OD/min based 
on the method by Makler & Hinrichs, 1993 
(Ochola, unpublished observations) 
RBCs pLDH enzyme activity in IRBC reflects circulating parasites and are thus a 
direct measure of parasitaemia, 
 
Makler  and Hinrichs, 
1993 
Piper et al, 1991 
Pigmented PMNs  count number of pigments/ 200 PMNs  
(units counts/µl) 
Pigmented Mono s Count number of pigments/ 200 mono  
(units counts/µl) 
 
Giemsa stained thick 
blood smears 
The malarial parasite metabolizes haemoglobin and the by-product is 
pigment. At schizont rupture this is released into blood circulation and is 
engulfed by WBCs so quantification of this could relate to sequestered load. 
 
Nguyen et al, 1995;  
Day et al, 1996,  
Lyke et al, 2003 
 
Circulating pDNA  Quantify using real-time PCR results in genomes/ 
µl, used developed method gal 
 
Plasma 
During schizont rupture circulating pDNA is released into supernatant of 
invitro cultures and this could relate to the sequestered mass.  Previous work 
has quantified parasite DNA in plasma from patients. 
Gal et al, 2001; Gal 
personal communication 
 
Candidate host markers of sequestration 
PCV FBC Whole blood Haematocrit rapidly falls in patients with severe disease due to destruction 
of red blood cells. Davis and others (1990) claimed that PCV provides an 
indirect estimate of sequestered load 
Davis et al, 1990 
 
sTNF-R75 ELISA kit from Biosource (sTNF-RII EASIA kit, 
KAC 1772), in ng/ml 
 
Plasma 
Schizont rupture causes release of TNF-α and pyrogenic factors. Soluble 
TNFs forms complexes with TNF-α acting as an antagonist. sTNF-R75 
levels could correlate with estimates of sequestered load 
Hurt et al, 1995 
 
 
Circulating host DNA Quantify using real-time PCR results given us 
ng/ml, used developed method gal 
 
Plasma 
Malarial infections can lead to damage of tissues within the host leading to 
pathology  
Gal et al (personal 
communication);  
Saiki etal, 1985 
RBCs, red blood cells; IRBCs, infected red blood cells; WBCs, white blood cells; FBC, full blood count analyzer; Hb, haemoglobin; PMNs, polymorphonucleated cells; mono, monocytes, PCV, packed cell volume. 
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Associations between markers  
We anticipated that measures of different markers of parasite sequestration should be correlated 
with each other, and tested the associations at admission using Spearman correlations.  Since the 
levels of almost all the markers were correlated with admission parasitaemia, in addition we used 
partial (Spearman) correlations allowing for the admission parasitaemia, to test whether the 
levels of the remaining markers were correlated. 
 
Estimates of sequestered load from longitudinal peripheral parasitaemia profiles 
Estimates of the sequestered load were derived using the longitudinal pattern of peripheral 
parasitaemia, and also using the baseline levels of those parasitological and biochemical markers 
that were most correlated with this estimate of the sequestered load. 
We fitted a discrete-time age-stage model recently used to estimate the sequestered parasite load 
in severe malaria patients in Kilifi (Smith et al 2004).  This approach uses 4 hourly peripheral 
parasitaemia determinations to provide estimates of the numbers of parasites during therapy of 
the patients (Smith et al 2004).  It differs from other recent statistical models used to address this 
problem (Gravenor et al 1998,Gravenor et al 2002) in assuming a fixed 48 hour duration of the 
asexual cycle of the parasite, and uses literature-based ter Kuile estimates of pharmacodynamic 
and pharmacokinetic parameters.  The model is fitted using a Markov chain Monte Carlo 
approach that allows it to be fitted simultaneously to the entire data set allowing point and 
interval estimates for both population and individual patient parameters.   
Using this model we obtained estimates for the 4-hour time period immediately after hospital 
admission of 1iS , the sequestered mass. i.e. the number of sequestered IRBCs per unit of blood 
volume at baseline for patient i.  Full details of this model are provided by (Smith et al 2004) 
 
Estimates of sequestered load from peripheral parasitaemia, circulating parasite DNA and 
sTNF-R75. 
We used the levels of the biochemical markers at baseline to make estimates of the sequestered 
loads (see Appendix).  Estimates were made only for those markers that correlated with 1iS , the 
estimated sequestered load based on the longitudinal model in patient i.  These comprised the 
levels of peripheral parasitaemia, circulating parasite DNA (pDNA), sTNF-R75 which were used 
to derive estimates 2 3 4,   and i i iS S S , respectively of the sequestered mass.  In addition we derived 
further estimates 5iS  and 6iS  by combining the data of 2 3 4,   and i i iS S S  and 3iS , 4iS  respectively. 
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7.4 Results 
Clinical data and marker profiles 
Data were available for a total of 22 children, with median age 2.6 years (interquartile range 1-6 
years), with a wide range of levels of admission parasitaemia (Table 7.2).  Of the two children 
who died, one had a final diagnosis of encephalopathy while the other patient had a co-infection 
of P. falciparum and Salmonella spp and final diagnosis of septicaemia/ sepsis.  The 
measurement of the various markers in admission samples and the mean longitudinal patterns in 
this population during follow up are shown in Table 7.2 and Figure 7.1 respectively.   
 
Table 7.2 Admission clinical and laboratory data from 22 patients with severe malaria. 
 
 Median (Inter Quartile Range)  
Parasite count (per/µl) 157220 (21750-526920) 
HRP2 (ng/ml) 63.08 (10.37-161.25) 
pLDH in plasma (OD/min) 1.75 (0.02-4.98) 
pLDH in RBCs (OD/min) 31.74 (17.5-74.52) 
Total no. pigmented PMNs/µl 0 (0-389.75) 
Total no. pigmented monos/µl 277 (74.25-861.75) 
sTNF-R75 (ng/ml) 55.75 (44.45-74.6) 
Circulating pDNA(genomes/µl×105)† 524.89 (205.58-1838.5) 
Circulating host DNA (ng/ml) † 284.27 (175.02-719.29) 
Venous haematocrit* 25.75 (19.78-32.1) 
*as a percentage; † assessed in 21 patients, PMNs, polymorphonucleated cells; 
mono, monocytes, no. number 
 
Longitudinal patterns within this population revealed the persistence of HRP2, pigment in 
monocytes, sTNF-R75 and host DNA over the two days (Figure 1: a, f, g, h) while circulating 
pDNA, pLDH activity measured in RBCs and pigment in polymorphonucleated cells (PMNs) 
declined over this time (Figure 1: b, c, e).  pLDH activity in plasma increased 8 hours after 
admission, probably due to release of the enzyme from rupturing schizonts from the sequestered 
mass.  Estimates of the sequestered load declined more rapidly than peripheral parasitaemia 
during the two days (Figure 1: I and J).   
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Figure 7.1 Longitudinal plots for markers (a) HRP2, (b) circulating pDNA, (c) pLDH 
activity in RBC, (d) pLDH activity in plasma, (e) total number of pigment in PMNs, (f) total 
number of pigments in monocytes, (g) sTNF-R75,(h) circulating host DNA and (i) estimate 
of sequestered load 1iS and (j) peripheral parasitaemia. Error bars, mean at each time point 
and standard deviation. 
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Associations between estimated sequestered parameters and markers 
The analysis of the Spearman correlations between the various markers on admission confirmed 
that the pLDH levels in plasma were not correlated with that in erythrocytes (Table 7.3a), 
suggesting that plasma pLDH does not arise simply from lysis of a constant proportion of the 
infected erythrocytes.  HRP2 correlated positively with all other markers except PCV.  The PCV 
is reduced by high parasitaemia and showed negative correlations with most markers.  The 
amounts of pigment in the two different cell types were strongly correlated with each other, but 
showed somewhat different patterns of correlation with the other markers, with pigment counts 
in PMNs most strongly correlated with the parasite density.  The levels of circulating pDNA 
correlated with circulating host DNA. 
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Table 7.3 Spearman Correlation between levels of markers on admission 
 
a. Correlations unadjusted for peripheral parasite density 
 Measured 
peripheral 
parasitaemia 
1iS  HRP2 pLDH_P pLDH_R PCV Poly/µl Mono/µl sTNF-R75 pDNA human DNA 
1iS  0.89*** 1.00          
HRP2 0.59** 0.63** 1.00         
pLDH_P 0.11 0.16 0.48*  1.00        
pLDH_R 0.69*** 0.73*** 0.76*** -0.04  1.00       
PCV -0.22 
-0.26 -0.38 0.07 -0.60** 1.00      
Poly/µl 0.70*** 0.56** 0.60** 0.15 0.57** -0.28 1.00     
Mono/µl 0.33 0.31 0.67*** 0.16 0.54** -0.49* 0.69*** 1.00    
sTNF-R75 0.65*** 0.72*** 0.70***  0.40 0.63*  -0.19 0.25 0.13 1.00   
pDNA 0.46* 0.53** 0.58** 0.36 0.37  0.13 0.08 0.03 0.67**  1.00  
human DNA 0.49* 0.42* 0.57**  0. 34 0.31  0.18 0.38 0.31 0.56**  0.60**  1.00 
 
b. Partial correlations adjusted for admission peripheral parasite density 
 
1iS  HRP2 pLDH in plasma 
pLDH 
in RBC 
PCV Poly/µl Mono/µl sTNF-R75 pDNA human 
DNA 
1iS  1.00          
HRP2 0.28 1.00         
pLDH_P 0.12 0.51* 1.00        
pLDH_R 0.31 0.61** -0.11 1.00       
PCV 
-0.13 -0.32 0.09 -0.63** 1.00      
Poly/µl 
-0.25 0.32 0.05 0.21 -0.22 1.00     
Mono/µl 0.01 0.61** 0.07 0.50* -0.51* 0.66** 1.00    
sTNF-R75 0.44* 0.52* 0.48* 0.32 -0.04 -0.32 -0.05 1.00   
pDNA 0.30 0.43 0.37 0.07 0.27 -0.39 -0.15 0.57** 1.00  
human 
DNA 
-0.02 0.40 0.34 -0.01 0.32 0.08 0.23 0.57** 0.41 1.00 
1iS is the estimate of sequestered load based on analysis of longitudinal patterns of parasitaemia; pLDH_P, pLDH,in plasma; pLDH_R, pLDH in RBC PCV, packed cell 
volume; PMNs, polymorphonucleated cells/µl; mono/ µl monocytes/µl; pDNA, circulating parasite DNA; human DNA, circulating host DNA 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001
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The model fitted to the longitudinal patterns of parasitaemia gave estimates of the sequestered 
load at each time point during follow-up (Figure 7.1).  We initially considered good candidate 
markers of sequestration to be those that showed a strong correlation with the estimates of 
sequestered load on admission.  Significant correlations were observed with the level of pLDH 
measured in RBCs, sTNF-R75, HRP2, circulating parasite DNA and pigment in PMNs.  The 
measured peripheral parasite density was most strongly correlated with 1iS .  We carried out a 
partial correlation analysis, adjusting for the initial peripheral densities to identify those markers 
that provide information about the sequestered load additional to that contained in the baseline 
parasitaemia (Table 7.3b).  This analysis found a significant residual correlation only with the 
level of sTNF-R75.  The next highest correlation was with the level of pLDH in erythrocytes, 
and third highest with circulating pDNA. 
 
The kinetics of HRP2 levels during follow-up are clearly very different from those of 
sequestered parasites (Figure 7.1a), so we did not consider this marker further as a candidate 
indicator of sequestration.  pLDH in RBCs was also eliminated as a candidate because the levels 
in erythrocytes directly measures the peripheral parasite density (Figure 7.1c), while those in 
plasma show little correlation with either peripheral parasitaemia or 1iS  (Figure 7.1d).  Although 
the levels of pigment in PMNs showed a decline with time since admission, similar to that for 
1iS  (Figure 7.1e), the baseline levels were negatively correlated with 1iS  when adjusted for the 
levels of parasitaemia.  We therefore further considered only estimates of the sequestered load 
that made use of circulating pDNA, the sTNF-R75 and peripheral densities. 
 
Concordance between different estimates of levels of sequestration at admission 
The agreement between the distinct estimates of the sequestered load, 1 2 3 4 5,  ,  ,  ,  and i i i i iS S S S S   
was assessed by computing concordance correlation coefficients (CCC) between the 
logarithmically transformed estimates (Shoukri and Pause 1999).  This method is valuable when 
precision and accuracy are required in the evaluation of two methods that attempt to measure the 
same thing. As a graphical indication of agreement with the estimate derived from the 
longitudinal pattern of parasitaemia, 1iS , we also plotted the values of 
1 1ln ln ln ln
 against 
2 2
i ki i kiS S S S− +
 for each of the other measures, k=2…5. (Figure 7.2) 
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Figure 7.2 Bland –Altman plots at baseline; differences between duplicate measurements plotted 
against their average. 
(A) estimate of sequestered load (S1i) and alternative estimate of sequestered using peripheral 
parasitaemia (S2i), ρc=0.91,;  
(B) estimate of sequestered load (S1i) and alternative estimate of sequestered using circulating 
pDNA (S3i), ρc=0.53; 
(C) estimate of sequestered load (S1i) and alternative estimate of sequestered using sTNF-R75 
(S4i) ρc=0.65 
 
Both the peripheral density and the circulating pDNA level appear to be directly proportional to 
1iS  (Figure 7.3a, b) justifying the derivation of estimates 2iS  and 3iS that assume direct 
proportionality.  The sTNF-R75 levels were strongly correlated with 1iS  (Figure 7.3c) but the 
relationship was not one of direct proportionality, thus requiring the regression model of 
equation 3 in order to obtain an estimate, 4iS , of the sequestered load from the sTNF-R75 levels.   
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Concordance Correlation Coefficients 
The plots of the differences between the logarithmically transformed estimates 2 3 4,  ,  ,i i iS S S  and 
1iS  against the averages, confirmed that these estimates of sequestered loads were approximately 
directly proportional to each other (Figure 7.2).  The analysis of levels of agreement showed that 
the inclusion of the sTNF-R75 data in the estimation gave stronger agreement with 1iS than could 
be obtained using just the peripheral parasitaemia.  No more improvement was made by 
including in addition the circulating pDNA data (Table 7.4). 
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Figure 7.3. Baseline data for markers plotted against estimate from longitudinal pattern of 
sequestered load ( 1iS ) and (A) observed peripheral parasitaemia (B) measured circulating pDNA 
and (C) measured sTNF-R75.  
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Table 7.4. Concordance correlation coefficients of estimates of the log density of sequestered 
parasites 
 sTNF pDNA Obs. peri sTNF and peri 1iS  
sTNF 1.00     
pDNA 0.58 1.00    
Obs. Peri 0.52 0.46 1.00   
sTNF & per 0.71 0.54 0.96 1.00  
1iS  0.65 0.53 0.91 0.94 1.00 
Obs. peri- observed peripheral parasitaemia, sTNF-sTNF-R75; pDNA, circulating parasite DNA 
 
 
7.5 Discussion 
Peripheral counts of P. falciparum parasitaemia are in general related to disease severity, yet in 
endemic areas, asymptomatic parasitaemia with high densities are common and up to 37% has 
been recorded (Warrell et al 1990).  On the other hand, those admitted to hospital with severe 
disease or coma, may have parasitaemias as low as 0.01% (White 2002).  Much of this variation 
in outcome associated with the measured parasite load is presumed to be due to differences in the 
proportions of parasites that are sequestered.  We have now assessed a range of biochemical 
markers as predictors of the extent of sequestration in a series of patients. 
 
The parasite protein levels which we quantified are the most obvious candidates as measures of 
the sequestered load.  As expected and in keeping with other studies, levels of the pLDH 
glycolytic enzyme in RBCs were strongly associated with peripheral parasite density (Makler 
and Hinrichs 1993,Piper et al 1999).  In vitro studies have revealed that pLDH is released during 
lysis of RBCs (unpublished observations) and levels in plasma should therefore be a direct 
measure of the rate of schizont rupture.  However as a consequence of a short half-life of the free 
protein in the circulation, plasma levels of pLDH were much lower than those in RBCs, making 
it difficult to measure them.  Plasma pLDH on admission was poorly correlated with both the 
observed peripheral parasitaemia and the estimates of sequestration in vivo.  The partial 
correlations with 1iS ,  allowing for the peripheral parasitaemia, suggested that neither pLDH in 
RBCs nor in plasma added much information about sequestered loads on admission to that 
provided by the peripheral parasite counts.  The increase in plasma pLDH in most patients 
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following admission may reflect the fact that it is released only at the very end of the parasite 
cycle.  Further analyses of the post-admission kinetics are needed to test this. 
 
In vitro studies have demonstrated release of HRP2 from rings, trophozoite and schizont parasite 
stages (Desakorn et al 2005a,Desakorn et al 1997,Howard et al 1986) and in vivo studies have 
shown that it correlates with parasitaemia (Desakorn et al 1997).  It has been proposed that it is a 
good marker of the level of sequestration in Thai patients (Dondorp et al., in press).  We 
confirmed the correlation with levels of peripheral parasitaemia, but found only a weak 
relationship with the estimated sequestered load at admission.  HRP2 persists in the bloodstream 
for at least 2 weeks (Mayxay et al 2001), and in our study the average level showed no decay 
during the follow-up, so its dynamics indicate that it cannot provide a good estimate of 
concurrent levels of sequestration. 
 
Haemozoin is released during schizont rupture, phagocytosed initially by scavenger PMNs and 
subsequently taken up into monocytes (Day et al 1996,Schwarzer et al 1992).  Day and others 
(1996) showed that pigment measured in PMNs have clearance times of 49 to 95 hours, while 
pigments in monocytes, 180 to 240 hours.  We observed a rapid decline in pigmented PMNs 
while there was no overall change with time since admission in the number of pigmented 
monocytes.  Pigment levels counted in PMNs were better correlated with peripheral parasitaemia 
than those in monocytes.  On the other hand, pigment levels were not correlated with our model-
based estimates of sequestered loads in analyses in which peripheral density was adjusted.  It is 
known that pigment can remain attached to remnants of the IRBCs, which are attached to 
endothelia, from where it is later cleared by circulating WBCs.  Consequently a number of 
factors other than the rate of schizont rupture have a major influence on the amounts that can be 
measured and this limits the value of pigment assessment in quantifying schizogony or 
sequestration. 
 
In view of these problems with the use of established diagnostic assays to estimate sequestered 
loads, we considered quantitation of circulating pDNA as an alternative.  Studies on circulating 
pDNA have focused mainly on whole blood (Lee et al 2002,Perandin et al 2004,Richardson et al 
2002) yet it can also be measured in plasma gal 2001.  Circulating pDNA levels in plasma were 
correlated with peripheral parasitaemia, with the estimate, 1iS , of sequestered loads.  The 
moderate correlation with 1iS  encouraged us to develop the estimate 3iS , based on the circulating 
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pDNA level, but the scatter in the relationships between circulating pDNA levels and the other 
estimates raises questions as to whether this is because of variation in circulating pDNA levels, 
due to other causes, or because the other estimates, 1 2 and ,i iS S  are themselves imprecise.  
Circulating pDNA levels in plasma declined much faster than did 1iS  suggesting that the release 
of circulating pDNA from ruptured schizonts does not explain the variation in levels.   
 
sTNF-R75 levels have previously been shown to correlate with parasite density in both 
symptomatic and asymptomatic children (Hurt et al 1995,Leeuwenberg et al 1994).  Since TNF-
α release is a key part of the whole cascade of events precipated by schizont rupture, we 
anticipated that the level of this receptor should correlate with the recent sequestered load.  
Making use of the relationships between sTNF-R75 levels and the estimates 1 2 3, ,  and  i i iS S S of 
the sequestered load, we therefore derived the further estimates 4 6,  and  i iS S .  As with HRP2, the 
average level showed no decay during the follow-up, so the dynamics of sTNF-R75 argue 
against its value as an indicator of concurrent levels of sequestration. 
 
We considered a number of other host markers.  Davis et al (1990) found that anaemia levels 
could be used to measure sequestration in Thai patients.  However, these patients were unlikely 
to have suffered a long history of repeated infections and so their PCVs reflected very recent 
events.  Only weak relationships between PCV and levels of parasitaemia were found in our 
more highly endemic population.  The PCV measures the extent of red cell destruction and so 
might be expected to correlate with sequestration over an extended period, but variations during 
the time course of an infection are very small in Kilifi, and so it is unsurprising that the PCV 
appears to be a poor marker of current sequestered loads.  Gal and others (personal 
communications) showed that circulating host DNA measured in plasma is not elevated in severe 
malaria and we have further shown that it is not associated with estimates of sequestered load. 
 
Together with peripheral parasitaemia, measures of sTNF-R75 and of circulating pDNA 
therefore appear most useful as predictors of the sequestered load on admission.  These markers 
do not appear to be good indicators of changes in sequestered loads during the course of a 
clinical episode.  We were particularly disappointed by the lack of relationship between pLDH 
levels in plasma and the estimated sequestered loads.  However, we may well have undervalued 
some markers by assuming the validity of the model for longitudinal patterns of parasitaemia and 
ignoring the dynamics of the markers.  At the price of making the analyses even more complex, 
 113 
it would be possible to model these dynamics using knowledge from in vitro studies of the stage 
specificity of release and of drug effects, and to allow for the estimated pre-treatment rate of 
expansion of the parasite population.  
 
The various markers also need to be evaluated as measures of population average levels of 
sequestration in the absence of acute illness.  Highly persistent markers, such as HRP2 may be 
particularly appropriate for this purpose.  The identification of a suitable method for estimating 
sequestered loads of P. falciparum remains a major challenge. 
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Chapter 8 
 
General Discussion and Conclusions 
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8.1 Discussion 
Sequestration is one of the underlying features of clinical P. falciparum malaria.  
Despite this knowledge there is still no reliable means for determining the hidden mass of 
parasites, given the complications related to the use of parasitaemia, use of antimalarials 
and varying sensitivity and specificity under different epidemiological settings.  Hence 
the focus of this thesis is on evaluating both parasite and host products as potential 
markers of sequestration.   
Several of our potential markers of sequestration are already in use in diagnostic 
tests for malaria, so we first reviewed available literature on malaria rapid diagnostic tests 
(RDTs) for different population groups under different epidemiological settings (Chapter 
3).  In order to identify potential markers of sequestration in vitro cultures were used to 
determine stage specific release of parasite products in the presence and absence of anti-
malarials (Chapter 4).  The performance of these parasite products and a host receptor 
(soluble tumour necrosis factor R75) were assessed in vivo (Chapter 5).  On the basis of 
earlier findings, we evaluated histidine rich protein 2 as a marker of disease severity 
(Chapter 6).  We then looked at other parasite and host products in relation to 
parasitaemia and estimates of sequestered loads (Chapter 7).   
This work is unique in that it considers a combination of different in vitro and in 
vivo measurements of parasite (8.1) and host (8.2) products and statistical models (8.3) 
for estimating sequestered loads. The implications of these findings on malaria research, 
appropriate treatment and management are highlighted. 
 
8.2 Parasite biochemical markers of sequestration 
 
8.2.1 D-lactate  
We showed that D-lactate a product of P. falciparum carbohydrate metabolism, 
can be measured using an alternative sensitive fluorescent-based enzymatic assay 
(Chapter 4).  However, it cannot act as a potential marker of sequestration as it is not 
released predominantly during sequestered stages but during ring and trophozoites stages 
(Vander Jagt et al 1990).  Its release is influenced by the presence of antimalarials 
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(quinine and pyrimethamine) which in turn leads to either a decline or increase in levels 
of this marker and as such is not a reliable marker of disease severity.  Despite the fact 
that the new assay is much more sensitive than previous approaches for measuring D-
lactate, the levels in plasma were close to the limit of detection, probably because this 
molecule is cleared very rapidly. 
 
8.2.2 Histidine rich protein 2 
With respect to Histidine rich protein 2 (HRP2) a water soluble protein implicated 
in the detoxification process of haemoglobin, we found that as a diagnostic tool it 
performs better than optical microscopy in determining malaria infection among clinical 
cases in endemic areas and in field studies of asymptomatics (Chapter 3).   
To evaluate its use as a marker of sequestration, we used a quantitative sandwich 
ELISA was developed based on methods by Taylor and Voller, 1993 and Desakorn et al., 
1997 from which we confirmed the release of HRP2 into culture supernatant during 
trophozoite and schizont stages (Desakorn et al 1997,Howard et al 1986). 
In vivo HRP2 release is known to be significantly higher in severe malaria in 
comparison to uncomplicated malaria (Desakorn et al, 1997) and we further found that it 
was a good measure of disease severity (Chapter 5), with severe malaria cases having the 
highest levels of HRP2.  Although HRP2 levels in plasma correlated with circulating 
parasite density they did not correlate well with estimates of sequestered loads from 
longitudinal analyses of parasitaemia.  The strong correlation between measures in 
plasma and peripheral parasitaemia reflects its release throughout the life cycle of 
parasite.  Dondorp and others (personal communication) were able to estimate the total 
parasite load by considering multiple factors: the rate of release at schizont rupture; the 
number of parasites present at schizont rupture; the multiplication factor; and the 
elimination half-life of HRP2.  This approach may give better results than the one we 
evaluated, as we assumed a monotonic relationship between total parasite load and the 
HRP2 concentration.  However, it is important to note that antimalarial drugs like quinine 
or pyrimethamine can also interfere with the release of HRP2 resulting in release that is 
no longer stage specific (observations in Chapter 4).  Such findings may also interfere 
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with measurement of sequestered loads in individuals who have been treated with anti-
malarials. 
 
8.2.3 Parasite lactate dehydrogenase 
Parasite lactate dehydrogenase is an enzyme involved in the glycolysis pathway 
of P. falciparum and forms part of the metabolic process generating ATP as a source of 
energy (Basco et al, 1995).  It was found to be reliable in diagnosis of malaria in non-
endemic areas (travellers) (Chapter 3).  We further showed that parasite lactate 
dehydrogenase (pLDH) enzyme activity can be measured in culture supernatant and 
increased enzyme activity was associated with ring stages, which implies that it remains 
bound to cell membranes after schizont rupture (Chapter 4).  We observed that it can be 
measured in plasma samples from malaria patients, though pLDH enzyme activity in 
these plasma samples was lower than that measured within IRBCs.   
In vivo, pLDH enzyme activity in plasma is a predictor of disease severity with 
severe cases showing significantly higher levels than mild cases (Chapter 5).  pLDH 
enzyme activity in plasma correlated poorly with both peripheral parasitaemia and 
estimates of sequestered loads from longitudinal analyses of parasitaemia.  However, 
longitudinal measurements of pLDH enzyme activity in plasma showed an increase post-
admission, then a gradual decrease after 16 hours (Chapter 7C).  This increase could be 
related to its release from sequestered load.  Our in vitro observations were in accord with 
previous reports that the presence of antimalarial drugs (Chapter 4) like quinine can cause 
damage to cell membrane (Gu and Inselberg, 1989), and therefore result in enzyme 
release that is no longer stage specific.  Using our current measures of sequestration and 
correlation, we were unable to detect such changes in the kinetics of this enzyme and 
therefore, other models are required that take into consideration these dynamics. 
 
8.2.4 Malaria pigment 
Malaria pigment is produced by P. falciparum during its intra-erythrocytic 
development as an end-product of haemoglobin digestion (Slater et al 1991). It is 
released during schizont rupture into the blood circulation where it is engulfed by 
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polymorphonucleated cells (PMNs) or monocytes following which it is detected and 
counted using blood smears.  This points to its importance as a marker of sequestration.   
Measures of pigment in either PMNs or monocytes may not always be a reliable 
indicator of disease severity because some patients despite being slide positive for P. 
falciparum, had no visible pigment (Chapter 6).  Alternatively, low parasitaemia and the 
absence of pigment within WBCs suggests an infection that is either very recent, or the 
degree of sequestration within such individuals is extremely low.  We further found that 
pigmented PMNs were better correlated with peripheral parasitaemia than were 
pigmented monocytes.  The presence of pigmented PMNs represents a recently acquired 
malaria infection while pigmented monocytes indicate an infection that has been present 
for many days or weeks (Day et al, 1996).  We have shown pigmented PMNs and 
pigmented monocytes were unable to estimate the sequestered loads.   
Despite not being useful as markers of sequestration in patients, measures of 
malaria pigment in PMNs could be useful in monitoring recovery from an infection and 
thus response to treatment as observed in some patients (Appendix 4 and 5).  In contrast, 
monitoring the progress of an infection through pigmented monocytes is not suitable as it 
persists for long periods.  Day and others (1996) assessed pigment in Vietamese adults 
and showed that pigmented PMNs have clearance times of 49 to 95 hours, while in 
monocytes it is 180 to 240 hours.  Among children in endemic settings like Kilifi, these 
clearance times may be different and could explain the poor correlation to sequestered 
load estimates that we observed.  The impairment of macrophage function due to 
ingestion of P. falciparum pigment (Schwartzer et al, 1992) could lead to rapid clearance 
of such cells from circulation also resulting in lower levels.  Other more sensitive 
methods are therefore required to assess pigments as markers of sequestration. 
 
8.2.5 Circulating parasite DNA  
Circulating parasite DNA (pDNA) which is released into culture supernatant 
during schizont rupture, can be detected using an extremely sensitive method known as 
real-time PCR (Chapter 7).  Though we did not test the effect of antimalarials on release 
of circulating pDNA, it is possible that damage to host cell membrane by drugs could 
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result in release of this marker that is no longer stage specific.  There is a need to assess 
drug effects on stage-specific release of circulating pDNA in vitro. 
The novel real-time PCR method can detect up to 0.7 parasites/µl of circulating P. 
falciparum, pDNA (Perandin et al 2004).  Measures of circulating pDNA in plasma 
correlated with peripheral parasitaemia and this molecule was the only parasite marker 
that correlated with estimates of sequestered load on admission.  However, during follow-
up measures of circulating pDNA and estimates of sequestered loads, there was no longer 
any correlation (Chapter 6).  As with HRP2, we hypothesize that measures of circulating 
pDNA released during schizont rupture within P. falciparum cultures, together with in 
vivo measures and an estimation of the rate of clearance, would better enable estimation 
of the degree of sequestration within patients.   
 
8.3 Host biochemical markers of sequestration 
 
8.3.1 Soluble tumor necrosis factor R75 
Soluble tumor necrosis factor R75 (sTNF-R75) is up-regulated during release of 
toxins at schizont rupture and forms complexes with tumour necrosis factor α (TNF- α) 
buffering and regulating its release (Tartaglia and Goeddel, 1992).   
We observed a significant elevation in the concentration of these receptors in 
severe cases within young children from in malaria endemic Kilifi (Chapter 4).  The 
presence of bacterial infections will lead to up-regulation of this receptor (Leeuwenberg 
et al, 1994).  Indeed we observed an increase in plasma levels of sTNF-R75 in children 
with Salmonella spp, Streptococcus group A., E. coli and neonatal tetanus (Chapter 5).   
We found that sTNF-R75 levels correlated with parasite density as shown by 
others (Kern et al, 1992; Hurt et al, 1995) and was the only host marker that gave a 
strong correlation with estimates of sequestered load on admission (Chapter 6).  Though 
sTNF-R75 correlated with estimates of sequestered loads on admission, this receptor did 
not appear to be suitable post-admission as it showed very different dynamics to 
estimates of sequestered loads.   
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8.3.2 Packed cell volume 
A drop in the packed cell volume (PCV) can be used as a measure of 
sequestration and has been assessed in non-immune Thai adults (Davis et al, 1990) in a 
very low transmission area who probably suffered from a recent malaria event. This 
results in great variation in PCV levels.  We found that changes in PCV during acute 
malaria did not correlate with our estimates of sequestered loads in partially immune 
malaria patients (Chapter 5).  In endemic areas young children will most likely suffer 
from a long history of repeated infections that leads to very small changes in the PCV 
levels.  This marker is therefore not an appropriate measure of sequestration within young 
children in malaria endemic areas.   
 
8.3.3 Circulating host DNA 
The presence of P. falciparum infections leading to the rupture of schizonts with 
the concomitant release of toxins is thought to lead to host tissue damage (Clark et al 
1989) and hence, release of circulating host DNA.  Levels of circulating host DNA had 
no direct correlation with parasitaemia as previously shown by Gal and others (personal 
communication) and it further showed no correlation with estimates of sequestered loads.  
Host tissue damage may also be caused by other factors within the host, and as the 
changes over time with this marker occur slowly as with PCV, and it is thus not 
measurable.  We have shown that circulating host DNA would therefore not be a suitable 
marker of sequestration in malaria patients.   
 
8.4 Statistical modelling and sequestration 
 Our attempts to correlate estimates of sequestered loads with measures in vivo, 
were not successful especially when applied to longitudinal data collected after 
admission.  The use of correlations in assessing estimates of sequestered load and 
measures of parasite or host markers are not sufficient.  Peripheral parasite counts 
correlate with estimates of sequestered load, but this reflects the fact that the latter was 
derived from peripheral counts.  However, measures of correlation are not suitable 
because parasitaemia is dependent on the fact that: (1) on the number of merozoites 
 122 
released per schizont and not all of those released will re-invade RBCs due to the 
presence of agglutinating antibodies (Lyon et al 1989,Lyon et al 1997); (2) some 
merozoites are unable to invade RBCs as a result of erythrocyte receptor polymorphisms 
(Gaur et al 2004) (3) counting parasites using blood smear in malaria patients is itself an 
under estimation of the total number of circulating parasites within a patient, as 
preparations of thick blood films without fixing with methanol results in loss of cells (lab 
observations); (5) fever, a pyrogenic response to production of toxins could lead to 
reduction in the multiplication rate and inhibit parasite growth (Gravenor et al 
1995,Kwiatkowski 1990).  Measures of peripheral of parasite density alone are not good 
estimates of sequestered load.  Other biochemical markers could improve correlations 
with estimate of sequestered load. 
The model for longitudinal parasitaemia used in Chapter 7 considered the effects 
of quinine on parasite density, but one should also include measures of markers when 
exposed to anti-malarial drugs which interfere with the release from IRBCs (Chapter 3).  
During their analysis on estimates of parasite load in Thai patients, Dondorp and others 
(personal communication) took into consideration the release of HRP2 at the different 
parasite stages as well as the half-life of markers in patients.  However, continuous 
culturing of parasites will lead to loss of certain functions (Biggs et al 1991) because of 
DNA arrangement (McKenzie and Bossert 1997) and therefore the data gathered from in 
vitro experiments should be considered with caution.  Methods that include the half-life 
of markers such as HRP2 need to consider local estimates from the population to be 
studied.  We found that the half-life of HRP2 in an endemic setting like Kilifi is shorter 
than in Thailand and that this is dependent on age and exposure (Chapter 7).   
Furthermore, our assessment of sequestered loads in patients is influenced by the 
complex interactions between the host and parasite, recognition of parasite strains, host 
genetics (Thalassemia; glucose-6-phosphate dehydrogenase deficiency; TNF gene 
change), exposure to malaria and whether a person has multiple parasite strains (Farnert 
et al 1997,Hill et al 1991,McGuire et al 1998,Ruwende et al 1995,Smith et al 
1999b,Williams et al 2005).  This is summarized in Figure 8.1.  We did not exclude 
patients who had previously taken antimalarial drugs before admission, but in endemic 
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areas like Kilifi, it is possible that usage is high and might affect our current measures of 
sequestration. 
 
Parasite Burden
peripheral
parasite load
sequestered 
parasite load+
Virulence
Clinical outcome
Host factors
chemotherapy Immune response
• Genetic traits-thalassemia
• Co-infections
• Age and exposure
• Body temperature
 
 
Figure 8.1 Factors involved in the virulence of P. falciparum  
(Adapted from Rivas et al, 2004). 
 
8.5 Application and limitations 
Though we have so far not been able to estimate the sequestered load using host 
or parasite markers in partially immune patients, analysis of individual patient profiles 
(Appendices 3, 4, 5) provides important information on the sequestered load of parasites, 
especially in situations where parasite density decreases and marker increases.  In a 
patient with low parasite density (500 parasites/µl) we found that there was an increase in 
all biochemical markers we assessed (Appendix 4).  Therefore, together with clinical 
conditions such as prostration this patient may have some hidden mass of P. falciparum 
parasites.  Rapid and accurate diagnosis is still of importance and as observed measures 
of pLDH, HRP2, sTNF-R75 and circulating pDNA in plasma, could provide valuable 
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information for clinicians treating the disease even in situations where the parasite 
densities are low.  If host markers are used, one should not ignore the fact that young 
children may harbour other concomitant infections and measures of host receptors 
(sTNF-R75, circulating host DNA) may decrease in patients who are co-infected with 
measles or influenza virus (Cox 2001,Rooth and Bjorkman 1992).   
Further evidence is provided using HRP2 firstly as a diagnostic tool in clinical 
cases in endemic areas where it can detect P. falciparum with a higher sensitivity than 
optical microscopy.  However, it is not currently available as a diagnostic tool in clinical 
studies because of its high cost.  It requires constant quality control and should be 
assessed in an area before being implemented as a diagnostic tool.  Though HRP2 
persists, we noted that the quantitative ELISA method is more specific as it can be used 
to differentiate between those with from those without clinical disease.  In clinical 
situations, the biggest problem is determining the prognostic significance of any given 
level of parasitaemia especially when parasite densities are low.  Apart from clinical 
indicators of disease such as prostration, levels of coma and anaemia the implementation 
of another method like the detection of HRP2, could provide a better indication of disease 
severity within an individual. 
 
8.6 Conclusions 
Within this study we have shown that the markers that should be excluded from 
future studies for assessment of sequestered loads include: D-lactate, pigmented PMNs, 
pigmented monocytes, PCV and circulating host DNA.  The use of host biochemical 
markers to estimate sequestration does not seem to be feasible, as these are prone to 
fluctuations due to age, genetics and immune status.  In addition, co-infection with other 
bacterial or viral infections causes further variation. Future models assessing sequestered 
loads that use longitudinal parasitaemia should be modified to make better use of the 
available in vitro data (HRP2, pLDH, circulating pDNA) and should attempt to capture 
effects of quinine on the release of these markers.   
Analyses of longitudinal patterns of markers should incorporate what we know 
about the stage specific release and drug effects from in vitro experiments, and should 
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allow for different clearance rates of the different markers.  Further correlations between 
marker levels and estimated sequestered loads should allow for the estimated pre-
treatment rate of expansion of the parasite population.  Therefore, previous exposure to 
other antimalarials in patients should be determined.  Further investigations are required 
in community samples and across different ages as this would also incorporate the effects 
of acquired immunity to P. falciparum infections. 
In conclusion, the parasite biochemical markers appear to offer the best approach 
for estimating sequestered loads, but further analysis of their dynamics are needed before 
a reliable method is available. 
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Appendix 3. An Addendum 
 
Re: The estimation of sequestered parasite loads during infections with Plasmodium 
falciparum (SCC 593) 
By Lucy Ochola, Dr. Tom Smith, Brett Lowe, Prof. Gerd Pluschke, Prof Kevin 
Marsh 
 
Background 
The main objective of the current study is to quantify the sequestered parasite loads in 
malaria infections.  Blood samples are being collected from patients with severe malaria 
over the first 48 hours of admission and analysed for several parasite products or markers 
(HRP2, pLDH, sTNF-R75, pigments).  These will be used in a Bayesian model to 
estimate parasite load in patients.  One of the applications of parasite load estimations is a 
better understanding of the difference between asymptomatic parasitaemia and clinical 
disease, which may ultimately lead to better differentiation of the two conditions by 
laboratory testing and modeling. 
 
Summary or work and justification of the addendum 
An ELISA for HRP2 has been successfully adapted and developed to measure HRP2 in 
Kilifi.  The assay is sensitive to low levels of HRP2 and provides a concentration based 
result in nanograms/ml with reference to an artificial standard serum (courtesy of Dr, 
Hans Peter Beck).  We have so far recruited 53 patients in whom we have measured the 
dynamics of HRP2 over a 48 hour period.  Concentrations of HRP2 are uniformly high- a 
finding consistent with the previous work of Desakorn et al (1997) in Thailand who used 
a semi-quantitative assay.  These and other scientists have attempted to use semi-
quantitative HRP2 measurements to differentiate between uncomplicated and severe 
malaria (Desakorn et al, 1997; Parra et al, 1991).  As HRP2 is a unique product of P. 
falciparum it is likely to be absent in those without parasitaemia and to be found in low 
concentration with asymptomatic parasitaemia.  There is a prospect therefore that finely 
quantitated measurements of HRP2, as are now possible with the HRP2 ELISA, could be 
used to differentiate different classes of malaria infection and disease.  Such an assay 
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would provide a more specific diagnostic test of malaria disease than is currently possible 
using a combination of parasitaemia and clinical signs.  In order to assess this possibility 
we propose to examine the distribution of concentrations of HRP2 in patients with mild 
malaria and in healthy controls, to compliment our observations in patients with severe 
malaria.  We propose to achieve this using existing stored samples. 
Clearly the specificity of the assay in asymptomatic individuals depends to some extent 
on the half-life of HRP2 following a clinical episode of malaria.  To estimate the half-life 
we also propose below to examine existing stored samples. 
 
Proposed additional methods: 
The diagnostic utility of HRP2 will be evaluated by assaying three populations of 
samples.  (1) Sensitivity for severe malaria will be defined in 100 patients already 
recruited to the parent study (SSC 593) equally distributed by year of age between the 
age of 12-59m.  (2) Specificity will be defined by analyzing 150 stored samples from a 
cross-sectional venesection study of malaria undertaken in 1999 (The natural history of 
acquired immunity to malaria with particular reference to response to P. falciparum 
antigens expressed at the infected red cell surface, SCC 485).  Samples will be selected at 
random within the age rage 12-59m, but stratified to ensure that 100 are parasitaemic and 
50 non-parasitaemic.  (3) The potentially confounding role of patients with mild malaria 
will be analysed in 100 samples from patients defined as mild malaria in the same 
completed study (The natural history of acquired immunity to malaria with particular 
reference to response to P. falciparum antigens expressed at the infected red cell surface, 
SCC 485).  Finally, to examine the dynamics of HRP2 after clearance of parasites by 
therapy we propose to assay 35 specimen- series from among a set of 200 that are being 
collected for a pharmacodynamic study of Coartemether (Coartem/ SP efficacy trial, 
2003, SCC731).  The sampling interval of this study (0, 3, 7, 14, 28 days) is ideal for the 
evaluation of the decline in HRP2 which has been found, in others centres, persist for 
approximately 3 weeks (Desakorn et al, 1997) 
 
Sensitivity and specificity will be optimized by plotting an ROC curve and selecting the 
ideal cut-off value for concentration of HRP2.  The sample size has been determined to 
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minimize the confidence limits around a sensitivity or specificity measure and at the 
same time minimize the laboratory load.  With 100 subjects in the asymptomatic 
parasitaemic group and 100 severe malaria patients, for example, a sensitivity or 
specificity would have confidence limits of 91-99%. 
 
Ethical Issues 
In order to minimize the harms involved in pursuing research on the diagnosis of malaria 
within the community in Kilifi we have decided to confine this work entirely to samples 
collected for other studies.  The protocols and consent forms for these two studies are 
provided with this addendum.  No additional blood sampling is proposed to evaluate the 
aims of this addendum. 
 
Submitted to SCC for consideration and accepted Feb 2004 
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Kinetics of various markers in a patient with a starting parasitaemia of 7000/µl, (a) circulating host 
DNA, (b) circulating host DNA, (c) HRP2, (d) pLDH enzyme activity in plasma, (e) pLDH enzyme 
activity in RBC, (f) number of pigmented PMNs, (g) number of pigmented monocytes, (h) sTNF-R75. 
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Kinetics of various markers in a patient with a starting parasitaemia of 500/µl, (a) circulating host 
DNA, (b) circulating host DNA, (c) HRP2, (d) pLDH enzyme activity in plasma, (e) pLDH enzyme 
activity in RBC, (f) number of pigmented PMNs, (g) number of pigmented monocytes, (h) sTNF-R75. 
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Kinetics of various markers in a patient with a starting parasitaemia of 1.7×106/µl, (a) circulating host 
DNA, (b) circulating host DNA, (c) HRP2, (d) pLDH enzyme activity in plasma, (e) pLDH enzyme 
activity in RBC, (f) number of pigmented PMNs, (g) number of pigmented monocytes, (h) sTNF-R75. 
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